<!DOCTYPE html>

<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">

<head>
  <meta charset="utf-8"/>
  <meta name="viewport" content="width=device-width, initial-scale=1"/>
  <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1"/>
  <meta name="generator" content="distill" />

  <style type="text/css">
  /* Hide doc at startup (prevent jankiness while JS renders/transforms) */
  body {
    visibility: hidden;
  }
  </style>

 <!--radix_placeholder_import_source-->
 <!--/radix_placeholder_import_source-->

<style type="text/css">code{white-space: pre;}</style>
<style type="text/css" data-origin="pandoc">
html { -webkit-text-size-adjust: 100%; }
pre > code.sourceCode { white-space: pre; position: relative; }
pre > code.sourceCode > span { display: inline-block; line-height: 1.25; }
pre > code.sourceCode > span:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode > span { color: inherit; text-decoration: inherit; }
div.sourceCode { margin: 1em 0; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
pre > code.sourceCode { white-space: pre-wrap; }
pre > code.sourceCode > span { text-indent: -5em; padding-left: 5em; }
}
pre.numberSource code
  { counter-reset: source-line 0; }
pre.numberSource code > span
  { position: relative; left: -4em; counter-increment: source-line; }
pre.numberSource code > span > a:first-child::before
  { content: counter(source-line);
    position: relative; left: -1em; text-align: right; vertical-align: baseline;
    border: none; display: inline-block;
    -webkit-touch-callout: none; -webkit-user-select: none;
    -khtml-user-select: none; -moz-user-select: none;
    -ms-user-select: none; user-select: none;
    padding: 0 4px; width: 4em;
    color: #aaaaaa;
  }
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa;  padding-left: 4px; }
div.sourceCode
  { color: #00769e; background-color: #f1f3f5; }
@media screen {
pre > code.sourceCode > span > a:first-child::before { text-decoration: underline; }
}
code span { color: #00769e; } /* Normal */
code span.al { color: #ad0000; } /* Alert */
code span.an { color: #5e5e5e; } /* Annotation */
code span.at { color: #657422; } /* Attribute */
code span.bn { color: #ad0000; } /* BaseN */
code span.bu { } /* BuiltIn */
code span.cf { color: #00769e; } /* ControlFlow */
code span.ch { color: #20794d; } /* Char */
code span.cn { color: #8f5902; } /* Constant */
code span.co { color: #5e5e5e; } /* Comment */
code span.cv { color: #5e5e5e; font-style: italic; } /* CommentVar */
code span.do { color: #5e5e5e; font-style: italic; } /* Documentation */
code span.dt { color: #ad0000; } /* DataType */
code span.dv { color: #ad0000; } /* DecVal */
code span.er { color: #ad0000; } /* Error */
code span.ex { } /* Extension */
code span.fl { color: #ad0000; } /* Float */
code span.fu { color: #4758ab; } /* Function */
code span.im { } /* Import */
code span.in { color: #5e5e5e; } /* Information */
code span.kw { color: #00769e; } /* Keyword */
code span.op { color: #5e5e5e; } /* Operator */
code span.ot { color: #00769e; } /* Other */
code span.pp { color: #ad0000; } /* Preprocessor */
code span.sc { color: #5e5e5e; } /* SpecialChar */
code span.ss { color: #20794d; } /* SpecialString */
code span.st { color: #20794d; } /* String */
code span.va { color: #111111; } /* Variable */
code span.vs { color: #20794d; } /* VerbatimString */
code span.wa { color: #5e5e5e; font-style: italic; } /* Warning */
</style>

<style>
  div.csl-bib-body { }
  div.csl-entry {
    clear: both;
      margin-bottom: 0em;
    }
  .hanging div.csl-entry {
    margin-left:2em;
    text-indent:-2em;
  }
  div.csl-left-margin {
    min-width:2em;
    float:left;
  }
  div.csl-right-inline {
    margin-left:2em;
    padding-left:1em;
  }
  div.csl-indent {
    margin-left: 2em;
  }
</style>

  <!--radix_placeholder_meta_tags-->
<title>boinet: An R Package for Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes</title>

<meta property="description" itemprop="description" content="Bayesian optimal interval based on both efficacy and toxicity outcomes&#10;(BOIN-ET) design is a model-assisted oncology phase I/II trial design,&#10;aiming to establish an optimal biological dose accounting for efficacy&#10;and toxicity in the framework of dose-finding. Some extensions of&#10;BOIN-ET design are also available to allow for time-to-event efficacy&#10;and toxicity outcomes based on cumulative and pending data&#10;(time-to-event BOIN-ET: TITE-BOIN-ET), ordinal graded efficacy and&#10;toxicity outcomes (generalized BOIN-ET: gBOIN-ET), and their&#10;combination (TITE-gBOIN-ET). The R package boinet implements the&#10;BOIN-ET design family. The package supports&#10;the conduct of simulation studies to assess operating characteristics&#10;of BOIN-ET, TITE-BOIN-ET, gBOIN-ET, and TITE-gBOIN-ET designs, where&#10;users can choose design parameters in flexible and straightforward&#10;ways depending on their own application. We demonstrate its capability&#10;and effectiveness using several simulation studies."/>

<link rel="canonical" href="https://doi.org/10.32614/RJ-2025-012/"/>
<link rel="license" href="https://creativecommons.org/licenses/by/4.0/"/>
<link rel="icon" type="image/vnd.microsoft.icon" href="../../resources/favicon.ico"/>

<!--  https://schema.org/Article -->
<meta property="article:published" itemprop="datePublished" content="2025-09-23"/>
<meta property="article:created" itemprop="dateCreated" content="2025-09-23"/>
<meta name="article:author" content="Yusuke Yamaguchi"/>
<meta name="article:author" content="Kentaro Takeda"/>
<meta name="article:author" content="Kazushi Maruo"/>

<!--  https://developers.facebook.com/docs/sharing/webmasters#markup -->
<meta property="og:title" content="boinet: An R Package for Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes"/>
<meta property="og:type" content="article"/>
<meta property="og:description" content="Bayesian optimal interval based on both efficacy and toxicity outcomes&#10;(BOIN-ET) design is a model-assisted oncology phase I/II trial design,&#10;aiming to establish an optimal biological dose accounting for efficacy&#10;and toxicity in the framework of dose-finding. Some extensions of&#10;BOIN-ET design are also available to allow for time-to-event efficacy&#10;and toxicity outcomes based on cumulative and pending data&#10;(time-to-event BOIN-ET: TITE-BOIN-ET), ordinal graded efficacy and&#10;toxicity outcomes (generalized BOIN-ET: gBOIN-ET), and their&#10;combination (TITE-gBOIN-ET). The R package boinet implements the&#10;BOIN-ET design family. The package supports&#10;the conduct of simulation studies to assess operating characteristics&#10;of BOIN-ET, TITE-BOIN-ET, gBOIN-ET, and TITE-gBOIN-ET designs, where&#10;users can choose design parameters in flexible and straightforward&#10;ways depending on their own application. We demonstrate its capability&#10;and effectiveness using several simulation studies."/>
<meta property="og:url" content="https://doi.org/10.32614/RJ-2025-012/"/>
<meta property="og:locale" content="en_US"/>
<meta property="og:site_name" content="The R Journal"/>

<!--  https://dev.twitter.com/cards/types/summary -->
<meta property="twitter:card" content="summary"/>
<meta property="twitter:title" content="boinet: An R Package for Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes"/>
<meta property="twitter:description" content="Bayesian optimal interval based on both efficacy and toxicity outcomes&#10;(BOIN-ET) design is a model-assisted oncology phase I/II trial design,&#10;aiming to establish an optimal biological dose accounting for efficacy&#10;and toxicity in the framework of dose-finding. Some extensions of&#10;BOIN-ET design are also available to allow for time-to-event efficacy&#10;and toxicity outcomes based on cumulative and pending data&#10;(time-to-event BOIN-ET: TITE-BOIN-ET), ordinal graded efficacy and&#10;toxicity outcomes (generalized BOIN-ET: gBOIN-ET), and their&#10;combination (TITE-gBOIN-ET). The R package boinet implements the&#10;BOIN-ET design family. The package supports&#10;the conduct of simulation studies to assess operating characteristics&#10;of BOIN-ET, TITE-BOIN-ET, gBOIN-ET, and TITE-gBOIN-ET designs, where&#10;users can choose design parameters in flexible and straightforward&#10;ways depending on their own application. We demonstrate its capability&#10;and effectiveness using several simulation studies."/>
<meta property="twitter:url" content="https://doi.org/10.32614/RJ-2025-012/"/>

<!--  https://scholar.google.com/intl/en/scholar/inclusion.html#indexing -->
<meta name="citation_title" content="boinet: An R Package for Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes"/>
<meta name="citation_fulltext_html_url" content="https://doi.org/10.32614/RJ-2025-012"/>
<meta name="citation_pdf_url" content="RJ-2025-012.pdf"/>
<meta name="citation_volume" content="17"/>
<meta name="citation_issue" content="2"/>
<meta name="citation_doi" content="10.32614/RJ-2025-012"/>
<meta name="citation_journal_title" content="The R Journal"/>
<meta name="citation_issn" content="2073-4859"/>
<meta name="citation_firstpage" content="15"/>
<meta name="citation_lastpage" content="34"/>
<meta name="citation_fulltext_world_readable" content=""/>
<meta name="citation_online_date" content="2025/09/23"/>
<meta name="citation_publication_date" content="2025/09/23"/>
<meta name="citation_author" content="Yusuke Yamaguchi"/>
<meta name="citation_author_institution" content="Quantitative Sciences and Evidence Generation, Astellas Pharma Global&#10;Development, Inc."/>
<meta name="citation_author" content="Kentaro Takeda"/>
<meta name="citation_author_institution" content="Quantitative Sciences and Evidence Generation, Astellas Pharma Global&#10;Development, Inc."/>
<meta name="citation_author" content="Kazushi Maruo"/>
<meta name="citation_author_institution" content="Department of Biostatistics, Faculty of Medicine, University of&#10;Tsukuba"/>
<!--/radix_placeholder_meta_tags-->
  
  <meta name="citation_reference" content="citation_title=The joint i3+3 (Ji3+3) design for phase i/II adoptive cell therapy clinical trials;citation_volume=30;citation_author=Xiaolei Lin;citation_author=Yuan Ji"/>
  <meta name="citation_reference" content="citation_title=Dose-finding based on efficacy-toxicity trade-offs;citation_volume=60;citation_author=Peter F. Thall;citation_author=John D. Cook"/>
  <meta name="citation_reference" content="citation_title=Bayesian designs for phase i-II clinical trials;citation_publisher=Chapman; Hall/CRC;citation_author=Ying Yuan;citation_author=Hoang Q. Nguyen;citation_author=Peter F. Thall"/>
  <meta name="citation_reference" content="citation_title=Phase i/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization;citation_volume=27;citation_author=Marie-Karelle Riviere;citation_author=Ying Yuan;citation_author=Jacques-Henri Jourdan;citation_author=Frederic Dubois;citation_author=Sarah Zohar"/>
  <meta name="citation_reference" content="citation_title=TEPI-2 and UBI: Designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy;citation_volume=30;citation_author=Pin Li;citation_author=Rachael Liu;citation_author=Jianchang Lin;citation_author=Yuan Ji"/>
  <meta name="citation_reference" content="citation_title=Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology;citation_volume=30;citation_author=Xiaolei Lin;citation_author=Yuan Ji"/>
  <meta name="citation_reference" content="citation_title=BOIN12: Bayesian optimal interval phase i/II trial design for utility-based dose finding in immunotherapy and targeted therapies;citation_volume=4;citation_author=Ruitao Lin;citation_author=Yanhong Zhou;citation_author=Fangrong Yan;citation_author=Daniel Li;citation_author=Ying Yuan"/>
  <meta name="citation_reference" content="citation_title=Checkerboard: A Bayesian efficacy and toxicity interval design for phase i/II dose-finding trials;citation_volume=30;citation_author=Jun Yin;citation_author=Ying Yuan"/>
  <meta name="citation_reference" content="citation_title=U-shaped dose-responses in biology, toxicology, and public health;citation_volume=22;citation_author=Edward J. Calabrese;citation_author=Linda A. Baldwin"/>
  <meta name="citation_reference" content="citation_title=An overview of the optimal planning, design, and conduct of phase i studies of new therapeutics;citation_volume=16;citation_author=Patricia M. LoRusso;citation_author=Scott A. Boerner;citation_author=Lesley Seymour"/>
  <meta name="citation_reference" content="citation_title=Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer;citation_volume=8;citation_author=Andrew R. Reynolds"/>
  <meta name="citation_reference" content="citation_title=Clinical efficacy of the optimal biological dose in earlyphase trials of anti-cancer targeted therapies;citation_volume=120;citation_author=Pauline Corbaux;citation_author=Mevidette El-Madani;citation_author=Michel Tod;citation_author=Julien Peron;citation_author=Denis Maillet;citation_author=Jonathan Lopez;citation_author=Gilles Freyer;citation_author=Benoit You"/>
  <meta name="citation_reference" content="citation_title=Optimal biological dose: A systematic review in cancer phase i clinical trials;citation_volume=21;citation_author=Julien Fraisse;citation_author=Derek Dinart;citation_author=Diego Tosi;citation_author=Carine Bellera;citation_author=Caroline Mollevi"/>
  <meta name="citation_reference" content="citation_title=Clinical benefit in phase-i trials of novel molecularly targeted agents: Does dose matter?;citation_volume=100;citation_author=Sophie Postel-Vinay;citation_author=Hendrik-Tobias Arkenau;citation_author=David Olmos;citation_author=Joo Ern Ang;citation_author=Jorge Barriuso;citation_author=Shukuru Ashley;citation_author=Udoyan Banerji;citation_author=Johann De-Bono;citation_author=Ian Judson;citation_author=Stanley Kaye"/>
  <meta name="citation_reference" content="citation_title=Toxicities of immunotherapy for the practitioner;citation_volume=33;citation_author=Jeffrey S. Weber;citation_author=James C. Yang;citation_author=Michael B. Atkins;citation_author=Mary L. Disis"/>
  <meta name="citation_reference" content="citation_title=Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: Comparison of cytotoxic versus non-cytotoxic drugs;citation_volume=29;citation_author=Nicolas Penel;citation_author=Antoine Adenis;citation_author=Stephanie Clisant;citation_author=Jacques Bonneterre"/>
  <meta name="citation_reference" content="citation_title=BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes;citation_volume=17;citation_author=Kentaro Takeda;citation_author=Masataka Taguri;citation_author=Satoshi Morita"/>
  <meta name="citation_reference" content="citation_title=TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes;citation_volume=19;citation_author=Kentaro Takeda;citation_author=Satoshi Morita;citation_author=Masataka Taguri"/>
  <meta name="citation_reference" content="citation_title=TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades;citation_volume=21;citation_author=Kentaro Takeda;citation_author=Qing Xia;citation_author=Shufang Liu;citation_author=Alan Rong"/>
  <meta name="citation_reference" content="citation_title=GBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials;citation_volume=64;citation_author=Kentaro Takeda;citation_author=Satoshi Morita;citation_author=Masataka Taguri"/>
  <meta name="citation_reference" content="citation_title=TITE-gBOIN-ET: Time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes;citation_volume=64;citation_author=Kentaro Takeda;citation_author=Yusuke Yamaguchi;citation_author=Masataka Taguri;citation_author=Satoshi Morita"/>
  <meta name="citation_reference" content="citation_title=Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: A simulation study;citation_volume=34;citation_author=Yusuke Yamaguchi;citation_author=Kentaro Takeda;citation_author=Satoshi Yoshida;citation_author=Kazushi Maruo"/>
  <meta name="citation_reference" content="citation_title=Model-assisted designs for early-phase clinical trials: Simplicity meets superiority;citation_volume=3;citation_author=Ying Yuan;citation_author=J. Jack Lee;citation_author=Susan G. Hilsenbeck"/>
  <meta name="citation_reference" content="citation_title=The continual reassessment method for multiple toxicity grades: A Bayesian quasi-likelihood approach;citation_volume=63;citation_author=Ying Yuan;citation_author=Richard Chappell;citation_author=Howard Bailey"/>
  <meta name="citation_reference" content="citation_title=Isotonic regression in two independent variables;citation_volume=33;citation_author=Gordon Bril;citation_author=Richard Dykstra;citation_author=Carolyn Pillers;citation_author=Tim Robertson"/>
  <meta name="citation_reference" content="citation_title=STEIN: A simple toxicity and efficacy interval design for seamless phase i/II clinical trials;citation_volume=36;citation_author=Ruitao Lin;citation_author=Guosheng Yin"/>
  <meta name="citation_reference" content="citation_title=A utility-based Bayesian optimal interval (U-BOIN) phase i/II design to identify the optimal biological dose for targeted and immune therapies;citation_volume=38;citation_author=Yanhong Zhou;citation_author=J. Jack Lee;citation_author=Ying Yuan"/>
  <meta name="citation_reference" content="citation_title=Boinet: Conduct simulation study of Bayesian optimal interval design with BOIN-ET family;citation_author=Yusuke Yamaguchi;citation_author=Kentaro Takeda"/>
  <meta name="citation_reference" content="citation_title=Statistical inference under order restrictions: The theory and application of isotonic regression;citation_publisher=Wiley;citation_author=R. E. Barlow;citation_author=D. J. Bartholomew;citation_author=J. M. Bremner;citation_author=H. D. Brunk"/>
  <meta name="citation_reference" content="citation_title=Time-to-event model-assisted designs for dose-finding trials with delayed toxicity;citation_volume=21;citation_author=Ruitao Lin;citation_author=Ying Yuan"/>
  <meta name="citation_reference" content="citation_title=Keyboard: Bayesian designs for early phase clinical trials;citation_author=Xiaomeng Yuan;citation_author=Chen Li;citation_author=Hongying Sun;citation_author=Li Tang;citation_author=Haitao Pan"/>
  <meta name="citation_reference" content="citation_title=Escalation: A modular approach to dose-finding clinical trials;citation_author=Kristian Brock;citation_author=Daniel Slade;citation_author=Michael Sweeting"/>
  <meta name="citation_reference" content="citation_title=Combining ESA and Luspatercept in non-RS MDS patients having failed ESA - results of the phase 1-2 part a of the GFM combola study;citation_volume=144;citation_author=Lionel Ades;citation_author=Thomas Cluzeau;citation_author=Thibault Comont;citation_author=Lorea Aguinaga;citation_author=Aspasia Stamatoullas;citation_author=Mathieu Meunier;citation_author=Emmanuel Gyan;citation_author=Alice Garnier;citation_author=Maud D’Aveni;citation_author=Sylvain Thepot;citation_author=Marie Sebert;citation_author=Marius Moldovan;citation_author=Anouk Walter Petrich;citation_author=Karine Lemarie;citation_author=Fatiha Chermat;citation_author=Michaela Fontenay;citation_author=Sylvie Chevret;citation_author=Pierre Fenaux"/>
  <!--radix_placeholder_rmarkdown_metadata-->

<script type="text/json" id="radix-rmarkdown-metadata">
{"type":"list","attributes":{"names":{"type":"character","attributes":{},"value":["title","description","author","date","date_received","journal","volume","issue","slug","citation_url","packages","preview","bibliography","CTV","legacy_pdf","legacy_converted","output","draft","pdf_url","doi","creative_commons","csl","canonical_url"]}},"value":[{"type":"character","attributes":{},"value":["boinet: An R Package for Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes"]},{"type":"character","attributes":{},"value":["Bayesian optimal interval based on both efficacy and toxicity outcomes\n(BOIN-ET) design is a model-assisted oncology phase I/II trial design,\naiming to establish an optimal biological dose accounting for efficacy\nand toxicity in the framework of dose-finding. Some extensions of\nBOIN-ET design are also available to allow for time-to-event efficacy\nand toxicity outcomes based on cumulative and pending data\n(time-to-event BOIN-ET: TITE-BOIN-ET), ordinal graded efficacy and\ntoxicity outcomes (generalized BOIN-ET: gBOIN-ET), and their\ncombination (TITE-gBOIN-ET). The R package boinet implements the\nBOIN-ET design family. The package supports\nthe conduct of simulation studies to assess operating characteristics\nof BOIN-ET, TITE-BOIN-ET, gBOIN-ET, and TITE-gBOIN-ET designs, where\nusers can choose design parameters in flexible and straightforward\nways depending on their own application. We demonstrate its capability\nand effectiveness using several simulation studies."]},{"type":"list","attributes":{},"value":[{"type":"list","attributes":{"names":{"type":"character","attributes":{},"value":["name","affiliation","address"]}},"value":[{"type":"character","attributes":{},"value":["Yusuke Yamaguchi"]},{"type":"character","attributes":{},"value":["Quantitative Sciences and Evidence Generation, Astellas Pharma Global\nDevelopment, Inc."]},{"type":"character","attributes":{},"value":["2375 Waterview Drive, Northbrook, Illinois 60062","United States","[yusuke-yamaguchi@astellas.com](yusuke-yamaguchi@astellas.com){.uri}\n"]}]},{"type":"list","attributes":{"names":{"type":"character","attributes":{},"value":["name","affiliation","address"]}},"value":[{"type":"character","attributes":{},"value":["Kentaro Takeda"]},{"type":"character","attributes":{},"value":["Quantitative Sciences and Evidence Generation, Astellas Pharma Global\nDevelopment, Inc."]},{"type":"character","attributes":{},"value":["2375 Waterview Drive, Northbrook, Illinois 60062","United States","[kentaro.takeda@astellas.com](kentaro.takeda@astellas.com){.uri}\n"]}]},{"type":"list","attributes":{"names":{"type":"character","attributes":{},"value":["name","affiliation","address"]}},"value":[{"type":"character","attributes":{},"value":["Kazushi Maruo"]},{"type":"character","attributes":{},"value":["Department of Biostatistics, Faculty of Medicine, University of\nTsukuba"]},{"type":"character","attributes":{},"value":["1-1-1, Tennodai, Tsukuba, Ibaraki 305-8577","Japan","[kazushi.maruo@gmail.com](kazushi.maruo@gmail.com){.uri}\n"]}]}]},{"type":"character","attributes":{},"value":["2025-09-23"]},{"type":"character","attributes":{},"value":["2023-07-02"]},{"type":"list","attributes":{"names":{"type":"character","attributes":{},"value":["title","issn","firstpage","lastpage"]}},"value":[{"type":"character","attributes":{},"value":["The R Journal"]},{"type":"character","attributes":{},"value":["2073-4859"]},{"type":"integer","attributes":{},"value":[15]},{"type":"integer","attributes":{},"value":[34]}]},{"type":"integer","attributes":{},"value":[17]},{"type":"integer","attributes":{},"value":[2]},{"type":"character","attributes":{},"value":["RJ-2025-012"]},{"type":"character","attributes":{},"value":["https://doi.org/10.32614/RJ-2025-012"]},{"type":"list","attributes":{"names":{"type":"character","attributes":{},"value":["cran","bioc"]}},"value":[{"type":"character","attributes":{},"value":["boinet","Keyboard","escalation"]},{"type":"list","attributes":{},"value":[]}]},{"type":"character","attributes":{},"value":["preview.png"]},{"type":"character","attributes":{},"value":["RJ-boinet.bib"]},{"type":"character","attributes":{},"value":["ClinicalTrials"]},{"type":"logical","attributes":{},"value":[true]},{"type":"logical","attributes":{},"value":[true]},{"type":"list","attributes":{"names":{"type":"character","attributes":{},"value":["distill::distill_article"]}},"value":[{"type":"list","attributes":{"names":{"type":"character","attributes":{},"value":["self_contained","toc","mathjax","md_extension"]}},"value":[{"type":"logical","attributes":{},"value":[true]},{"type":"logical","attributes":{},"value":[false]},{"type":"character","attributes":{},"value":["https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml-full.js"]},{"type":"character","attributes":{},"value":["-tex_math_single_backslash"]}]}]},{"type":"logical","attributes":{},"value":[false]},{"type":"character","attributes":{},"value":["RJ-2025-012.pdf"]},{"type":"character","attributes":{},"value":["10.32614/RJ-2025-012"]},{"type":"character","attributes":{},"value":["CC BY"]},{"type":"character","attributes":{},"value":["/home/mitchell/R/x86_64-pc-linux-gnu-library/4.5/rjtools/rjournal.csl"]},{"type":"character","attributes":{},"value":["https://doi.org/10.32614/RJ-2025-012/"]}]}
</script>
<!--/radix_placeholder_rmarkdown_metadata-->
  
  <script type="text/json" id="radix-resource-manifest">
  {"type":"character","attributes":{},"value":["figure1.png","RJ-2025-012_files/anchor-4.2.2/anchor.min.js","RJ-2025-012_files/bowser-1.9.3/bowser.min.js","RJ-2025-012_files/distill-2.2.21/template.v2.js","RJ-2025-012_files/header-attrs-2.29/header-attrs.js","RJ-2025-012_files/jquery-3.6.0/jquery-3.6.0.js","RJ-2025-012_files/jquery-3.6.0/jquery-3.6.0.min.js","RJ-2025-012_files/jquery-3.6.0/jquery-3.6.0.min.map","RJ-2025-012_files/popper-2.6.0/popper.min.js","RJ-2025-012_files/tippy-6.2.7/tippy-bundle.umd.min.js","RJ-2025-012_files/tippy-6.2.7/tippy-light-border.css","RJ-2025-012_files/tippy-6.2.7/tippy.css","RJ-2025-012_files/tippy-6.2.7/tippy.umd.min.js","RJ-2025-012_files/webcomponents-2.0.0/webcomponents.js","RJ-2025-012.pdf","RJ-boinet.bib","RJ-boinet.tex","RJournal.sty","RJwrapper.log","RJwrapper.tex"]}
  </script>
  <!--radix_placeholder_navigation_in_header-->
<meta name="distill:offset" content="../.."/>

<script type="application/javascript">

  window.headroom_prevent_pin = false;

  window.document.addEventListener("DOMContentLoaded", function (event) {

    // initialize headroom for banner
    var header = $('header').get(0);
    var headerHeight = header.offsetHeight;
    var headroom = new Headroom(header, {
      tolerance: 5,
      onPin : function() {
        if (window.headroom_prevent_pin) {
          window.headroom_prevent_pin = false;
          headroom.unpin();
        }
      }
    });
    headroom.init();
    if(window.location.hash)
      headroom.unpin();
    $(header).addClass('headroom--transition');

    // offset scroll location for banner on hash change
    // (see: https://github.com/WickyNilliams/headroom.js/issues/38)
    window.addEventListener("hashchange", function(event) {
      window.scrollTo(0, window.pageYOffset - (headerHeight + 25));
    });

    // responsive menu
    $('.distill-site-header').each(function(i, val) {
      var topnav = $(this);
      var toggle = topnav.find('.nav-toggle');
      toggle.on('click', function() {
        topnav.toggleClass('responsive');
      });
    });

    // nav dropdowns
    $('.nav-dropbtn').click(function(e) {
      $(this).next('.nav-dropdown-content').toggleClass('nav-dropdown-active');
      $(this).parent().siblings('.nav-dropdown')
         .children('.nav-dropdown-content').removeClass('nav-dropdown-active');
    });
    $("body").click(function(e){
      $('.nav-dropdown-content').removeClass('nav-dropdown-active');
    });
    $(".nav-dropdown").click(function(e){
      e.stopPropagation();
    });
  });
</script>

<style type="text/css">

/* Theme (user-documented overrideables for nav appearance) */

.distill-site-nav {
  color: rgba(255, 255, 255, 0.8);
  background-color: #0F2E3D;
  font-size: 15px;
  font-weight: 300;
}

.distill-site-nav a {
  color: inherit;
  text-decoration: none;
}

.distill-site-nav a:hover {
  color: white;
}

@media print {
  .distill-site-nav {
    display: none;
  }
}

.distill-site-header {

}

.distill-site-footer {

}


/* Site Header */

.distill-site-header {
  width: 100%;
  box-sizing: border-box;
  z-index: 3;
}

.distill-site-header .nav-left {
  display: inline-block;
  margin-left: 8px;
}

@media screen and (max-width: 768px) {
  .distill-site-header .nav-left {
    margin-left: 0;
  }
}


.distill-site-header .nav-right {
  float: right;
  margin-right: 8px;
}

.distill-site-header a,
.distill-site-header .title {
  display: inline-block;
  text-align: center;
  padding: 14px 10px 14px 10px;
}

.distill-site-header .title {
  font-size: 18px;
  min-width: 150px;
}

.distill-site-header .logo {
  padding: 0;
}

.distill-site-header .logo img {
  display: none;
  max-height: 20px;
  width: auto;
  margin-bottom: -4px;
}

.distill-site-header .nav-image img {
  max-height: 18px;
  width: auto;
  display: inline-block;
  margin-bottom: -3px;
}



@media screen and (min-width: 1000px) {
  .distill-site-header .logo img {
    display: inline-block;
  }
  .distill-site-header .nav-left {
    margin-left: 20px;
  }
  .distill-site-header .nav-right {
    margin-right: 20px;
  }
  .distill-site-header .title {
    padding-left: 12px;
  }
}


.distill-site-header .nav-toggle {
  display: none;
}

.nav-dropdown {
  display: inline-block;
  position: relative;
}

.nav-dropdown .nav-dropbtn {
  border: none;
  outline: none;
  color: rgba(255, 255, 255, 0.8);
  padding: 16px 10px;
  background-color: transparent;
  font-family: inherit;
  font-size: inherit;
  font-weight: inherit;
  margin: 0;
  margin-top: 1px;
  z-index: 2;
}

.nav-dropdown-content {
  display: none;
  position: absolute;
  background-color: white;
  min-width: 200px;
  border: 1px solid rgba(0,0,0,0.15);
  border-radius: 4px;
  box-shadow: 0px 8px 16px 0px rgba(0,0,0,0.1);
  z-index: 1;
  margin-top: 2px;
  white-space: nowrap;
  padding-top: 4px;
  padding-bottom: 4px;
}

.nav-dropdown-content hr {
  margin-top: 4px;
  margin-bottom: 4px;
  border: none;
  border-bottom: 1px solid rgba(0, 0, 0, 0.1);
}

.nav-dropdown-active {
  display: block;
}

.nav-dropdown-content a, .nav-dropdown-content .nav-dropdown-header {
  color: black;
  padding: 6px 24px;
  text-decoration: none;
  display: block;
  text-align: left;
}

.nav-dropdown-content .nav-dropdown-header {
  display: block;
  padding: 5px 24px;
  padding-bottom: 0;
  text-transform: uppercase;
  font-size: 14px;
  color: #999999;
  white-space: nowrap;
}

.nav-dropdown:hover .nav-dropbtn {
  color: white;
}

.nav-dropdown-content a:hover {
  background-color: #ddd;
  color: black;
}

.nav-right .nav-dropdown-content {
  margin-left: -45%;
  right: 0;
}

@media screen and (max-width: 768px) {
  .distill-site-header a, .distill-site-header .nav-dropdown  {display: none;}
  .distill-site-header a.nav-toggle {
    float: right;
    display: block;
  }
  .distill-site-header .title {
    margin-left: 0;
  }
  .distill-site-header .nav-right {
    margin-right: 0;
  }
  .distill-site-header {
    overflow: hidden;
  }
  .nav-right .nav-dropdown-content {
    margin-left: 0;
  }
}


@media screen and (max-width: 768px) {
  .distill-site-header.responsive {position: relative; min-height: 500px; }
  .distill-site-header.responsive a.nav-toggle {
    position: absolute;
    right: 0;
    top: 0;
  }
  .distill-site-header.responsive a,
  .distill-site-header.responsive .nav-dropdown {
    display: block;
    text-align: left;
  }
  .distill-site-header.responsive .nav-left,
  .distill-site-header.responsive .nav-right {
    width: 100%;
  }
  .distill-site-header.responsive .nav-dropdown {float: none;}
  .distill-site-header.responsive .nav-dropdown-content {position: relative;}
  .distill-site-header.responsive .nav-dropdown .nav-dropbtn {
    display: block;
    width: 100%;
    text-align: left;
  }
}

/* Site Footer */

.distill-site-footer {
  width: 100%;
  overflow: hidden;
  box-sizing: border-box;
  z-index: 3;
  margin-top: 30px;
  padding-top: 30px;
  padding-bottom: 30px;
  text-align: center;
}

/* Headroom */

d-title {
  padding-top: 6rem;
}

@media print {
  d-title {
    padding-top: 4rem;
  }
}

.headroom {
  z-index: 1000;
  position: fixed;
  top: 0;
  left: 0;
  right: 0;
}

.headroom--transition {
  transition: all .4s ease-in-out;
}

.headroom--unpinned {
  top: -100px;
}

.headroom--pinned {
  top: 0;
}

/* adjust viewport for navbar height */
/* helps vertically center bootstrap (non-distill) content */
.min-vh-100 {
  min-height: calc(100vh - 100px) !important;
}

</style>

<script src="../../site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<link href="../../site_libs/font-awesome-6.5.2/css/all.min.css" rel="stylesheet"/>
<link href="../../site_libs/font-awesome-6.5.2/css/v4-shims.min.css" rel="stylesheet"/>
<script src="../../site_libs/headroom-0.9.4/headroom.min.js"></script>
<!--/radix_placeholder_navigation_in_header-->
  <!--radix_placeholder_distill-->

<style type="text/css">

body {
  background-color: white;
}

.pandoc-table {
  width: 100%;
}

.pandoc-table>caption {
  margin-bottom: 10px;
}

.pandoc-table th:not([align]) {
  text-align: left;
}

.pagedtable-footer {
  font-size: 15px;
}

d-byline .byline {
  grid-template-columns: 2fr 2fr;
}

d-byline .byline h3 {
  margin-block-start: 1.5em;
}

d-byline .byline .authors-affiliations h3 {
  margin-block-start: 0.5em;
}

.authors-affiliations .orcid-id {
  width: 16px;
  height:16px;
  margin-left: 4px;
  margin-right: 4px;
  vertical-align: middle;
  padding-bottom: 2px;
}

d-title .dt-tags {
  margin-top: 1em;
  grid-column: text;
}

.dt-tags .dt-tag {
  text-decoration: none;
  display: inline-block;
  color: rgba(0,0,0,0.6);
  padding: 0em 0.4em;
  margin-right: 0.5em;
  margin-bottom: 0.4em;
  font-size: 70%;
  border: 1px solid rgba(0,0,0,0.2);
  border-radius: 3px;
  text-transform: uppercase;
  font-weight: 500;
}

d-article table.gt_table td,
d-article table.gt_table th {
  border-bottom: none;
  font-size: 100%;
}

.html-widget {
  margin-bottom: 2.0em;
}

.l-screen-inset {
  padding-right: 16px;
}

.l-screen .caption {
  margin-left: 10px;
}

.shaded {
  background: rgb(247, 247, 247);
  padding-top: 20px;
  padding-bottom: 20px;
  border-top: 1px solid rgba(0, 0, 0, 0.1);
  border-bottom: 1px solid rgba(0, 0, 0, 0.1);
}

.shaded .html-widget {
  margin-bottom: 0;
  border: 1px solid rgba(0, 0, 0, 0.1);
}

.shaded .shaded-content {
  background: white;
}

.text-output {
  margin-top: 0;
  line-height: 1.5em;
}

.hidden {
  display: none !important;
}

hr.section-separator {
  border: none;
  border-top: 1px solid rgba(0, 0, 0, 0.1);
  margin: 0px;
}


d-byline {
  border-top: none;
}

d-article {
  padding-top: 2.5rem;
  padding-bottom: 30px;
  border-top: none;
}

d-appendix {
  padding-top: 30px;
}

d-article>p>img {
  width: 100%;
}

d-article h2 {
  margin: 1rem 0 1.5rem 0;
}

d-article h3 {
  margin-top: 1.5rem;
}

d-article iframe {
  border: 1px solid rgba(0, 0, 0, 0.1);
  margin-bottom: 2.0em;
  width: 100%;
}

/* Tweak code blocks */

d-article div.sourceCode code,
d-article pre code {
  font-family: Consolas, Monaco, 'Andale Mono', 'Ubuntu Mono', monospace;
}

d-article pre,
d-article div.sourceCode,
d-article div.sourceCode pre {
  overflow: auto;
}

d-article div.sourceCode {
  background-color: white;
}

d-article div.sourceCode pre {
  padding-left: 10px;
  font-size: 12px;
  border-left: 2px solid rgba(0,0,0,0.1);
}

d-article pre {
  font-size: 12px;
  color: black;
  background: none;
  margin-top: 0;
  text-align: left;
  white-space: pre;
  word-spacing: normal;
  word-break: normal;
  word-wrap: normal;
  line-height: 1.5;

  -moz-tab-size: 4;
  -o-tab-size: 4;
  tab-size: 4;

  -webkit-hyphens: none;
  -moz-hyphens: none;
  -ms-hyphens: none;
  hyphens: none;
}

d-article pre a {
  border-bottom: none;
}

d-article pre a:hover {
  border-bottom: none;
  text-decoration: underline;
}

d-article details {
  grid-column: text;
  margin-bottom: 0.8em;
}

@media(min-width: 768px) {

d-article pre,
d-article div.sourceCode,
d-article div.sourceCode pre {
  overflow: visible !important;
}

d-article div.sourceCode pre {
  padding-left: 18px;
  font-size: 14px;
}

/* tweak for Pandoc numbered line within distill */
d-article pre.numberSource code > span {
    left: -2em;
}

d-article pre {
  font-size: 14px;
}

}

figure img.external {
  background: white;
  border: 1px solid rgba(0, 0, 0, 0.1);
  box-shadow: 0 1px 8px rgba(0, 0, 0, 0.1);
  padding: 18px;
  box-sizing: border-box;
}

/* CSS for d-contents */

.d-contents {
  grid-column: text;
  color: rgba(0,0,0,0.8);
  font-size: 0.9em;
  padding-bottom: 1em;
  margin-bottom: 1em;
  padding-bottom: 0.5em;
  margin-bottom: 1em;
  padding-left: 0.25em;
  justify-self: start;
}

@media(min-width: 1000px) {
  .d-contents.d-contents-float {
    height: 0;
    grid-column-start: 1;
    grid-column-end: 4;
    justify-self: center;
    padding-right: 3em;
    padding-left: 2em;
  }
}

.d-contents nav h3 {
  font-size: 18px;
  margin-top: 0;
  margin-bottom: 1em;
}

.d-contents li {
  list-style-type: none
}

.d-contents nav > ul {
  padding-left: 0;
}

.d-contents ul {
  padding-left: 1em
}

.d-contents nav ul li {
  margin-top: 0.6em;
  margin-bottom: 0.2em;
}

.d-contents nav a {
  font-size: 13px;
  border-bottom: none;
  text-decoration: none
  color: rgba(0, 0, 0, 0.8);
}

.d-contents nav a:hover {
  text-decoration: underline solid rgba(0, 0, 0, 0.6)
}

.d-contents nav > ul > li > a {
  font-weight: 600;
}

.d-contents nav > ul > li > ul {
  font-weight: inherit;
}

.d-contents nav > ul > li > ul > li {
  margin-top: 0.2em;
}


.d-contents nav ul {
  margin-top: 0;
  margin-bottom: 0.25em;
}

.d-article-with-toc h2:nth-child(2) {
  margin-top: 0;
}


/* Figure */

.figure {
  position: relative;
  margin-bottom: 2.5em;
  margin-top: 1.5em;
}

.figure .caption {
  color: rgba(0, 0, 0, 0.6);
  font-size: 12px;
  line-height: 1.5em;
}

.figure img.external {
  background: white;
  border: 1px solid rgba(0, 0, 0, 0.1);
  box-shadow: 0 1px 8px rgba(0, 0, 0, 0.1);
  padding: 18px;
  box-sizing: border-box;
}

.figure .caption a {
  color: rgba(0, 0, 0, 0.6);
}

.figure .caption b,
.figure .caption strong, {
  font-weight: 600;
  color: rgba(0, 0, 0, 1.0);
}

/* Citations */

d-article .citation {
  color: inherit;
  cursor: inherit;
}

div.hanging-indent{
  margin-left: 1em; text-indent: -1em;
}

/* Citation hover box */

.tippy-box[data-theme~=light-border] {
  background-color: rgba(250, 250, 250, 0.95);
}

.tippy-content > p {
  margin-bottom: 0;
  padding: 2px;
}


/* Tweak 1000px media break to show more text */

@media(min-width: 1000px) {
  .base-grid,
  distill-header,
  d-title,
  d-abstract,
  d-article,
  d-appendix,
  distill-appendix,
  d-byline,
  d-footnote-list,
  d-citation-list,
  distill-footer {
    grid-template-columns: [screen-start] 1fr [page-start kicker-start] 80px [middle-start] 50px [text-start kicker-end] 65px 65px 65px 65px 65px 65px 65px 65px [text-end gutter-start] 65px [middle-end] 65px [page-end gutter-end] 1fr [screen-end];
    grid-column-gap: 16px;
  }

  .grid {
    grid-column-gap: 16px;
  }

  d-article {
    font-size: 1.06rem;
    line-height: 1.7em;
  }
  figure .caption, .figure .caption, figure figcaption {
    font-size: 13px;
  }
}

@media(min-width: 1180px) {
  .base-grid,
  distill-header,
  d-title,
  d-abstract,
  d-article,
  d-appendix,
  distill-appendix,
  d-byline,
  d-footnote-list,
  d-citation-list,
  distill-footer {
    grid-template-columns: [screen-start] 1fr [page-start kicker-start] 60px [middle-start] 60px [text-start kicker-end] 60px 60px 60px 60px 60px 60px 60px 60px [text-end gutter-start] 60px [middle-end] 60px [page-end gutter-end] 1fr [screen-end];
    grid-column-gap: 32px;
  }

  .grid {
    grid-column-gap: 32px;
  }
}


/* Get the citation styles for the appendix (not auto-injected on render since
   we do our own rendering of the citation appendix) */

d-appendix .citation-appendix,
.d-appendix .citation-appendix {
  font-size: 11px;
  line-height: 15px;
  border-left: 1px solid rgba(0, 0, 0, 0.1);
  padding-left: 18px;
  border: 1px solid rgba(0,0,0,0.1);
  background: rgba(0, 0, 0, 0.02);
  padding: 10px 18px;
  border-radius: 3px;
  color: rgba(150, 150, 150, 1);
  overflow: hidden;
  margin-top: -12px;
  white-space: pre-wrap;
  word-wrap: break-word;
}

/* Include appendix styles here so they can be overridden */

d-appendix {
  contain: layout style;
  font-size: 0.8em;
  line-height: 1.7em;
  margin-top: 60px;
  margin-bottom: 0;
  border-top: 1px solid rgba(0, 0, 0, 0.1);
  color: rgba(0,0,0,0.5);
  padding-top: 60px;
  padding-bottom: 48px;
}

d-appendix h3 {
  grid-column: page-start / text-start;
  font-size: 15px;
  font-weight: 500;
  margin-top: 1em;
  margin-bottom: 0;
  color: rgba(0,0,0,0.65);
}

d-appendix h3 + * {
  margin-top: 1em;
}

d-appendix ol {
  padding: 0 0 0 15px;
}

@media (min-width: 768px) {
  d-appendix ol {
    padding: 0 0 0 30px;
    margin-left: -30px;
  }
}

d-appendix li {
  margin-bottom: 1em;
}

d-appendix a {
  color: rgba(0, 0, 0, 0.6);
}

d-appendix > * {
  grid-column: text;
}

d-appendix > d-footnote-list,
d-appendix > d-citation-list,
d-appendix > distill-appendix {
  grid-column: screen;
}

/* Include footnote styles here so they can be overridden */

d-footnote-list {
  contain: layout style;
}

d-footnote-list > * {
  grid-column: text;
}

d-footnote-list a.footnote-backlink {
  color: rgba(0,0,0,0.3);
  padding-left: 0.5em;
}



/* Anchor.js */

.anchorjs-link {
  /*transition: all .25s linear; */
  text-decoration: none;
  border-bottom: none;
}
*:hover > .anchorjs-link {
  margin-left: -1.125em !important;
  text-decoration: none;
  border-bottom: none;
}

/* Social footer */

.social_footer {
  margin-top: 30px;
  margin-bottom: 0;
  color: rgba(0,0,0,0.67);
}

.disqus-comments {
  margin-right: 30px;
}

.disqus-comment-count {
  border-bottom: 1px solid rgba(0, 0, 0, 0.4);
  cursor: pointer;
}

#disqus_thread {
  margin-top: 30px;
}

.article-sharing a {
  border-bottom: none;
  margin-right: 8px;
}

.article-sharing a:hover {
  border-bottom: none;
}

.sidebar-section.subscribe {
  font-size: 12px;
  line-height: 1.6em;
}

.subscribe p {
  margin-bottom: 0.5em;
}


.article-footer .subscribe {
  font-size: 15px;
  margin-top: 45px;
}


.sidebar-section.custom {
  font-size: 12px;
  line-height: 1.6em;
}

.custom p {
  margin-bottom: 0.5em;
}

/* Styles for listing layout (hide title) */
.layout-listing d-title, .layout-listing .d-title {
  display: none;
}

/* Styles for posts lists (not auto-injected) */


.posts-with-sidebar {
  padding-left: 45px;
  padding-right: 45px;
}

.posts-list .description h2,
.posts-list .description p {
  font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", Arial, sans-serif;
}

.posts-list .description h2 {
  font-weight: 700;
  border-bottom: none;
  padding-bottom: 0;
}

.posts-list h2.post-tag {
  border-bottom: 1px solid rgba(0, 0, 0, 0.2);
  padding-bottom: 12px;
}
.posts-list {
  margin-top: 60px;
  margin-bottom: 24px;
}

.posts-list .post-preview {
  text-decoration: none;
  overflow: hidden;
  display: block;
  border-bottom: 1px solid rgba(0, 0, 0, 0.1);
  padding: 24px 0;
}

.post-preview-last {
  border-bottom: none !important;
}

.posts-list .posts-list-caption {
  grid-column: screen;
  font-weight: 400;
}

.posts-list .post-preview h2 {
  margin: 0 0 6px 0;
  line-height: 1.2em;
  font-style: normal;
  font-size: 24px;
}

.posts-list .post-preview p {
  margin: 0 0 12px 0;
  line-height: 1.4em;
  font-size: 16px;
}

.posts-list .post-preview .thumbnail {
  box-sizing: border-box;
  margin-bottom: 24px;
  position: relative;
  max-width: 500px;
}
.posts-list .post-preview img {
  width: 100%;
  display: block;
}

.posts-list .metadata {
  font-size: 12px;
  line-height: 1.4em;
  margin-bottom: 18px;
}

.posts-list .metadata > * {
  display: inline-block;
}

.posts-list .metadata .publishedDate {
  margin-right: 2em;
}

.posts-list .metadata .dt-authors {
  display: block;
  margin-top: 0.3em;
  margin-right: 2em;
}

.posts-list .dt-tags {
  display: block;
  line-height: 1em;
}

.posts-list .dt-tags .dt-tag {
  display: inline-block;
  color: rgba(0,0,0,0.6);
  padding: 0.3em 0.4em;
  margin-right: 0.2em;
  margin-bottom: 0.4em;
  font-size: 60%;
  border: 1px solid rgba(0,0,0,0.2);
  border-radius: 3px;
  text-transform: uppercase;
  font-weight: 500;
}

.posts-list img {
  opacity: 1;
}

.posts-list img[data-src] {
  opacity: 0;
}

.posts-more {
  clear: both;
}


.posts-sidebar {
  font-size: 16px;
}

.posts-sidebar h3 {
  font-size: 16px;
  margin-top: 0;
  margin-bottom: 0.5em;
  font-weight: 400;
  text-transform: uppercase;
}

.sidebar-section {
  margin-bottom: 30px;
}

.categories ul {
  list-style-type: none;
  margin: 0;
  padding: 0;
}

.categories li {
  color: rgba(0, 0, 0, 0.8);
  margin-bottom: 0;
}

.categories li>a {
  border-bottom: none;
}

.categories li>a:hover {
  border-bottom: 1px solid rgba(0, 0, 0, 0.4);
}

.categories .active {
  font-weight: 600;
}

.categories .category-count {
  color: rgba(0, 0, 0, 0.4);
}


@media(min-width: 768px) {
  .posts-list .post-preview h2 {
    font-size: 26px;
  }
  .posts-list .post-preview .thumbnail {
    float: right;
    width: 30%;
    margin-bottom: 0;
  }
  .posts-list .post-preview .description {
    float: left;
    width: 45%;
  }
  .posts-list .post-preview .metadata {
    float: left;
    width: 20%;
    margin-top: 8px;
  }
  .posts-list .post-preview p {
    margin: 0 0 12px 0;
    line-height: 1.5em;
    font-size: 16px;
  }
  .posts-with-sidebar .posts-list {
    float: left;
    width: 75%;
  }
  .posts-with-sidebar .posts-sidebar {
    float: right;
    width: 20%;
    margin-top: 60px;
    padding-top: 24px;
    padding-bottom: 24px;
  }
}


/* Improve display for browsers without grid (IE/Edge <= 15) */

.downlevel {
  line-height: 1.6em;
  font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", Arial, sans-serif;
  margin: 0;
}

.downlevel .d-title {
  padding-top: 6rem;
  padding-bottom: 1.5rem;
}

.downlevel .d-title h1 {
  font-size: 50px;
  font-weight: 700;
  line-height: 1.1em;
  margin: 0 0 0.5rem;
}

.downlevel .d-title p {
  font-weight: 300;
  font-size: 1.2rem;
  line-height: 1.55em;
  margin-top: 0;
}

.downlevel .d-byline {
  padding-top: 0.8em;
  padding-bottom: 0.8em;
  font-size: 0.8rem;
  line-height: 1.8em;
}

.downlevel .section-separator {
  border: none;
  border-top: 1px solid rgba(0, 0, 0, 0.1);
}

.downlevel .d-article {
  font-size: 1.06rem;
  line-height: 1.7em;
  padding-top: 1rem;
  padding-bottom: 2rem;
}


.downlevel .d-appendix {
  padding-left: 0;
  padding-right: 0;
  max-width: none;
  font-size: 0.8em;
  line-height: 1.7em;
  margin-bottom: 0;
  color: rgba(0,0,0,0.5);
  padding-top: 40px;
  padding-bottom: 48px;
}

.downlevel .footnotes ol {
  padding-left: 13px;
}

.downlevel .base-grid,
.downlevel .distill-header,
.downlevel .d-title,
.downlevel .d-abstract,
.downlevel .d-article,
.downlevel .d-appendix,
.downlevel .distill-appendix,
.downlevel .d-byline,
.downlevel .d-footnote-list,
.downlevel .d-citation-list,
.downlevel .distill-footer,
.downlevel .appendix-bottom,
.downlevel .posts-container {
  padding-left: 40px;
  padding-right: 40px;
}

@media(min-width: 768px) {
  .downlevel .base-grid,
  .downlevel .distill-header,
  .downlevel .d-title,
  .downlevel .d-abstract,
  .downlevel .d-article,
  .downlevel .d-appendix,
  .downlevel .distill-appendix,
  .downlevel .d-byline,
  .downlevel .d-footnote-list,
  .downlevel .d-citation-list,
  .downlevel .distill-footer,
  .downlevel .appendix-bottom,
  .downlevel .posts-container {
  padding-left: 150px;
  padding-right: 150px;
  max-width: 900px;
}
}

.downlevel pre code {
  display: block;
  border-left: 2px solid rgba(0, 0, 0, .1);
  padding: 0 0 0 20px;
  font-size: 14px;
}

.downlevel code, .downlevel pre {
  color: black;
  background: none;
  font-family: Consolas, Monaco, 'Andale Mono', 'Ubuntu Mono', monospace;
  text-align: left;
  white-space: pre;
  word-spacing: normal;
  word-break: normal;
  word-wrap: normal;
  line-height: 1.5;

  -moz-tab-size: 4;
  -o-tab-size: 4;
  tab-size: 4;

  -webkit-hyphens: none;
  -moz-hyphens: none;
  -ms-hyphens: none;
  hyphens: none;
}

.downlevel .posts-list .post-preview {
  color: inherit;
}



</style>

<script type="application/javascript">

function is_downlevel_browser() {
  if (bowser.isUnsupportedBrowser({ msie: "12", msedge: "16"},
                                 window.navigator.userAgent)) {
    return true;
  } else {
    return window.load_distill_framework === undefined;
  }
}

// show body when load is complete
function on_load_complete() {

  // add anchors
  if (window.anchors) {
    window.anchors.options.placement = 'left';
    window.anchors.add('d-article > h2, d-article > h3, d-article > h4, d-article > h5');
  }


  // set body to visible
  document.body.style.visibility = 'visible';

  // force redraw for leaflet widgets
  if (window.HTMLWidgets) {
    var maps = window.HTMLWidgets.findAll(".leaflet");
    $.each(maps, function(i, el) {
      var map = this.getMap();
      map.invalidateSize();
      map.eachLayer(function(layer) {
        if (layer instanceof L.TileLayer)
          layer.redraw();
      });
    });
  }

  // trigger 'shown' so htmlwidgets resize
  $('d-article').trigger('shown');
}

function init_distill() {

  init_common();

  // create front matter
  var front_matter = $('<d-front-matter></d-front-matter>');
  $('#distill-front-matter').wrap(front_matter);

  // create d-title
  $('.d-title').changeElementType('d-title');

  // separator
  var separator = '<hr class="section-separator" style="clear: both"/>';
  // prepend separator above appendix
  $('.d-byline').before(separator);
  $('.d-article').before(separator);

  // create d-byline
  var byline = $('<d-byline></d-byline>');
  $('.d-byline').replaceWith(byline);

  // create d-article
  var article = $('<d-article></d-article>');
  $('.d-article').wrap(article).children().unwrap();

  // move posts container into article
  $('.posts-container').appendTo($('d-article'));

  // create d-appendix
  $('.d-appendix').changeElementType('d-appendix');

  // flag indicating that we have appendix items
  var appendix = $('.appendix-bottom').children('h3').length > 0;

  // replace footnotes with <d-footnote>
  $('.footnote-ref').each(function(i, val) {
    appendix = true;
    var href = $(this).attr('href');
    var id = href.replace('#', '');
    var fn = $('#' + id);
    var fn_p = $('#' + id + '>p');
    fn_p.find('.footnote-back').remove();
    var text = fn_p.html();
    var dtfn = $('<d-footnote></d-footnote>');
    dtfn.html(text);
    $(this).replaceWith(dtfn);
  });
  // remove footnotes
  $('.footnotes').remove();

  // move refs into #references-listing
  $('#references-listing').replaceWith($('#refs'));

  $('h1.appendix, h2.appendix').each(function(i, val) {
    $(this).changeElementType('h3');
  });
  $('h3.appendix').each(function(i, val) {
    var id = $(this).attr('id');
    $('.d-contents a[href="#' + id + '"]').parent().remove();
    appendix = true;
    $(this).nextUntil($('h1, h2, h3')).addBack().appendTo($('d-appendix'));
  });

  // show d-appendix if we have appendix content
  $("d-appendix").css('display', appendix ? 'grid' : 'none');

  // localize layout chunks to just output
  $('.layout-chunk').each(function(i, val) {

    // capture layout
    var layout = $(this).attr('data-layout');

    // apply layout to markdown level block elements
    var elements = $(this).children().not('details, div.sourceCode, pre, script');
    elements.each(function(i, el) {
      var layout_div = $('<div class="' + layout + '"></div>');
      if (layout_div.hasClass('shaded')) {
        var shaded_content = $('<div class="shaded-content"></div>');
        $(this).wrap(shaded_content);
        $(this).parent().wrap(layout_div);
      } else {
        $(this).wrap(layout_div);
      }
    });


    // unwrap the layout-chunk div
    $(this).children().unwrap();
  });

  // remove code block used to force  highlighting css
  $('.distill-force-highlighting-css').parent().remove();

  // remove empty line numbers inserted by pandoc when using a
  // custom syntax highlighting theme, except when numbering line
  // in code chunk
  $('pre:not(.numberLines) code.sourceCode a:empty').remove();

  // load distill framework
  load_distill_framework();

  // wait for window.distillRunlevel == 4 to do post processing
  function distill_post_process() {

    if (!window.distillRunlevel || window.distillRunlevel < 4)
      return;

    // hide author/affiliations entirely if we have no authors
    var front_matter = JSON.parse($("#distill-front-matter").html());
    var have_authors = front_matter.authors && front_matter.authors.length > 0;
    if (!have_authors)
      $('d-byline').addClass('hidden');

    // article with toc class
    $('.d-contents').parent().addClass('d-article-with-toc');

    // strip links that point to #
    $('.authors-affiliations').find('a[href="#"]').removeAttr('href');

    // add orcid ids
    $('.authors-affiliations').find('.author').each(function(i, el) {
      var orcid_id = front_matter.authors[i].orcidID;
      var author_name = front_matter.authors[i].author
      if (orcid_id) {
        var a = $('<a></a>');
        a.attr('href', 'https://orcid.org/' + orcid_id);
        var img = $('<img></img>');
        img.addClass('orcid-id');
        img.attr('alt', author_name ? 'ORCID ID for ' + author_name : 'ORCID ID');
        img.attr('src','data:image/png;base64,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');
        a.append(img);
        $(this).append(a);
      }
    });

    // hide elements of author/affiliations grid that have no value
    function hide_byline_column(caption) {
      $('d-byline').find('h3:contains("' + caption + '")').parent().css('visibility', 'hidden');
    }

    // affiliations
    var have_affiliations = false;
    for (var i = 0; i<front_matter.authors.length; ++i) {
      var author = front_matter.authors[i];
      if (author.affiliation !== "&nbsp;") {
        have_affiliations = true;
        break;
      }
    }
    if (!have_affiliations)
      $('d-byline').find('h3:contains("Affiliations")').css('visibility', 'hidden');

    // published date
    if (!front_matter.publishedDate)
      hide_byline_column("Published");

    // document object identifier
    var doi = $('d-byline').find('h3:contains("DOI")');
    var doi_p = doi.next().empty();
    if (!front_matter.doi) {
      // if we have a citation and valid citationText then link to that
      if ($('#citation').length > 0 && front_matter.citationText) {
        doi.html('Citation');
        $('<a href="#citation"></a>')
          .text(front_matter.citationText)
          .appendTo(doi_p);
      } else {
        hide_byline_column("DOI");
      }
    } else {
      $('<a></a>')
         .attr('href', "https://doi.org/" + front_matter.doi)
         .html(front_matter.doi)
         .appendTo(doi_p);
    }

     // change plural form of authors/affiliations
    if (front_matter.authors.length === 1) {
      var grid = $('.authors-affiliations');
      grid.children('h3:contains("Authors")').text('Author');
      grid.children('h3:contains("Affiliations")').text('Affiliation');
    }

    // remove d-appendix and d-footnote-list local styles
    $('d-appendix > style:first-child').remove();
    $('d-footnote-list > style:first-child').remove();

    // move appendix-bottom entries to the bottom
    $('.appendix-bottom').appendTo('d-appendix').children().unwrap();
    $('.appendix-bottom').remove();

    // hoverable references
    $('span.citation[data-cites]').each(function() {
      const citeChild = $(this).children()[0]
      // Do not process if @xyz has been used without escaping and without bibliography activated
      // https://github.com/rstudio/distill/issues/466
      if (citeChild === undefined) return true

      if (citeChild.nodeName == "D-FOOTNOTE") {
        var fn = citeChild
        $(this).html(fn.shadowRoot.querySelector("sup"))
        $(this).id = fn.id
        fn.remove()
      }
      var refs = $(this).attr('data-cites').split(" ");
      var refHtml = refs.map(function(ref) {
        // Could use CSS.escape too here, we insure backward compatibility in navigator
        return "<p>" + $('div[id="ref-' + ref + '"]').html() + "</p>";
      }).join("\n");
      window.tippy(this, {
        allowHTML: true,
        content: refHtml,
        maxWidth: 500,
        interactive: true,
        interactiveBorder: 10,
        theme: 'light-border',
        placement: 'bottom-start'
      });
    });

    // fix footnotes in tables (#411)
    // replacing broken distill.pub feature
    $('table d-footnote').each(function() {
      // we replace internal showAtNode methode which is triggered when hovering a footnote
      this.hoverBox.showAtNode = function(node) {
        // ported from https://github.com/distillpub/template/pull/105/files
        calcOffset = function(elem) {
            let x = elem.offsetLeft;
            let y = elem.offsetTop;
            // Traverse upwards until an `absolute` element is found or `elem`
            // becomes null.
            while (elem = elem.offsetParent && elem.style.position != 'absolute') {
                x += elem.offsetLeft;
                y += elem.offsetTop;
            }

            return { left: x, top: y };
        }
        // https://developer.mozilla.org/en-US/docs/Web/API/HTMLElement/offsetTop
        const bbox = node.getBoundingClientRect();
        const offset = calcOffset(node);
        this.show([offset.left + bbox.width, offset.top + bbox.height]);
      }
    })

    // clear polling timer
    clearInterval(tid);

    // show body now that everything is ready
    on_load_complete();
  }

  var tid = setInterval(distill_post_process, 50);
  distill_post_process();

}

function init_downlevel() {

  init_common();

   // insert hr after d-title
  $('.d-title').after($('<hr class="section-separator"/>'));

  // check if we have authors
  var front_matter = JSON.parse($("#distill-front-matter").html());
  var have_authors = front_matter.authors && front_matter.authors.length > 0;

  // manage byline/border
  if (!have_authors)
    $('.d-byline').remove();
  $('.d-byline').after($('<hr class="section-separator"/>'));
  $('.d-byline a').remove();

  // remove toc
  $('.d-contents').remove();

  // move appendix elements
  $('h1.appendix, h2.appendix').each(function(i, val) {
    $(this).changeElementType('h3');
  });
  $('h3.appendix').each(function(i, val) {
    $(this).nextUntil($('h1, h2, h3')).addBack().appendTo($('.d-appendix'));
  });


  // inject headers into references and footnotes
  var refs_header = $('<h3></h3>');
  refs_header.text('References');
  $('#refs').prepend(refs_header);

  var footnotes_header = $('<h3></h3');
  footnotes_header.text('Footnotes');
  $('.footnotes').children('hr').first().replaceWith(footnotes_header);

  // move appendix-bottom entries to the bottom
  $('.appendix-bottom').appendTo('.d-appendix').children().unwrap();
  $('.appendix-bottom').remove();

  // remove appendix if it's empty
  if ($('.d-appendix').children().length === 0)
    $('.d-appendix').remove();

  // prepend separator above appendix
  $('.d-appendix').before($('<hr class="section-separator" style="clear: both"/>'));

  // trim code
  $('pre>code').each(function(i, val) {
    $(this).html($.trim($(this).html()));
  });

  // move posts-container right before article
  $('.posts-container').insertBefore($('.d-article'));

  $('body').addClass('downlevel');

  on_load_complete();
}


function init_common() {

  // jquery plugin to change element types
  (function($) {
    $.fn.changeElementType = function(newType) {
      var attrs = {};

      $.each(this[0].attributes, function(idx, attr) {
        attrs[attr.nodeName] = attr.nodeValue;
      });

      this.replaceWith(function() {
        return $("<" + newType + "/>", attrs).append($(this).contents());
      });
    };
  })(jQuery);

  // prevent underline for linked images
  $('a > img').parent().css({'border-bottom' : 'none'});

  // mark non-body figures created by knitr chunks as 100% width
  $('.layout-chunk').each(function(i, val) {
    var figures = $(this).find('img, .html-widget');
    // ignore leaflet img layers (#106)
    figures = figures.filter(':not(img[class*="leaflet"])')
    if ($(this).attr('data-layout') !== "l-body") {
      figures.css('width', '100%');
    } else {
      figures.css('max-width', '100%');
      figures.filter("[width]").each(function(i, val) {
        var fig = $(this);
        fig.css('width', fig.attr('width') + 'px');
      });

    }
  });

  // auto-append index.html to post-preview links in file: protocol
  // and in rstudio ide preview
  $('.post-preview').each(function(i, val) {
    if (window.location.protocol === "file:")
      $(this).attr('href', $(this).attr('href') + "index.html");
  });

  // get rid of index.html references in header
  if (window.location.protocol !== "file:") {
    $('.distill-site-header a[href]').each(function(i,val) {
      $(this).attr('href', $(this).attr('href').replace(/^index[.]html/, "./"));
    });
  }

  // add class to pandoc style tables
  $('tr.header').parent('thead').parent('table').addClass('pandoc-table');
  $('.kable-table').children('table').addClass('pandoc-table');

  // add figcaption style to table captions
  $('caption').parent('table').addClass("figcaption");

  // initialize posts list
  if (window.init_posts_list)
    window.init_posts_list();

  // implmement disqus comment link
  $('.disqus-comment-count').click(function() {
    window.headroom_prevent_pin = true;
    $('#disqus_thread').toggleClass('hidden');
    if (!$('#disqus_thread').hasClass('hidden')) {
      var offset = $(this).offset();
      $(window).resize();
      $('html, body').animate({
        scrollTop: offset.top - 35
      });
    }
  });
}

document.addEventListener('DOMContentLoaded', function() {
  if (is_downlevel_browser())
    init_downlevel();
  else
    window.addEventListener('WebComponentsReady', init_distill);
});

</script>

<style type="text/css">
/* base variables */

/* Edit the CSS properties in this file to create a custom
   Distill theme. Only edit values in the right column
   for each row; values shown are the CSS defaults.
   To return any property to the default,
   you may set its value to: unset
   All rows must end with a semi-colon.                      */

/* Optional: embed custom fonts here with `@import`          */
/* This must remain at the top of this file.                 */



html {
  /*-- Main font sizes --*/
  --title-size:      50px;
  --body-size:       1.06rem;
  --code-size:       14px;
  --aside-size:      12px;
  --fig-cap-size:    13px;
  /*-- Main font colors --*/
  --title-color:     #000000;
  --header-color:    rgba(0, 0, 0, 0.8);
  --body-color:      rgba(0, 0, 0, 0.8);
  --aside-color:     rgba(0, 0, 0, 0.6);
  --fig-cap-color:   rgba(0, 0, 0, 0.6);
  /*-- Specify custom fonts ~~~ must be imported above   --*/
  --heading-font:    sans-serif;
  --mono-font:       monospace;
  --body-font:       sans-serif;
  --navbar-font:     sans-serif;  /* websites + blogs only */
}

/*-- ARTICLE METADATA --*/
d-byline {
  --heading-size:    0.6rem;
  --heading-color:   rgba(0, 0, 0, 0.5);
  --body-size:       0.8rem;
  --body-color:      rgba(0, 0, 0, 0.8);
}

/*-- ARTICLE TABLE OF CONTENTS --*/
.d-contents {
  --heading-size:    18px;
  --contents-size:   13px;
}

/*-- ARTICLE APPENDIX --*/
d-appendix {
  --heading-size:    15px;
  --heading-color:   rgba(0, 0, 0, 0.65);
  --text-size:       0.8em;
  --text-color:      rgba(0, 0, 0, 0.5);
}

/*-- WEBSITE HEADER + FOOTER --*/
/* These properties only apply to Distill sites and blogs  */

.distill-site-header {
  --title-size:       18px;
  --text-color:       rgba(255, 255, 255, 0.8);
  --text-size:        15px;
  --hover-color:      white;
  --bkgd-color:       #0F2E3D;
}

.distill-site-footer {
  --text-color:       rgba(255, 255, 255, 0.8);
  --text-size:        15px;
  --hover-color:      white;
  --bkgd-color:       #0F2E3D;
}

/*-- Additional custom styles --*/
/* Add any additional CSS rules below                      */
</style>
<style type="text/css">
/* base variables */

/* Edit the CSS properties in this file to create a custom
   Distill theme. Only edit values in the right column
   for each row; values shown are the CSS defaults.
   To return any property to the default,
   you may set its value to: unset
   All rows must end with a semi-colon.                      */

/* Optional: embed custom fonts here with `@import`          */
/* This must remain at the top of this file.                 */



html {
  /*-- Main font sizes --*/
  --title-size:      50px;
  --body-size:       1.06rem;
  --code-size:       14px;
  --aside-size:      12px;
  --fig-cap-size:    13px;
  /*-- Main font colors --*/
  --title-color:     #000000;
  --header-color:    rgba(0, 0, 0, 0.8);
  --body-color:      rgba(0, 0, 0, 0.8);
  --aside-color:     rgba(0, 0, 0, 0.6);
  --fig-cap-color:   rgba(0, 0, 0, 0.6);
  /*-- Specify custom fonts ~~~ must be imported above   --*/
  --heading-font:    sans-serif;
  --mono-font:       monospace;
  --body-font:       sans-serif;
  --navbar-font:     sans-serif;  /* websites + blogs only */
}

/*-- ARTICLE METADATA --*/
d-byline {
  --heading-size:    0.6rem;
  --heading-color:   rgba(0, 0, 0, 0.5);
  --body-size:       0.8rem;
  --body-color:      rgba(0, 0, 0, 0.8);
}

/*-- ARTICLE TABLE OF CONTENTS --*/
.d-contents {
  --heading-size:    18px;
  --contents-size:   13px;
}

/*-- ARTICLE APPENDIX --*/
d-appendix {
  --heading-size:    15px;
  --heading-color:   rgba(0, 0, 0, 0.65);
  --text-size:       0.8em;
  --text-color:      rgba(0, 0, 0, 0.7);
}

/*-- WEBSITE HEADER + FOOTER --*/
/* These properties only apply to Distill sites and blogs  */

.distill-site-header {
  --title-size:       18px;
  --text-color:       rgba(0, 0, 0, 0.8);
  --text-size:        15px;
  --hover-color:      black;
  --bkgd-color:       #ffffff;
}

.distill-site-footer {
  --text-color:       rgba(0, 0, 0, 0.8);
  --text-size:        15px;
  --hover-color:      black;
  --bkgd-color:       #fafafa;
}

/*-- Additional custom styles --*/
/* Add any additional CSS rules below                      */

.nav-right > a {
  text-transform: uppercase;
}

d-title h1, d-title p, d-title figure,
d-abstract p, d-abstract b {
  grid-column: page;
}

.rj-blue {
  color: #2467bb;
}

ul li {
  line-height: 1.6;
  margin-top: 0em;
  margin-bottom: 0em;
}</style>
<style type="text/css">
/* base style */

/* FONT FAMILIES */

:root {
  --heading-default: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", Arial, sans-serif;
  --mono-default: Consolas, Monaco, 'Andale Mono', 'Ubuntu Mono', monospace;
  --body-default: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", Arial, sans-serif;
}

body,
.posts-list .post-preview p,
.posts-list .description p {
  font-family: var(--body-font), var(--body-default);
}

h1, h2, h3, h4, h5, h6,
.posts-list .post-preview h2,
.posts-list .description h2 {
  font-family: var(--heading-font), var(--heading-default);
}

d-article div.sourceCode code,
d-article pre code {
  font-family: var(--mono-font), var(--mono-default);
}


/*-- TITLE --*/
d-title h1,
.posts-list > h1 {
  color: var(--title-color, black);
}

d-title h1 {
  font-size: var(--title-size, 50px);
}

/*-- HEADERS --*/
d-article h1,
d-article h2,
d-article h3,
d-article h4,
d-article h5,
d-article h6 {
  color: var(--header-color, rgba(0, 0, 0, 0.8));
}

/*-- BODY --*/
d-article > p,  /* only text inside of <p> tags */
d-article > ul, /* lists */
d-article > ol {
  color: var(--body-color, rgba(0, 0, 0, 0.8));
  font-size: var(--body-size, 1.06rem);
}


/*-- CODE --*/
d-article div.sourceCode code,
d-article pre code {
  font-size: var(--code-size, 14px);
}

/*-- ASIDE --*/
d-article aside {
  font-size: var(--aside-size, 12px);
  color: var(--aside-color, rgba(0, 0, 0, 0.6));
}

/*-- FIGURE CAPTIONS --*/
figure .caption,
figure figcaption,
.figure .caption {
  font-size: var(--fig-cap-size, 13px);
  color: var(--fig-cap-color, rgba(0, 0, 0, 0.6));
}

/*-- METADATA --*/
d-byline h3 {
  font-size: var(--heading-size, 0.6rem);
  color: var(--heading-color, rgba(0, 0, 0, 0.5));
}

d-byline {
  font-size: var(--body-size, 0.8rem);
  color: var(--body-color, rgba(0, 0, 0, 0.8));
}

d-byline a,
d-article d-byline a {
  color: var(--body-color, rgba(0, 0, 0, 0.8));
}

/*-- TABLE OF CONTENTS --*/
.d-contents nav h3 {
  font-size: var(--heading-size, 18px);
}

.d-contents nav a {
  font-size: var(--contents-size, 13px);
}

/*-- APPENDIX --*/
d-appendix h3 {
  font-size: var(--heading-size, 15px);
  color: var(--heading-color, rgba(0, 0, 0, 0.65));
}

d-appendix {
  font-size: var(--text-size, 0.8em);
  color: var(--text-color, rgba(0, 0, 0, 0.5));
}

d-appendix d-footnote-list a.footnote-backlink {
  color: var(--text-color, rgba(0, 0, 0, 0.5));
}

/*-- WEBSITE HEADER + FOOTER --*/
.distill-site-header .title {
  font-size: var(--title-size, 18px);
  font-family: var(--navbar-font), var(--heading-default);
}

.distill-site-header a,
.nav-dropdown .nav-dropbtn {
  font-family: var(--navbar-font), var(--heading-default);
}

.nav-dropdown .nav-dropbtn {
  color: var(--text-color, rgba(255, 255, 255, 0.8));
  font-size: var(--text-size, 15px);
}

.distill-site-header a:hover,
.nav-dropdown:hover .nav-dropbtn {
  color: var(--hover-color, white);
}

.distill-site-header {
  font-size: var(--text-size, 15px);
  color: var(--text-color, rgba(255, 255, 255, 0.8));
  background-color: var(--bkgd-color, #0F2E3D);
}

.distill-site-footer {
  font-size: var(--text-size, 15px);
  color: var(--text-color, rgba(255, 255, 255, 0.8));
  background-color: var(--bkgd-color, #0F2E3D);
}

.distill-site-footer a:hover {
  color: var(--hover-color, white);
}</style>
<!--/radix_placeholder_distill-->
  <script src="../../site_libs/header-attrs-2.29/header-attrs.js"></script>
  <script src="../../site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
  <script src="../../site_libs/popper-2.6.0/popper.min.js"></script>
  <link href="../../site_libs/tippy-6.2.7/tippy.css" rel="stylesheet" />
  <link href="../../site_libs/tippy-6.2.7/tippy-light-border.css" rel="stylesheet" />
  <script src="../../site_libs/tippy-6.2.7/tippy.umd.min.js"></script>
  <script src="../../site_libs/anchor-4.2.2/anchor.min.js"></script>
  <script src="../../site_libs/bowser-1.9.3/bowser.min.js"></script>
  <script src="../../site_libs/webcomponents-2.0.0/webcomponents.js"></script>
  <script src="../../site_libs/distill-2.2.21/template.v2.js"></script>
  <!--radix_placeholder_site_in_header-->
<!--/radix_placeholder_site_in_header-->
  <script>
    $(function() {
      console.log("Starting...")

      // Mathjax config (add automatic linebreaks when supported)
      // MathJax = {
      //    tex: {
      //        inlineMath: [['$', '$'], ['\\(', '\\)']],
      //        displayMath: [['$$', '$$'], ['\\[', '\\]']],
      //        tags: 'ams',
      //        multline: true,
      //    },
      //    options: {
      //        linebreaks: { automatic: true },
      //    },
      // };

      // Always show Published - distill hides it if not set
      function show_byline_column(caption) {
        $('d-byline').find('h3:contains("' + caption + '")').parent().css('visibility', 'visible');
      }

      show_byline_column('Published')

      // tweak function
      var rmd_meta = JSON.parse($("#radix-rmarkdown-metadata").html());
      function get_meta(name, meta) {
        var ind = meta.attributes.names.value.findIndex((e) => e == name)
        var val = meta.value[ind]
        if (val.type != 'list') {
          return val.value.toString()
        }
        return val
      }

      // tweak description
      // Add clickable tags
      const slug = get_meta('slug', rmd_meta)
      const cite_url = get_meta('citation_url', rmd_meta)

      var title = $("d-title").text

      const buttons = $('<div class="dt-tags" style="grid-column: page;">')
      buttons.append('<a href="#citation" class="dt-tag"><i class="fas fa-quote-left"></i> Cite</a>')
      buttons.append('<a href="' + slug + '.pdf" class="dt-tag"><i class="fas fa-file-pdf"></i> PDF</a>')
      buttons.append('<a href="' + slug + '.zip" class="dt-tag"><i class="fas fa-file-zipper"></i> Supplement</a>')

      // adds Abstract: in front of the first <p> in the title section --
      // unless it happens to be the subtitle (FIXME: this is a bad hack - can't distill do this?)
      var tpar = $("d-title p:not(:empty)").filter(function() {
        return !$(this).hasClass("subtitle");
      }).first();
      if (tpar) {
        const abstract = $('<d-abstract>')
        abstract.append('<b>Abstract:</b><br>')
        abstract.append(tpar) // Move description to d-abstract
        $("d-title p:empty").remove() // Remove empty paragraphs after title
        abstract.append(buttons)
        abstract.insertAfter($('d-title')) // Add abstract section after title */
      }

      // tweak by-line
      var byline = $("d-byline div.byline")
      ind = rmd_meta.attributes.names.value.findIndex((e) => e == "journal")
      const journal = get_meta('journal', rmd_meta)
      const volume = get_meta('volume', rmd_meta)
      const issue = get_meta('issue', rmd_meta)
      const jrtitle = get_meta('title', journal)
      const year = ((jrtitle == "R News") ? 2000 : 2008) + parseInt(volume)
      const firstpage = get_meta('firstpage', journal)
      const lastpage = get_meta('lastpage', journal)
      byline.append('<div class="rjournal grid">')
      $('div.rjournal').append('<h3>Volume</h3>')
      $('div.rjournal').append('<h3>Pages</h3>')
      $('div.rjournal').append('<a class="volume" href="../../issues/'+year+'-'+issue+'">'+volume+'/'+issue+'</a>')
      $('div.rjournal').append('<p class="pages">'+firstpage+' - '+lastpage+'</p>')

      const received_date = new Date(get_meta('date_received', rmd_meta))
      byline.find('h3:contains("Published")').parent().append('<h3>Received</h3><p>'+received_date.toLocaleDateString('en-US', {month: 'short'})+' '+received_date.getDate()+', '+received_date.getFullYear()+'</p>')

    })
  </script>

  <style>
      /*
    .nav-dropdown-content .nav-dropdown-header {
      text-transform: lowercase;
    }
    */

    d-byline .byline {
      grid-template-columns: 2fr 2fr 2fr 2fr;
    }

    d-byline .rjournal {
      grid-column-end: span 2;
      grid-template-columns: 1fr 1fr;
      margin-bottom: 0;
    }

    d-title h1, d-title p, d-title figure,
    d-abstract p, d-abstract b {
      grid-column: page;
    }

    d-title .dt-tags {
      grid-column: page;
    }

    .dt-tags .dt-tag {
      text-transform: lowercase;
    }

    d-article h1 {
      line-height: 1.1em;
    }

    d-abstract p, d-article p {
      text-align: justify;
    }

    @media(min-width: 1000px) {
      .d-contents.d-contents-float {
        justify-self: end;
      }

      nav.toc {
        border-right: 1px solid rgba(0, 0, 0, 0.1);
        border-right-width: 1px;
        border-right-style: solid;
        border-right-color: rgba(0, 0, 0, 0.1);
      }
    }

    .posts-list .dt-tags .dt-tag {
      text-transform: lowercase;
    }

    @keyframes highlight-target {
      0% {
        background-color: #ffa;
      }
      66% {
        background-color: #ffa;
      }
      100% {
        background-color: none;
      }
    }

    d-article :target, d-appendix :target {
       animation: highlight-target 3s;
    }

    .header-section-number {
      margin-right: 0.5em;
    }
    
    d-appendix .citation-appendix,
    .d-appendix .citation-appendix {
      color: rgb(60, 60, 60);
    }

    d-article h2 {
      border-bottom: 0px solid rgba(0, 0, 0, 0.1);
      padding-bottom: 0rem;
    }
    d-article h3 {
      font-size: 20px;
    }
    d-article h4 {
      font-size: 18px;
      text-transform: none;
    }

    @media (min-width: 1024px) {
      d-article h2 {
        font-size: 32px;
      }
      d-article h3 {
        font-size: 24px;
      }
      d-article h4 {
        font-size: 20px;
      }
    }
  </style>


</head>

<body>

<!--radix_placeholder_front_matter-->

<script id="distill-front-matter" type="text/json">
{"title":"boinet: An R Package for Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes","description":"Bayesian optimal interval based on both efficacy and toxicity outcomes\n(BOIN-ET) design is a model-assisted oncology phase I/II trial design,\naiming to establish an optimal biological dose accounting for efficacy\nand toxicity in the framework of dose-finding. Some extensions of\nBOIN-ET design are also available to allow for time-to-event efficacy\nand toxicity outcomes based on cumulative and pending data\n(time-to-event BOIN-ET: TITE-BOIN-ET), ordinal graded efficacy and\ntoxicity outcomes (generalized BOIN-ET: gBOIN-ET), and their\ncombination (TITE-gBOIN-ET). The R package boinet implements the\nBOIN-ET design family. The package supports\nthe conduct of simulation studies to assess operating characteristics\nof BOIN-ET, TITE-BOIN-ET, gBOIN-ET, and TITE-gBOIN-ET designs, where\nusers can choose design parameters in flexible and straightforward\nways depending on their own application. We demonstrate its capability\nand effectiveness using several simulation studies.","doi":"10.32614/RJ-2025-012","authors":[{"author":"Yusuke Yamaguchi","authorURL":"#","affiliation":"Quantitative Sciences and Evidence Generation, Astellas Pharma Global\nDevelopment, Inc.","affiliationURL":"#","orcidID":""},{"author":"Kentaro Takeda","authorURL":"#","affiliation":"Quantitative Sciences and Evidence Generation, Astellas Pharma Global\nDevelopment, Inc.","affiliationURL":"#","orcidID":""},{"author":"Kazushi Maruo","authorURL":"#","affiliation":"Department of Biostatistics, Faculty of Medicine, University of\nTsukuba","affiliationURL":"#","orcidID":""}],"publishedDate":"2025-09-23T00:00:00.000+00:00","citationText":"Yamaguchi, et al., 2025"}
</script>

<!--/radix_placeholder_front_matter-->
<!--radix_placeholder_navigation_before_body-->
<header class="header header--fixed" role="banner">
<nav class="distill-site-nav distill-site-header">
<div class="nav-left">
<a class="logo" href="../../index.html">
<img src="../../resources/rlogo.png" alt="Logo"/>
</a>
<a href="../../index.html" class="title">The R Journal</a>
</div>
<div class="nav-right">
<a href="../../index.html">Home</a>
<a href="../../issues/2025-2">Current</a>
<a href="../../issues.html">Issues</a>
<a href="../../news.html">News</a>
<a href="../../submissions.html">Submit</a>
<a href="../../contribute.html">Contribute</a>
<a href="../../editors.html">Editorial board</a>
<a href="../../articles.xml">
<i class="fa fa-rss" aria-hidden="true"></i>
</a>
<a href="javascript:void(0);" class="nav-toggle">&#9776;</a>
</div>
</nav>
</header>
<!--/radix_placeholder_navigation_before_body-->
<!--radix_placeholder_site_before_body-->
<!--/radix_placeholder_site_before_body-->

<div class="d-title">
<h1>boinet: An R Package for Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes</h1>

<!--radix_placeholder_categories-->
<!--/radix_placeholder_categories-->
<p><p>Bayesian optimal interval based on both efficacy and toxicity outcomes
(BOIN-ET) design is a model-assisted oncology phase I/II trial design,
aiming to establish an optimal biological dose accounting for efficacy
and toxicity in the framework of dose-finding. Some extensions of
BOIN-ET design are also available to allow for time-to-event efficacy
and toxicity outcomes based on cumulative and pending data
(time-to-event BOIN-ET: TITE-BOIN-ET), ordinal graded efficacy and
toxicity outcomes (generalized BOIN-ET: gBOIN-ET), and their
combination (TITE-gBOIN-ET). The R package boinet implements the
BOIN-ET design family. The package supports
the conduct of simulation studies to assess operating characteristics
of BOIN-ET, TITE-BOIN-ET, gBOIN-ET, and TITE-gBOIN-ET designs, where
users can choose design parameters in flexible and straightforward
ways depending on their own application. We demonstrate its capability
and effectiveness using several simulation studies.</p></p>
</div>

<div class="d-byline">
  Yusuke Yamaguchi  (Quantitative Sciences and Evidence Generation, Astellas Pharma Global
Development, Inc.)
  
,   Kentaro Takeda  (Quantitative Sciences and Evidence Generation, Astellas Pharma Global
Development, Inc.)
  
,   Kazushi Maruo  (Department of Biostatistics, Faculty of Medicine, University of
Tsukuba)
  
<br/>2025-09-23
</div>

<div class="d-article">
<div class="article">
<h3 data-number="1" id="introduction"><span class="header-section-number">1</span> Introduction</h3>
<p>A paradigm shift in anti-cancer treatment with the emergence of
molecular targeted agents and immunotherapies is calling for a reform of
dose-finding strategy in phase I oncology clinical trials. Traditional
dose-finding procedures designed to establish the maximum tolerated dose
underlie an assumption of a monotonic dose-efficacy relationship; that
is, the higher dose level is assumed to be more toxic and efficacious.
However, the monotonic dose-efficacy relationship would be doubtful in
many cases of the targeted agents and immunotherapies, where the
efficacy may reach a plateau beyond a given dose level or even take an
umbrella shape <span class="citation" data-cites="calabrese:2001 lorusso:2010 reynolds:2010">(<a href="#ref-calabrese:2001" role="doc-biblioref">Calabrese and Baldwin 2001</a>; <a href="#ref-lorusso:2010" role="doc-biblioref">LoRusso et al. 2010</a>; <a href="#ref-reynolds:2010" role="doc-biblioref">Reynolds 2010</a>)</span>.
Accordingly, a concept of optimal biological dose (OBD) has been
introduced into the framework of dose-finding
<span class="citation" data-cites="corbaux:2019 fraisse:2021">(<a href="#ref-corbaux:2019" role="doc-biblioref">Corbaux et al. 2019</a>; <a href="#ref-fraisse:2021" role="doc-biblioref">Fraisse et al. 2021</a>)</span>. The OBD, which is generally defined as a
tolerable dose having adequate efficacy under an assumption of
non-monotonic dose-efficacy relationships, is established with a
dose-escalation rule based jointly on toxicity and efficacy. Numerous
dose-finding designs to incorporate the trade-off between toxicity and
efficacy have been proposed, broadly classified as algorithm-based
designs <span class="citation" data-cites="lin:2020a">(<a href="#ref-lin:2020a" role="doc-biblioref">Lin and Ji 2020</a>)</span>, model-based designs
<span class="citation" data-cites="thall:2004 yuan:2016 riviere:2018">(<a href="#ref-thall:2004" role="doc-biblioref">Thall and Cook 2004</a>; <a href="#ref-yuan:2016" role="doc-biblioref">Yuan et al. 2016</a>; <a href="#ref-riviere:2018" role="doc-biblioref">Riviere et al. 2018</a>)</span>, and model-assisted designs
<span class="citation" data-cites="takeda:2018 yuan:2019 li:2020 lin:2020b yin:2020 lin:2021">(<a href="#ref-takeda:2018" role="doc-biblioref">Takeda et al. 2018</a>; <a href="#ref-yuan:2019" role="doc-biblioref">Yuan et al. 2019</a>; <a href="#ref-li:2020" role="doc-biblioref">Li et al. 2020</a>; <a href="#ref-lin:2020b" role="doc-biblioref">Lin et al. 2020</a>; <a href="#ref-yin:2020" role="doc-biblioref">Yin and Yuan 2020</a>; <a href="#ref-lin:2021" role="doc-biblioref">Lin and Ji 2021</a>)</span>.
Particularly, the model-assisted designs are known to yield superior
performance compared with more complicated model-based designs and to be
implemented in as simple a way as the algorithm-based designs
<span class="citation" data-cites="yuan:2019">(<a href="#ref-yuan:2019" role="doc-biblioref">Yuan et al. 2019</a>)</span>.</p>
<p>Bayesian optimal interval based on efficacy and toxicity outcomes
(BOIN-ET) design proposed by <span class="citation" data-cites="takeda:2018">Takeda et al. (<a href="#ref-takeda:2018" role="doc-biblioref">2018</a>)</span> is one of the model-assisted
designs and has been widely used to establish the OBD, where the
dose-escalation decision is determined by minimizing a posterior
probability of incorrect dose assignments in terms of both efficacy and
toxicity. Furthermore, the BOIN-ET design has been extended in two ways
to accommodate important clinical features unique to molecular targeted
agents and immunotherapies. Firstly, the occurrence of efficacy
responses and/or adverse events may be delayed due to the mechanism of
the agents. Such late-onset efficacy and toxicity outcomes usually
require a longer assessment window than the typical first one or two
cycles for the traditional cytotoxic agents <span class="citation" data-cites="postel:2009 weber:2015">(<a href="#ref-postel:2009" role="doc-biblioref">Postel-Vinay et al. 2009</a>; <a href="#ref-weber:2015" role="doc-biblioref">Weber et al. 2015</a>)</span>.
Ignoring the feature of late-onset toxicity may cause potential dose
reductions or interruptions in later phase trials. To allow for
sequential enrollment even before patients have completed the required
efficacy and toxicity assessment window, <span class="citation" data-cites="takeda:2020">Takeda et al. (<a href="#ref-takeda:2020" role="doc-biblioref">2020</a>)</span> proposed
time-to-event BOIN-ET (TITE-BOIN-ET) design, which extends the BOIN-ET
design to use cumulative and pending data of both efficacy and toxicity
for the dose-escalation decision <span class="citation" data-cites="lin:2020c">(<a href="#ref-lin:2020c" role="doc-biblioref">Lin and Yuan 2020</a>)</span>. Secondly, the efficacy
and toxicity outcomes are often summarized by binary outcomes, scored as
an overall response (ORR) or not an ORR for efficacy, and scored as a
dose-limiting toxicity (DLT) or not a DLT for toxicity; however, the
molecular targeted agents and immunotherapies are more likely to be
featured by multiple low or moderate grades of toxicities than DLTs
<span class="citation" data-cites="penel:2011">(<a href="#ref-penel:2011" role="doc-biblioref">Penel et al. 2011</a>)</span>. Besides, the efficacy response may prefer to be evaluated
by the combination of ORR and long-term stable disease (SD) in solid
tumors and by accounting for the difference between complete remission
(CR) and partial remission (PR) in lymphoma. To allow for the ordinal
graded efficacy and toxicity assessment, <span class="citation" data-cites="takeda:2022b">Takeda et al. (<a href="#ref-takeda:2022b" role="doc-biblioref">2022a</a>)</span> proposed
generalized BOIN-ET (gBOIN-ET), which extends the BOIN-ET design to use
ordinal graded efficacy and toxicity data for the dose-escalation
decision. <span class="citation" data-cites="takeda:2023">Takeda et al. (<a href="#ref-takeda:2023" role="doc-biblioref">2023</a>)</span> proposed time-to-event generalized BOIN-ET
(TITE-gBOIN-ET) to address simultaneously the aforementioned challenges
of the late-onset ordinal graded efficacy and toxicity outcomes.
<a href="https://CRAN.R-project.org/package=Keyboard"><strong>Keyboard</strong></a>
<span class="citation" data-cites="xiaomeng:2025">(<a href="#ref-xiaomeng:2025" role="doc-biblioref">Yuan et al. 2025</a>)</span> and
<a href="https://CRAN.R-project.org/package=escalation"><strong>escalation</strong></a>
<span class="citation" data-cites="kristian:2024">(<a href="#ref-kristian:2024" role="doc-biblioref">Brock et al. 2024</a>)</span> are existing R packages that implement other types of
the OBD-finding designs, while there are no R packages that provide
functions to implement the BOIN-ET, TITE-BOIN-ET, gBOIN-ET, and
TITE-gBOIN-ET design.</p>
<p>The <a href="https://CRAN.R-project.org/package=boinet"><strong>boinet</strong></a>
<span class="citation" data-cites="yamaguchi:2025">(<a href="#ref-yamaguchi:2025" role="doc-biblioref">Yamaguchi and Takeda 2025</a>)</span> package implements the BOIN-ET design
family. The package supports the conduct of simulation studies to assess
operating characteristics of BOIN-ET, TITE-BOIN-ET, gBOIN-ET, and
TITE-gBOIN-ET, where users can choose design parameters in flexible and
straightforward ways depending on their own application. It should be
noted that the selection of OBD in the BOIN-ET design family is carried
out at the end of the trial after completing the dose-escalation
procedure: (i) the toxicity and efficacy probabilities at each dose
level are estimated using all data obtained from the entire cohort, and
then (ii) given the estimated toxicity and efficacy probabilities, the
utility to measure the toxicity-efficacy trade-off is computed and
serves as a basis for the OBD selection. The
<a href="https://CRAN.R-project.org/package=boinet"><strong>boinet</strong></a> package offers
several options regarding methods to estimate the efficacy probability
and measures to select the OBD. The operating characteristics of the
design are summarized by the percentage of times that each dose level is
selected as OBD and the average number of patients who are treated at
each dose level. The percentage of times that the study is terminated
and the expected study duration are also provided. We demonstrate the
capability and effectiveness of the
<a href="https://CRAN.R-project.org/package=boinet"><strong>boinet</strong></a> package.</p>
<p>This article is organized as follows. We first describe the BOIN-ET,
TITE-BOIN-ET, gBOIN-ET, and TITE-gBOIN-ET designs implemented by the
package. We then provide details on how to use the
<a href="https://CRAN.R-project.org/package=boinet"><strong>boinet</strong></a> package through
simulation studies. The article is concluded with a brief discussion.</p>
<h3 data-number="2" id="case-example"><span class="header-section-number">2</span> Case example</h3>
<p>The BOIN-ET design family is a relatively new methodological
development, and while they are being implemented in ongoing trials,
published case results using these specific designs are still
forthcoming. We here provide one case study that has actually
implemented the TITE-BOIN-ET design.</p>
<p>A two-part phase I/II study evaluating a combination of luspatercept and
erythropoiesis-stimulating agent (ESA) in patients with low-risk
myelodysplastic syndromes without ring sideroblasts having failed to
achieve a response after ESA without disease progression is being
conducted <span class="citation" data-cites="ades:2024">(<a href="#ref-ades:2024" role="doc-biblioref">Ades et al. 2024</a>)</span>. The primary objective of this dose-finding part
of the trial was to determine the optimal dose in terms of both toxicity
and efficacy for luspatercept + ESA, for selection in the randomized
part B of the trial. Based on a TITE-BOIN-ET design, four dose levels
were tested: Dose level 1 (n=3); Dose level 2 (n=3); Dose Level 3 (n=3);
Dose Level 4 (n=15). The toxicity was measured by a dose-limiting
toxicity at Day 21 of cycle 1 for non-hematological toxicity, up to Day
42 for hematological toxicity. The efficacy was measured by a response
rate (complete response + partial response + stable disease with
hematological improvement), and the assessment window for efficacy was
21 days.</p>
<h3 data-number="3" id="methodology"><span class="header-section-number">3</span> Methodology</h3>
<p>Consider a dose-finding trial aiming to determine the OBD of a test
drug, and suppose that <span class="math inline">\(J\)</span> dose levels are investigated by sequentially
assigning small cohorts of patients to the next dose levels until
reaching a maximum number of patients enrolled. Suppose that patients in
the current cohort have been treated at dose level <span class="math inline">\(j\)</span>, and let <span class="math inline">\(n_j\)</span>
denote the cumulative number of patients treated at dose level <span class="math inline">\(j\)</span> for
<span class="math inline">\(j=1,\ldots,J\)</span>. Let <span class="math inline">\(\tau_T\)</span> and <span class="math inline">\(\tau_E\)</span> be the assessment window for
toxicity and efficacy respectively. We below describe the
dose-escalation procedure in the BOIN-ET, TITE-BOIN-ET, gBOIN-ET, and
TITE-gBOIN-ET designs, followed by an introduction to the OBD selection.
Further details are found in the original articles
<span class="citation" data-cites="takeda:2018 takeda:2020 takeda:2022a takeda:2022b takeda:2023">(<a href="#ref-takeda:2018" role="doc-biblioref">Takeda et al. 2018</a>; <a href="#ref-takeda:2020" role="doc-biblioref">2020</a>; <a href="#ref-takeda:2022a" role="doc-biblioref">2022b</a>,<a href="#ref-takeda:2022b" role="doc-biblioref">a</a>; <a href="#ref-takeda:2023" role="doc-biblioref">2023</a>)</span>.</p>
<h4 class="unnumbered" data-number="3.1" id="dose-escalation-procedure-in-boin-et-and-tite-boin-et-design">Dose-escalation procedure in BOIN-ET and TITE-BOIN-ET design</h4>
<p>Let <span class="math inline">\(p_{Tj}\)</span> and <span class="math inline">\(p_{Ej}\)</span> be a true toxicity and efficacy probability at
dose level <span class="math inline">\(j\)</span> for <span class="math inline">\(j=1,\ldots,J\)</span>, respectively. Let <span class="math inline">\(\phi^p\)</span> and
<span class="math inline">\(\delta^p\)</span> be a target toxicity and efficacy probability respectively,
which are pre-specified by trial physicians according to the disease and
the definition of toxicity and efficacy. Lower and upper toxicity
boundaries are pre-specified as <span class="math inline">\(\lambda^p_1\)</span> and <span class="math inline">\(\lambda^p_2\)</span>
respectively, which satisfy a condition of
<span class="math inline">\(0\leq\lambda^p_1\leq\phi^p\leq\lambda^p_2&lt;1\)</span>. A lower efficacy boundary
is also pre-specified as <span class="math inline">\(\eta^p_1\)</span> with a condition of
<span class="math inline">\(0\leq\eta^p_1&lt;\delta^p&lt;1\)</span>. Let <span class="math inline">\(\hat{p}_{Tj}\)</span> and <span class="math inline">\(\hat{p}_{Ej}\)</span> be an
observed toxicity and efficacy probability at dose level <span class="math inline">\(j\)</span>
respectively, which are calculated using the cumulative toxicity and
efficacy data in different ways for the BOIN-ET and TITE-BOIN-ET design
(see subsections below). Then, the dose level used in the next cohort is
determined by the following rule:</p>
<ol type="1">
<li><p>If <span class="math inline">\(\hat{p}_{Tj}\leq\lambda^p_1\)</span> and <span class="math inline">\(\hat{p}_{Ej}\leq\eta^p_1\)</span>,
escalate to dose level <span class="math inline">\(j+1\)</span>.</p></li>
<li><p>If <span class="math inline">\(\hat{p}_{Tj}&lt;\lambda^p_2\)</span> and <span class="math inline">\(\hat{p}_{Ej}&gt;\eta^p_1\)</span>, stay at
the same dose level <span class="math inline">\(j\)</span>.</p></li>
<li><p>If <span class="math inline">\(\hat{p}_{Tj}\geq\lambda^p_2\)</span>, de-escalate to dose level <span class="math inline">\(j-1\)</span>.</p></li>
<li><p>If <span class="math inline">\(\lambda^p_1&lt;\hat{p}_{Tj}&lt;\lambda^p_2\)</span> and
<span class="math inline">\(\hat{p}_{Ej}\leq\eta^p_1\)</span>, consider the following additional rules:</p>
<ol type="1">
<li><p>If dose level <span class="math inline">\(j+1\)</span> has never been used until the current
cohort, escalate to dose level <span class="math inline">\(j+1\)</span>.</p></li>
<li><p>Otherwise, choose <span class="math inline">\(\arg\max_{j&#39;\in\{j-1,j,j+1\}}\hat{p}_{Ej&#39;}\)</span>
as the dose level for the next cohort; if more than two dose
levels have the same highest observed efficacy probability,
randomly select one of them.</p></li>
</ol></li>
</ol>
<p>Optimal values of <span class="math inline">\((\lambda^p_1,\lambda^p_2,\eta^p_1)\)</span> are determined as
values that minimize a posterior probability of incorrect decisions
under the following six hypotheses:
<span class="math display">\[\begin{gathered}
H_{1j}: (p_{Tj}=\phi^p_1,p_{Ej}=\delta^p_1),\quad H_{2j}: (p_{Tj}=\phi^p_1,p_{Ej}=\delta^p),\quad H_{3j}: (p_{Tj}=\phi^p,p_{Ej}=\delta^p_1), \\
H_{4j}: (p_{Tj}=\phi^p,p_{Ej}=\delta^p),\quad H_{5j}: (p_{Tj}=\phi^p_2,p_{Ej}=\delta^p_1),\quad H_{6j}: (p_{Tj}=\phi^p_2,p_{Ej}=\delta^p)
\end{gathered}\]</span>
where <span class="math inline">\(\phi^p_1\)</span> is the highest toxicity probability that is deemed
sub-therapeutic such that dose-escalation should be pursued, and
<span class="math inline">\(\phi^p_2\)</span> is the lowest toxicity probability that is deemed overly
toxic such that dose de-escalation is needed. <span class="math inline">\(\delta^p_1\)</span> is the
minimum probability deemed efficacious such that the dose levels with
less than <span class="math inline">\(\delta^p_1\)</span> are considered sub-therapeutic. Here, <span class="math inline">\(\phi^p_1\)</span>,
<span class="math inline">\(\phi^p_2\)</span>, and <span class="math inline">\(\delta^p_1\)</span> are design parameters to be pre-specified
along with the target probabilities of <span class="math inline">\(\phi^p\)</span> and <span class="math inline">\(\delta^p\)</span>. Given
non-informative prior probabilities of the six hypotheses; i.e.,
<span class="math inline">\(Pr(H_{1j})=Pr(H_{2j})=Pr(H_{3j})=Pr(H_{4j})=Pr(H_{5j})=Pr(H_{6j})=1/6\)</span>,
a grid search approach can be used to find the optimal values of
<span class="math inline">\((\lambda^p_1,\lambda^p_2,\eta^p_1)\)</span> conditioned on
<span class="math inline">\(\phi^p_1&lt;\lambda^p_1&lt;\phi^p&lt;\lambda^p_2&lt;\phi^p_2\)</span> and
<span class="math inline">\(\delta^p_2&lt;\eta^p_2&lt;\delta^p\)</span>. For example, considering <span class="math inline">\(\phi^p=0.3\)</span>,
<span class="math inline">\(\phi^p_1=0.1\phi^p\)</span>, <span class="math inline">\(\phi^p_2=1.4\phi^p\)</span>, <span class="math inline">\(\delta^p=0.6\)</span>, and
<span class="math inline">\(\delta^p_1=0.6\delta^p\)</span>, the optimal values of
<span class="math inline">\((\lambda^p_1,\lambda^p_2,\eta^p_1)\)</span> are given by <span class="math inline">\(\lambda^p_1=0.14\)</span>,
<span class="math inline">\(\lambda^p_2=0.35\)</span>, and <span class="math inline">\(\eta^p_1=0.48\)</span>.</p>
<p>A key difference between the BOIN-ET and TITE-BOIN-ET design is the
timing to determine the dose level used in the next cohort and to start
the enrollment for the next cohort. The BOIN-ET design requires all the
patients enrolled in the current cohort to complete the toxicity and
efficacy assessment windows; in other words, the decision time is always
the time when the last patient enrolled in the cohort completes the
toxicity and efficacy assessment windows. In contrast, the TITE-BOIN-ET
design allows for flexibility in the decision time, where the dose
escalation decision is based on the cumulative data at a certain
decision time. Differences in the decision time between the BOIN-ET and
TITE-BOIN-ET designs lead to different calculations of the observed
toxicity and efficacy probabilities, <span class="math inline">\(\hat{p}_{Tj}\)</span> and <span class="math inline">\(\hat{p}_{Ej}\)</span>
for <span class="math inline">\(i=1,\ldots,n_j\)</span>, which are described below.</p>
<h5 class="unnumbered" data-number="3.1.1" id="boin-et">BOIN-ET <span class="citation" data-cites="takeda:2018">(<a href="#ref-takeda:2018" role="doc-biblioref">Takeda et al. 2018</a>)</span>:</h5>
<p>Let <span class="math inline">\(y_{Tij}\)</span> and <span class="math inline">\(y_{Eij}\)</span> be a binary toxicity and efficacy outcome
observed within the assessment windows of <span class="math inline">\(\tau_T\)</span> and <span class="math inline">\(\tau_E\)</span> for the
<span class="math inline">\(i\)</span>-th patient at dose level <span class="math inline">\(j\)</span>, respectively. Given the cumulative
toxicity and efficacy data for dose level <span class="math inline">\(j\)</span>; i.e.,
<span class="math inline">\(\{y_{Tij}:i=1,\ldots,n_j\}\)</span> and <span class="math inline">\(\{y_{Eij}:i=1,\ldots,n_j\}\)</span>, we have
<span class="math inline">\(\hat{p}_{Tj}=\sum_{i=1}^{n_j}y_{Tij}/n_j\)</span> and
<span class="math inline">\(\hat{p}_{Ej}=\sum_{i=1}^{n_j}y_{Eij}/n_j\)</span>.</p>
<h5 class="unnumbered" data-number="3.1.2" id="tite-boin-et">TITE-BOIN-ET <span class="citation" data-cites="takeda:2020 lin:2020c">(<a href="#ref-lin:2020c" role="doc-biblioref">Lin and Yuan 2020</a>; <a href="#ref-takeda:2020" role="doc-biblioref">Takeda et al. 2020</a>)</span>:</h5>
<p>Let <span class="math inline">\(\tilde{y}_{Tij}\)</span> be a binary toxicity outcome observed at a certain
decision time for the <span class="math inline">\(i\)</span>-th patient at dose level <span class="math inline">\(j\)</span>, where
<span class="math inline">\(\tilde{y}_{Tij}=1\)</span> if the patient has experienced the toxicity and
<span class="math inline">\(\tilde{y}_{Tij}=0\)</span> if the patient has not yet experienced the toxicity.
Let <span class="math inline">\(\gamma_{Tij}\)</span> denote that <span class="math inline">\(\tilde{y}_{Tij}\)</span> is ascertained
(<span class="math inline">\(\gamma_{Tij}=1\)</span>) or is still pending (<span class="math inline">\(\gamma_{Tij}=0\)</span>) at the
decision time, and <span class="math inline">\(u_{Tij}\)</span> denote the time to the toxicity outcome if
<span class="math inline">\(\tilde{y}_{Tij}=1\)</span> and to censoring if <span class="math inline">\(\tilde{y}_{Tij}=0\)</span>. Note that
<span class="math inline">\((\tilde{y}_{Tij},\gamma_{Tij})=(0,1)\)</span> indicates the censoring at
<span class="math inline">\(u_{Tij}=\tau_T\)</span>, and <span class="math inline">\((\tilde{y}_{Tij},\gamma_{Tij})=(0,0)\)</span> indicates
the censoring at <span class="math inline">\(u_{Tij}&lt;\tau_T\)</span>. In the same way,
<span class="math inline">\((\tilde{y}_{Eij},\gamma_{Eij},u_{Eij})\)</span> is defined for efficacy data of
the <span class="math inline">\(i\)</span>-th patient at dose level <span class="math inline">\(j\)</span>. Given the cumulative toxicity and
efficacy data for dose level <span class="math inline">\(j\)</span> at the decision time; i.e.,
<span class="math inline">\(\{(\tilde{y}_{Tij},\gamma_{Tij},u_{Tij}):i=1,\ldots,n_j\}\)</span> and
<span class="math inline">\(\{(\tilde{y}_{Eij},\gamma_{Eij},u_{Eij}):i=1,\ldots,n_j\}\)</span>, we have
<span class="math inline">\(\hat{p}_{Tj}=\sum_{i=1}^{n_j}\tilde{y}_{Tij}/\tilde{n}_{Tj}\)</span> and
<span class="math inline">\(\hat{p}_{Ej}=\sum_{i=1}^{n_j}\tilde{y}_{Eij}/\tilde{n}_{Ej}\)</span>, where
<span class="math inline">\(\tilde{n}_{Tj}=\sum_{i=1}^{n_j}(\gamma_{Tij}+(1-\gamma_{Tij})u_{Tij}/\tau_T)\)</span>
and
<span class="math inline">\(\tilde{n}_{Ej}=\sum_{i=1}^{n_j}(\gamma_{Eij}+(1-\gamma_{Eij})u_{Eij}/\tau_E)\)</span>.</p>
<h4 class="unnumbered" data-number="3.2" id="dose-escalation-procedure-in-gboin-et-and-tite-gboin-et-design">Dose-escalation procedure in gBOIN-ET and TITE-gBOIN-ET design</h4>
<p><span class="citation" data-cites="yuan:2007">Yuan et al. (<a href="#ref-yuan:2007" role="doc-biblioref">2007</a>)</span> proposed an equivalent toxicity score (ETS) to measure the
relative severity of different toxicity grades in the dose allocation
procedure and established the following severity weights related to DLT:
(1) grade 0 and 1 toxicities are not of concern (no DLT); (2) two grade
2 toxicities are equivalent to a grade 3 toxicity (0.5 DLT); (3) a grade
3 toxicity is equivalent to a DLT (1 DLT); and (4) a grade 4 toxicity is
equivalent to 1.5 grade 3 toxicities (1.5 DLT). A target ETS is obtained
by a weighted sum of overall toxicity grades. <span class="citation" data-cites="takeda:2022b">Takeda et al. (<a href="#ref-takeda:2022b" role="doc-biblioref">2022a</a>)</span> extended
this concept to an efficacy score named the equivalent efficacy score
(EES) to measure the relative effectiveness of different efficacy
outcomes and used the relative effectiveness of different efficacy
outcomes: (1) progressive disease (PD) is not an effective outcome (no
response); (2) an SD is equivalent to 0.25 PRs (0.25 responses); (3) a
PR is equivalent to a response (1 response); and (4) a CR is equivalent
to 3.0 PRs (3.0 responses). A target EES is obtained by a weighted sum
of overall efficacy grades. In addition, the normalized ETS and EES are
defined as <span class="math inline">\(\text{ETS}^{\ast}=\text{ETS}/\text{ETS}_{max}\)</span> and
<span class="math inline">\(\text{EES}^{\ast}=\text{EES}/\text{EES}_{max}\)</span> respectively, where
<span class="math inline">\(\text{ETS}_{max}\)</span> is the ETS for the most severe toxicity grade and
<span class="math inline">\(\text{EES}_{max}\)</span> is the EES for the most desirable efficacy response.
The normalized ETS and EES ranging from 0 to 1 are assumed to follow
quasi-Bernoulli distributions.</p>
<p>Let <span class="math inline">\(\mu_{Tj}\)</span> and <span class="math inline">\(\mu_{Ej}\)</span> be a true quasi-Bernoulli toxicity and
efficacy probability at dose level <span class="math inline">\(j\)</span> for <span class="math inline">\(j=1,\ldots,J\)</span>, respectively.
Let <span class="math inline">\(\phi^{\mu}\)</span> and <span class="math inline">\(\delta^{\mu}\)</span> be a target quasi-Bernoulli toxicity
and efficacy probability respectively. Lower and upper quasi-Bernoulli
toxicity boundaries are pre-specified as <span class="math inline">\(\lambda^{\mu}_1\)</span> and
<span class="math inline">\(\lambda^{\mu}_2\)</span> respectively, which satisfy a condition of
<span class="math inline">\(0\leq\lambda^{\mu}_1\leq\phi^{\mu}\leq\lambda^{\mu}_2&lt;1\)</span>. A lower
quasi-Bernoulli efficacy boundary is also pre-specified as
<span class="math inline">\(\eta^{\mu}_1\)</span> with a condition of <span class="math inline">\(0\leq\eta^{\mu}_1&lt;\delta^{\mu}&lt;1\)</span>.
Let <span class="math inline">\(\hat{\mu}_{Tj}\)</span> and <span class="math inline">\(\hat{\mu}_{Ej}\)</span> be an observed quasi-Bernoulli
toxicity and efficacy probability at dose level <span class="math inline">\(j\)</span> respectively, which
are calculated using the cumulative toxicity and efficacy data in
different ways for the gBOIN-ET and TITE-gBOIN-ET design (see
subsections below). Then, the dose level used in the next cohort is
determined by the following rule:</p>
<ol type="1">
<li><p>If <span class="math inline">\(\hat{\mu}_{Tj}\leq\lambda^{\mu}_1\)</span> and
<span class="math inline">\(\hat{\mu}_{Ej}\leq\eta^{\mu}_1\)</span>, escalate to dose level <span class="math inline">\(j+1\)</span>.</p></li>
<li><p>If <span class="math inline">\(\hat{\mu}_{Tj}&lt;\lambda^{\mu}_2\)</span> and
<span class="math inline">\(\hat{\mu}_{Ej}&gt;\eta^{\mu}_1\)</span>, stay at the same dose level <span class="math inline">\(j\)</span>.</p></li>
<li><p>If <span class="math inline">\(\hat{\mu}_{Tj}\geq\lambda^{\mu}_2\)</span>, de-escalate to dose level
<span class="math inline">\(j-1\)</span>.</p></li>
<li><p>If <span class="math inline">\(\lambda^{\mu}_1&lt;\hat{\mu}_{Tj}&lt;\lambda^{\mu}_2\)</span> and
<span class="math inline">\(\hat{\mu}_{Ej}\leq\eta^{\mu}_1\)</span>, consider the following additional
rules:</p>
<ol type="1">
<li><p>If dose level <span class="math inline">\(j+1\)</span> has never been used until the current
cohort, escalate to dose level <span class="math inline">\(j+1\)</span>.</p></li>
<li><p>Otherwise, choose <span class="math inline">\(\arg\max_{j&#39;\in\{j-1,j,j+1\}}\hat{\mu}_{Ej&#39;}\)</span>
as the dose level for the next cohort; if more than two dose
levels have the same highest observed quasi-Bernoulli efficacy
probability, randomly select one of them.</p></li>
</ol></li>
</ol>
<p>Optimal values of <span class="math inline">\((\lambda^{\mu}_1,\lambda^{\mu}_2,\eta^{\mu}_1)\)</span> are
determined as values that minimize a posterior probability of incorrect
decisions under the following six hypotheses:
<span class="math display">\[\begin{gathered}
H_{1j}: (\mu_{Tj}=\phi^{\mu}_1,\mu_{Ej}=\delta^{\mu}_1),\quad H_{2j}: (\mu_{Tj}=\phi^{\mu}_1,\mu_{Ej}=\delta^{\mu}),\quad H_{3j}: (\mu_{Tj}=\phi^{\mu},\mu_{Ej}=\delta^{\mu}_1), \\
H_{4j}: (\mu_{Tj}=\phi^{\mu},\mu_{Ej}=\delta^{\mu}),\quad H_{5j}: (\mu_{Tj}=\phi^{\mu}_2,\mu_{Ej}=\delta^{\mu}_1),\quad H_{6j}: (\mu_{Tj}=\phi^{\mu}_2,\mu_{Ej}=\delta^{\mu})
\end{gathered}\]</span>
where <span class="math inline">\(\phi^{\mu}_1\)</span> is the highest quasi-Bernoulli toxicity probability
that is deemed sub-therapeutic such that dose-escalation should be
pursued, and <span class="math inline">\(\phi^{\mu}_2\)</span> is the lowest quasi-Bernoulli toxicity
probability that is deemed overly toxic such that dose de-escalation is
needed. <span class="math inline">\(\delta^{\mu}_1\)</span> is the minimum quasi-Bernoulli probability
deemed efficacious such that the dose levels with less than
<span class="math inline">\(\delta^{\mu}_1\)</span> are considered sub-therapeutic. Given non-informative
prior probabilities of the six hypotheses; i.e.,
<span class="math inline">\(Pr(H_{1j})=Pr(H_{2j})=Pr(H_{3j})=Pr(H_{4j})=Pr(H_{5j})=Pr(H_{6j})=1/6\)</span>,
a grid search approach can be used to find the optimal values of
<span class="math inline">\((\lambda^{\mu}_1,\lambda^{\mu}_2,\eta^{\mu}_1)\)</span> conditioned on
<span class="math inline">\(\phi^{\mu}_1&lt;\lambda^{\mu}_1&lt;\phi^{\mu}&lt;\lambda^{\mu}_2&lt;\phi^{\mu}_2\)</span>
and <span class="math inline">\(\delta^{\mu}_2&lt;\eta^{\mu}_2&lt;\delta^{\mu}\)</span>. For example, considering
<span class="math inline">\(\phi^{\mu}=0.313\)</span> (which is the case of target <span class="math inline">\(\text{ETS}=0.47\)</span> and
<span class="math inline">\(\text{ETS}_{max}=1.5\)</span>), <span class="math inline">\(\phi^{\mu}_1=0.1\phi^{\mu}\)</span>,
<span class="math inline">\(\phi^{\mu}_2=1.4\phi^{\mu}\)</span>, <span class="math inline">\(\delta^{\mu}=0.583\)</span> (which is the case of
target <span class="math inline">\(\text{EES}=1.75\)</span> and <span class="math inline">\(\text{EES}_{max}=3.0\)</span>), and
<span class="math inline">\(\delta^{\mu}_1=0.6\delta^{\mu}\)</span>, the optimal values of
<span class="math inline">\((\lambda^{\mu}_1,\lambda^{\mu}_2,\eta^{\mu}_1)\)</span> are given by
<span class="math inline">\(\lambda^{\mu}_1=0.14\)</span>, <span class="math inline">\(\lambda^{\mu}_2=0.37\)</span>, and <span class="math inline">\(\eta^{\mu}_1=0.46\)</span>.</p>
<p>The relationship between the gBOIN-ET and TITE-gBOIN-ET designs is the
same as that between the BOIN-ET and TITE-BOIN-ET designs. The gBOIN-ET
design requires all the patients enrolled in the current cohort to
complete the toxicity and efficacy assessment windows. In contrast, the
TITE-gBOIN-ET design allows for flexibility in the decision time, where
the dose escalation decision is based on the cumulative data at a
certain decision time. The observed quasi-Bernoulli toxicity and
efficacy probabilities, <span class="math inline">\(\hat{\mu}_{Tj}\)</span> and <span class="math inline">\(\hat{\mu}_{Ej}\)</span> for
<span class="math inline">\(i=1,\ldots,n_j\)</span>, in the gBOIN-ET and TITE-gBOIN-ET design are
calculated as follows.</p>
<h5 class="unnumbered" data-number="3.2.1" id="gboin-et">gBOIN-ET <span class="citation" data-cites="takeda:2022b">(<a href="#ref-takeda:2022b" role="doc-biblioref">Takeda et al. 2022a</a>)</span>:</h5>
<p>Let <span class="math inline">\(x_{Tij}\)</span> and <span class="math inline">\(x_{Eij}\)</span> be a quasi-Bernoulli toxicity and efficacy
outcome (i.e., normalized ETS and EES) observed within the assessment
windows of <span class="math inline">\(\tau_T\)</span> and <span class="math inline">\(\tau_E\)</span> for the <span class="math inline">\(i\)</span>-th patient at dose level
<span class="math inline">\(j\)</span>, respectively. Given the cumulative toxicity and efficacy data for
dose level <span class="math inline">\(j\)</span>; i.e., <span class="math inline">\(\{x_{Tij}:i=1,\ldots,n_j\}\)</span> and
<span class="math inline">\(\{x_{Eij}:i=1,\ldots,n_j\}\)</span>, we have
<span class="math inline">\(\hat{\mu}_{Tj}=\sum_{i=1}^{n_j}x_{Tij}/n_j\)</span> and
<span class="math inline">\(\hat{\mu}_{Ej}=\sum_{i=1}^{n_j}x_{Eij}/n_j\)</span>.</p>
<h5 class="unnumbered" data-number="3.2.2" id="tite-gboin-et">TITE-gBOIN-ET <span class="citation" data-cites="takeda:2023">(<a href="#ref-takeda:2023" role="doc-biblioref">Takeda et al. 2023</a>)</span>:</h5>
<p>Let <span class="math inline">\(\tilde{x}_{Tij}\)</span> be a quasi-Bernoulli toxicity outcome (i.e.,
normalized ETS) observed at a certain decision time for the <span class="math inline">\(i\)</span>-th
patient at dose level <span class="math inline">\(j\)</span>, where <span class="math inline">\(\tilde{x}_{Tij}=1\)</span> if the patient has
experienced the toxicity and <span class="math inline">\(\tilde{x}_{Tij}=0\)</span> if the patient has not
yet experienced the toxicity. Let <span class="math inline">\(\kappa_{Tij}\)</span> denote that
<span class="math inline">\(\tilde{x}_{Tij}\)</span> is ascertained (<span class="math inline">\(\kappa_{Tij}=1\)</span>) or is still pending
(<span class="math inline">\(\kappa_{Tij}=0\)</span>) at the decision time, and <span class="math inline">\(v_{Tij}\)</span> denote the time
to the toxicity outcome if <span class="math inline">\(\tilde{x}_{Tij}=1\)</span> and to censoring if
<span class="math inline">\(\tilde{x}_{Tij}=0\)</span>. Note that <span class="math inline">\((\tilde{x}_{Tij},\kappa_{Tij})=(0,1)\)</span>
indicates the censoring at <span class="math inline">\(v_{Tij}=\tau_T\)</span>, and
<span class="math inline">\((\tilde{x}_{Tij},\kappa_{Tij})=(0,0)\)</span> indicates the censoring at
<span class="math inline">\(v_{Tij}&lt;\tau_T\)</span>. In the same way,
<span class="math inline">\((\tilde{x}_{Eij},\kappa_{Eij},v_{Eij})\)</span> is defined for efficacy data of
the <span class="math inline">\(i\)</span>-th patient at dose level <span class="math inline">\(j\)</span>. Given the cumulative toxicity and
efficacy data for dose level <span class="math inline">\(j\)</span> at the decision time; i.e.,
<span class="math inline">\(\{(\tilde{x}_{Tij},\kappa_{Tij},v_{Tij}):i=1,\ldots,n_j\}\)</span> and
<span class="math inline">\(\{(\tilde{x}_{Eij},\kappa_{Eij},v_{Eij}):i=1,\ldots,n_j\}\)</span>, we have
<span class="math inline">\(\hat{\mu}_{Tj}=\sum_{i=1}^{n_j}\tilde{x}_{Tij}/\dot{n}_{Tj}\)</span> and
<span class="math inline">\(\hat{\mu}_{Ej}=\sum_{i=1}^{n_j}\tilde{x}_{Eij}/\dot{n}_{Ej}\)</span>, where
<span class="math inline">\(\dot{n}_{Tj}=\sum_{i=1}^{n_j}(\kappa_{Tij}+(1-\kappa_{Tij})v_{Tij}/\tau_T)\)</span>
and
<span class="math inline">\(\dot{n}_{Ej}=\sum_{i=1}^{n_j}(\kappa_{Eij}+(1-\kappa_{Eij})v_{Eij}/\tau_E)\)</span>.</p>
<h4 class="unnumbered" data-number="3.3" id="optimal-biological-dose-selection">Optimal biological dose selection</h4>
<p>In the BOIN-ET design family, the selection of OBD is carried out at the
end of the trial after completing the dose-escalation procedure.
Firstly, the (quasi-Bernoulli) toxicity and efficacy probabilities at
each dose level are estimated using all data obtained from the entire
cohort. Then, given the estimated (quasi-Bernoulli) toxicity and
efficacy probabilities, the utility to measure the toxicity-efficacy
trade-off is computed and serves as a basis for the OBD selection. We
below describe the estimation method of the toxicity and efficacy
probabilities and the OBD selection measures.</p>
<h5 class="unnumbered" data-number="3.3.1" id="estimation-of-quasi-bernoulli-toxicity-probability">Estimation of (quasi-Bernoulli) toxicity probability</h5>
<p>To ensure the monotonically increasing dose-toxicity relationship,
isotonic regression <span class="citation" data-cites="bril:1984">(<a href="#ref-bril:1984" role="doc-biblioref">Bril et al. 1984</a>)</span> is usually used to estimate the
(quasi-Bernoulli) toxicity probability. Specifically, the
pool-adjacent-violators algorithm <span class="citation" data-cites="barlow:1972">(<a href="#ref-barlow:1972" role="doc-biblioref">Barlow et al. 1972</a>)</span> is performed on the
observed (quasi-Bernoulli) toxicity probability to obtain the estimated
(quasi-Bernoulli) toxicity probability.</p>
<h5 class="unnumbered" data-number="3.3.2" id="estimation-of-quasi-bernoulli-efficacy-probability">Estimation of (quasi-Bernoulli) efficacy probability</h5>
<p>The dose-efficacy relationship is typically unknown at the design stage
and may show nonmonotonic patterns. There are three methods available to
estimate the (quasi-Bernoulli) efficacy probability:</p>
<ul>
<li><p>Simple use of the observed (quasi-Bernoulli) efficacy probability</p></li>
<li><p>Model averaging of multiple unimodal isotonic regressions
<span class="citation" data-cites="lin:2017">(<a href="#ref-lin:2017" role="doc-biblioref">Lin and Yin 2017</a>)</span></p></li>
<li><p>Fractional polynomial logistic regression <span class="citation" data-cites="takeda:2018">(<a href="#ref-takeda:2018" role="doc-biblioref">Takeda et al. 2018</a>)</span></p></li>
</ul>
<h5 class="unnumbered" data-number="3.3.3" id="measure-to-select-the-obd">Measure to select the OBD</h5>
<p>Given the estimated (quasi-Bernoulli) toxicity and efficacy
probabilities, there are four different measures to select the OBD.
Three of them are to select a dose that maximizes a utility quantifying
the toxicity-efficacy trade-off, and the other is to select an
admissible dose that offers the highest estimated efficacy probability.
Specifically, the OBD is selected as a dose level of:</p>
<ul>
<li><p>Maximizing utility defined by a weighted function
<span class="citation" data-cites="lin:2017 zhou:2019">(<a href="#ref-lin:2017" role="doc-biblioref">Lin and Yin 2017</a>; <a href="#ref-zhou:2019" role="doc-biblioref">Zhou et al. 2019</a>)</span></p></li>
<li><p>Maximizing utility defined by truncated linear functions
<span class="citation" data-cites="li:2020 lin:2021">(<a href="#ref-li:2020" role="doc-biblioref">Li et al. 2020</a>; <a href="#ref-lin:2021" role="doc-biblioref">Lin and Ji 2021</a>)</span></p></li>
<li><p>Maximizing utility defined by scoring <span class="citation" data-cites="lin:2020b">(<a href="#ref-lin:2020b" role="doc-biblioref">Lin et al. 2020</a>)</span></p></li>
<li><p>Having the highest (quasi-Bernoulli) efficacy probability among
admissible doses <span class="citation" data-cites="takeda:2018">(<a href="#ref-takeda:2018" role="doc-biblioref">Takeda et al. 2018</a>)</span></p></li>
</ul>
<p><span class="citation" data-cites="yamaguchi:2024">Yamaguchi et al. (<a href="#ref-yamaguchi:2024" role="doc-biblioref">2024</a>)</span> reported the comparative performance of several OBD
selection approaches, in which users can find guidance on the choice of
(i) the method to estimate the efficacy probability, and (ii) the
measure to select the OBD. In general, the most straightforward measure,
selecting an admissible dose with the highest efficacy, is recommended
for selecting the OBD due to its simplicity, and the efficacy
probability modeling would lead to limited gains in the OBD selection
<span class="citation" data-cites="yamaguchi:2024">(<a href="#ref-yamaguchi:2024" role="doc-biblioref">Yamaguchi et al. 2024</a>)</span>. Default options used in many functions of
<a href="https://CRAN.R-project.org/package=boinet"><strong>boinet</strong></a> package are (i)
simple use of the observed (quasi-Bernoulli) efficacy probability, and
(ii) having the highest (quasi-Bernoulli) efficacy probability among
admissible doses.</p>
<h4 class="unnumbered" data-number="3.4" id="additional-dose-escalation-rules">Additional dose-escalation rules</h4>
<p>Some additional dose-escalation rules implemented in the <strong>boinet</strong>
package are described below. During the dose-escalation, dose skipping
is not allowed from a safety viewpoint. In addition, a dose elimination
rule is introduced to avoid patient assignment to inefficient or
severely toxic dose levels. A dose level is eliminated from the
investigation if a posterior probability that the toxicity probability
is greater than the target toxicity probability is larger than a certain
threshold, which is set to 0.95 as the default. Apart from this, a dose
level is eliminated from the investigation if a posterior probability
that the efficacy probability is less than the minimum efficacy
probability is larger than a certain threshold, which is set to 0.99 as
the default. When dose levels at which the next cohort patients would be
assigned have been eliminated, the trial is terminated, and the patient
enrollment is stopped. At the end of the trial, if all dose levels are
eliminated due to these criteria, the OBD is determined as not
applicable.</p>
<p>Other cases in which early trial termination is implemented include (i)
when the decision is de-escalation from the lowest dose, and (ii) when
the number of patients treated at the current dose level reaches a
certain threshold, which is set to the maximum sample size as default.
Moreover, when the decision is escalation from the highest dose, the
stay decision is made alternatively. In addition, if no patients are
allocated to some dose levels (for example, a case where the
dose-escalation procedure does not reach the highest dose level), these
dose levels are not included in the estimation of toxicity and efficacy
probabilities.</p>
<h3 data-number="4" id="implementation"><span class="header-section-number">4</span> Implementation</h3>
<p>We below illustrate the four main functions from the
<a href="https://CRAN.R-project.org/package=boinet"><strong>boinet</strong></a> package:
<code>boinet()</code>, <code>tite.boinet()</code>, <code>gboinet()</code>, and <code>tite.gboinet()</code> which
conduct simulation studies with a particular scenario and provide
operating characteristics of the BOIN-ET, TITE-BOIN-ET, gBOIN-ET, and
TITE-gBOIN-ET designs, respectively. The <strong>boinet</strong> package is available
from the Comprehensive R Archive Network (CRAN) at
<a href="https://CRAN.R-project.org/package=boinet" class="uri">https://CRAN.R-project.org/package=boinet</a>. Further to the conduct of
simulation studies, the package offers a function, <code>obd.select()</code>, which
can be used for selecting the OBD at the end of an actual trial. The
illustration of this function is omitted here but it asks users to enter
the estimated toxicity and efficacy probabilities for each dose level,
the design parameters (e.g., target toxicity and efficacy probability),
and the measure to select the OBD, returning an OBD.</p>
<p>As simulation study settings used commonly for the BOIN-ET,
TITE-BOIN-ET, gBOIN-ET, and TITE-gBOIN-ET design, consider a
dose-finding trial with six dose levels and suppose that three patients
were enrolled per cohort. In particular, the trial treated three
patients at the lowest dose level in the first cohort and then
sequentially assigned three patients to the next dose level until
reaching the maximum sample size of 36 patients (i.e., 12 cohorts at the
maximum). The target (quasi-Bernoulli) toxicity and efficacy probability
were set to 0.33 and 0.60 respectively. The toxicity and efficacy
assessment windows were 30 and 45 days respectively, and the accrual
rate (average number of days necessary to enroll 1 patient) was 10 days.
These simulation study settings were given by:</p>
<div class="sourceCode" id="cb1"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb1-1"><a href="#cb1-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> n.dose      <span class="ot">&lt;-</span> <span class="dv">6</span>   <span class="co"># Six dose levels</span></span>
<span id="cb1-2"><a href="#cb1-2" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> start.dose  <span class="ot">&lt;-</span> <span class="dv">1</span>   <span class="co"># Starting with the lowest dose level</span></span>
<span id="cb1-3"><a href="#cb1-3" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> size.cohort <span class="ot">&lt;-</span> <span class="dv">3</span>   <span class="co"># Three patients assigned to each cohort</span></span>
<span id="cb1-4"><a href="#cb1-4" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> n.cohort    <span class="ot">&lt;-</span> <span class="dv">12</span>  <span class="co"># Twelve cohorts at the maximum</span></span>
<span id="cb1-5"><a href="#cb1-5" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb1-6"><a href="#cb1-6" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> <span class="co"># Target (quasi-Bernoulli) toxicity and efficacy probability</span></span>
<span id="cb1-7"><a href="#cb1-7" aria-hidden="true" tabindex="-1"></a><span class="er">&gt;</span> phi   <span class="ot">&lt;-</span> <span class="fl">0.33</span></span>
<span id="cb1-8"><a href="#cb1-8" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> delta <span class="ot">&lt;-</span> <span class="fl">0.60</span></span>
<span id="cb1-9"><a href="#cb1-9" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span></span>
<span id="cb1-10"><a href="#cb1-10" aria-hidden="true" tabindex="-1"></a><span class="er">&gt;</span> tau.T   <span class="ot">&lt;-</span> <span class="dv">30</span>  <span class="co"># Thirty days of toxicity assessment windows</span></span>
<span id="cb1-11"><a href="#cb1-11" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> tau.E   <span class="ot">&lt;-</span> <span class="dv">45</span>  <span class="co"># Forty-five days of efficacy assessment windows</span></span>
<span id="cb1-12"><a href="#cb1-12" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> accrual <span class="ot">&lt;-</span> <span class="dv">10</span>  <span class="co"># Ten days of accrual rate</span></span></code></pre></div>
<figure>
<img src="figure1.png" style="width:100.0%" alt="graphic without alt text" />
<figcaption> Dose-toxicity and dose-efficacy relationship considered in
simulation study.</figcaption>
</figure>
<h4 class="unnumbered" data-number="4.1" id="boin-et-1">BOIN-ET</h4>
<p>The <code>boinet()</code> function supports the conduct of simulation studies for
the BOIN-ET design and returns a list of the summary results. The usage
of the <code>boinet()</code> function is as follows:</p>
<div class="sourceCode" id="cb2"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb2-1"><a href="#cb2-1" aria-hidden="true" tabindex="-1"></a><span class="fu">boinet</span>(</span>
<span id="cb2-2"><a href="#cb2-2" aria-hidden="true" tabindex="-1"></a>  n.dose, start.dose, size.cohort, n.cohort,</span>
<span id="cb2-3"><a href="#cb2-3" aria-hidden="true" tabindex="-1"></a>  toxprob, effprob,</span>
<span id="cb2-4"><a href="#cb2-4" aria-hidden="true" tabindex="-1"></a>  <span class="at">phi=</span><span class="fl">0.3</span>, <span class="at">phi1=</span>phi<span class="sc">*</span><span class="fl">0.1</span>, <span class="at">phi2=</span>phi<span class="sc">*</span><span class="fl">1.4</span>, <span class="at">delta=</span><span class="fl">0.6</span>, <span class="at">delta1=</span>delta<span class="sc">*</span><span class="fl">0.6</span>,</span>
<span id="cb2-5"><a href="#cb2-5" aria-hidden="true" tabindex="-1"></a>  <span class="at">alpha.T1=</span><span class="fl">0.5</span>, <span class="at">alpha.E1=</span><span class="fl">0.5</span>, tau.T, tau.E,</span>
<span id="cb2-6"><a href="#cb2-6" aria-hidden="true" tabindex="-1"></a>  <span class="at">te.corr=</span><span class="fl">0.2</span>, <span class="at">gen.event.time=</span><span class="st">&quot;weibull&quot;</span>,</span>
<span id="cb2-7"><a href="#cb2-7" aria-hidden="true" tabindex="-1"></a>  accrual, <span class="at">gen.enroll.time=</span><span class="st">&quot;uniform&quot;</span>,</span>
<span id="cb2-8"><a href="#cb2-8" aria-hidden="true" tabindex="-1"></a>  <span class="at">stopping.npts=</span>size.cohort<span class="sc">*</span>n.cohort,</span>
<span id="cb2-9"><a href="#cb2-9" aria-hidden="true" tabindex="-1"></a>  <span class="at">stopping.prob.T=</span><span class="fl">0.95</span>, <span class="at">stopping.prob.E=</span><span class="fl">0.99</span>,</span>
<span id="cb2-10"><a href="#cb2-10" aria-hidden="true" tabindex="-1"></a>  <span class="at">estpt.method=</span><span class="st">&quot;obs.prob&quot;</span>, <span class="at">obd.method=</span><span class="st">&quot;max.effprob&quot;</span>,</span>
<span id="cb2-11"><a href="#cb2-11" aria-hidden="true" tabindex="-1"></a>  <span class="at">w1=</span><span class="fl">0.33</span>, <span class="at">w2=</span><span class="fl">1.09</span>,</span>
<span id="cb2-12"><a href="#cb2-12" aria-hidden="true" tabindex="-1"></a>  <span class="at">plow.ast=</span>phi1, <span class="at">pupp.ast=</span>phi2, <span class="at">qlow.ast=</span>delta1<span class="sc">/</span><span class="dv">2</span>, <span class="at">qupp.ast=</span>delta,</span>
<span id="cb2-13"><a href="#cb2-13" aria-hidden="true" tabindex="-1"></a>  <span class="at">psi00=</span><span class="dv">40</span>, <span class="at">psi11=</span><span class="dv">60</span>,</span>
<span id="cb2-14"><a href="#cb2-14" aria-hidden="true" tabindex="-1"></a>  <span class="at">n.sim=</span><span class="dv">1000</span>, <span class="at">seed.sim=</span><span class="dv">100</span>)</span></code></pre></div>
<p>Some of the key arguments are detailed in Tables <a href="#tab:T1">1</a>, <a href="#tab:T2">2</a>, <a href="#tab:T3">3</a>, and <a href="#tab:T4">4</a>, in the Appendix. Here, <code>toxprob</code> and <code>effprob</code> are vectors of true toxicity and
efficacy probabilities with a length equal to the number of dose levels
investigated.</p>
<p>We considered a scenario of the true toxicity and efficacy probabilities
as given in Figure 1(a):</p>
<div class="sourceCode" id="cb3"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb3-1"><a href="#cb3-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> toxprob <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="fl">0.05</span>,<span class="fl">0.15</span>,<span class="fl">0.25</span>,<span class="fl">0.35</span>,<span class="fl">0.45</span>,<span class="fl">0.55</span>)</span>
<span id="cb3-2"><a href="#cb3-2" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> effprob <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="fl">0.05</span>,<span class="fl">0.30</span>,<span class="fl">0.55</span>,<span class="fl">0.57</span>,<span class="fl">0.59</span>,<span class="fl">0.61</span>)</span></code></pre></div>
<p>and used (i) the observed efficacy probability for the efficacy
probability estimation and (ii) the highest estimated efficacy
probability as the measure to select the OBD:</p>
<div class="sourceCode" id="cb4"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb4-1"><a href="#cb4-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> estpt.method <span class="ot">&lt;-</span> <span class="st">&quot;obs.prob&quot;</span></span>
<span id="cb4-2"><a href="#cb4-2" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> obd.method   <span class="ot">&lt;-</span> <span class="st">&quot;max.effprob&quot;</span></span></code></pre></div>
<p>Then, the <code>boinet()</code> is implemented with the previously specified
arguments:</p>
<div class="sourceCode" id="cb5"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb5-1"><a href="#cb5-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> <span class="fu">boinet</span>(</span>
<span id="cb5-2"><a href="#cb5-2" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">n.dose=</span>n.dose, <span class="at">start.dose=</span>start.dose,</span>
<span id="cb5-3"><a href="#cb5-3" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">size.cohort=</span>size.cohort, <span class="at">n.cohort=</span>n.cohort,</span>
<span id="cb5-4"><a href="#cb5-4" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">toxprob=</span>toxprob, <span class="at">effprob=</span>effprob,</span>
<span id="cb5-5"><a href="#cb5-5" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">phi=</span>phi, <span class="at">delta=</span>delta,</span>
<span id="cb5-6"><a href="#cb5-6" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">tau.T=</span>tau.T, <span class="at">tau.E=</span>tau.E, <span class="at">accrual=</span>accrual,</span>
<span id="cb5-7"><a href="#cb5-7" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">estpt.method=</span>estpt.method, <span class="at">obd.method=</span>obd.method)</span></code></pre></div>
<p>and returns the following output:</p>
<div class="sourceCode" id="cb6"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb6-1"><a href="#cb6-1" aria-hidden="true" tabindex="-1"></a>Simulation results<span class="sc">:</span></span>
<span id="cb6-2"><a href="#cb6-2" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-3"><a href="#cb6-3" aria-hidden="true" tabindex="-1"></a>                 Dose1  Dose2  Dose3  Dose4  Dose5  Dose6</span>
<span id="cb6-4"><a href="#cb6-4" aria-hidden="true" tabindex="-1"></a>Toxicity prob.    <span class="fl">0.05</span>   <span class="fl">0.15</span>   <span class="fl">0.25</span>   <span class="fl">0.35</span>   <span class="fl">0.45</span>   <span class="fl">0.55</span></span>
<span id="cb6-5"><a href="#cb6-5" aria-hidden="true" tabindex="-1"></a>Efficacy prob.    <span class="fl">0.05</span>   <span class="fl">0.30</span>   <span class="fl">0.55</span>   <span class="fl">0.57</span>   <span class="fl">0.59</span>   <span class="fl">0.61</span></span>
<span id="cb6-6"><a href="#cb6-6" aria-hidden="true" tabindex="-1"></a>No. Pts treated   <span class="fl">3.40</span>   <span class="fl">7.00</span>  <span class="fl">15.90</span>   <span class="fl">7.00</span>   <span class="fl">2.00</span>   <span class="fl">0.60</span></span>
<span id="cb6-7"><a href="#cb6-7" aria-hidden="true" tabindex="-1"></a>Select %          <span class="fl">1.70</span>  <span class="fl">12.00</span>  <span class="fl">54.40</span>  <span class="fl">25.50</span>   <span class="fl">5.30</span>   <span class="fl">0.80</span></span>
<span id="cb6-8"><a href="#cb6-8" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-9"><a href="#cb6-9" aria-hidden="true" tabindex="-1"></a>No OBD %                 <span class="fl">0.3</span></span>
<span id="cb6-10"><a href="#cb6-10" aria-hidden="true" tabindex="-1"></a>Trial <span class="fu">duration</span> (days)  <span class="fl">778.9</span></span>
<span id="cb6-11"><a href="#cb6-11" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-12"><a href="#cb6-12" aria-hidden="true" tabindex="-1"></a>Trial design settings<span class="sc">:</span></span>
<span id="cb6-13"><a href="#cb6-13" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-14"><a href="#cb6-14" aria-hidden="true" tabindex="-1"></a>Target toxicity prob.    <span class="fl">0.330</span></span>
<span id="cb6-15"><a href="#cb6-15" aria-hidden="true" tabindex="-1"></a>Target efficacy prob.    <span class="fl">0.600</span></span>
<span id="cb6-16"><a href="#cb6-16" aria-hidden="true" tabindex="-1"></a>Lower toxicity boundary  <span class="fl">0.153</span></span>
<span id="cb6-17"><a href="#cb6-17" aria-hidden="true" tabindex="-1"></a>Upper toxicity boundary  <span class="fl">0.390</span></span>
<span id="cb6-18"><a href="#cb6-18" aria-hidden="true" tabindex="-1"></a>Lower efficacy boundary  <span class="fl">0.480</span></span>
<span id="cb6-19"><a href="#cb6-19" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-20"><a href="#cb6-20" aria-hidden="true" tabindex="-1"></a>Tox. assessment <span class="fu">window</span> (days)  <span class="dv">30</span></span>
<span id="cb6-21"><a href="#cb6-21" aria-hidden="true" tabindex="-1"></a>Eff. assessment <span class="fu">window</span> (days)  <span class="dv">45</span></span>
<span id="cb6-22"><a href="#cb6-22" aria-hidden="true" tabindex="-1"></a>Accrual <span class="fu">rate</span> (days)            <span class="dv">10</span></span>
<span id="cb6-23"><a href="#cb6-23" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-24"><a href="#cb6-24" aria-hidden="true" tabindex="-1"></a>Efficacy prob. estimation<span class="sc">:</span> obs.prob</span>
<span id="cb6-25"><a href="#cb6-25" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb6-26"><a href="#cb6-26" aria-hidden="true" tabindex="-1"></a>OBD selection<span class="sc">:</span> max.effprob</span></code></pre></div>
<p>The simulation results include the number or the percentage of times
that each dose level was selected as OBD (<code>Select %</code>), the average
number of patients who were treated at each dose level
(<code>No. Pts treated</code>), the percentage of times that the study was
terminated (<code>Stop %</code>), and the expected study duration
(<code>Trial duration (days)</code>). The trial design settings, such as the lower
and upper toxicity/efficacy boundaries used for the dose-escalation, are
also displayed. The average number of patients treated at Dose 3 was
15.90, and Dose 3 was selected as an OBD in 54.40% of the simulated
trials, on average. The OBD was not selected in 0.3% of the simulated
trials, on average. The trial duration was an average of 778.9 days.</p>
<h4 class="unnumbered" data-number="4.2" id="tite-boin-et-1">TITE-BOIN-ET</h4>
<p>The <code>tite.boinet()</code> function supports the conduct of simulation studies
for the TITE-BOIN-ET design and returns a list of the summary results.
The usage of the <code>tite.boinet()</code> function is as follows:</p>
<div class="sourceCode" id="cb7"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb7-1"><a href="#cb7-1" aria-hidden="true" tabindex="-1"></a><span class="fu">tite.boinet</span>(</span>
<span id="cb7-2"><a href="#cb7-2" aria-hidden="true" tabindex="-1"></a>  n.dose, start.dose, size.cohort, n.cohort,</span>
<span id="cb7-3"><a href="#cb7-3" aria-hidden="true" tabindex="-1"></a>  toxprob, effprob,</span>
<span id="cb7-4"><a href="#cb7-4" aria-hidden="true" tabindex="-1"></a>  <span class="at">phi=</span><span class="fl">0.3</span>, <span class="at">phi1=</span>phi<span class="sc">*</span><span class="fl">0.1</span>, <span class="at">phi2=</span>phi<span class="sc">*</span><span class="fl">1.4</span>, <span class="at">delta=</span><span class="fl">0.6</span>, <span class="at">delta1=</span>delta<span class="sc">*</span><span class="fl">0.6</span>,</span>
<span id="cb7-5"><a href="#cb7-5" aria-hidden="true" tabindex="-1"></a>  <span class="at">alpha.T1=</span><span class="fl">0.5</span>, <span class="at">alpha.E1=</span><span class="fl">0.5</span>, tau.T, tau.E,</span>
<span id="cb7-6"><a href="#cb7-6" aria-hidden="true" tabindex="-1"></a>  <span class="at">te.corr=</span><span class="fl">0.2</span>, <span class="at">gen.event.time=</span><span class="st">&quot;weibull&quot;</span>,</span>
<span id="cb7-7"><a href="#cb7-7" aria-hidden="true" tabindex="-1"></a>  accrual, <span class="at">gen.enroll.time=</span><span class="st">&quot;uniform&quot;</span>,</span>
<span id="cb7-8"><a href="#cb7-8" aria-hidden="true" tabindex="-1"></a>  <span class="at">stopping.npts=</span>size.cohort<span class="sc">*</span>n.cohort,</span>
<span id="cb7-9"><a href="#cb7-9" aria-hidden="true" tabindex="-1"></a>  <span class="at">stopping.prob.T=</span><span class="fl">0.95</span>, <span class="at">stopping.prob.E=</span><span class="fl">0.99</span>,</span>
<span id="cb7-10"><a href="#cb7-10" aria-hidden="true" tabindex="-1"></a>  <span class="at">estpt.method=</span><span class="st">&quot;obs.prob&quot;</span>, <span class="at">obd.method=</span><span class="st">&quot;max.effprob&quot;</span>,</span>
<span id="cb7-11"><a href="#cb7-11" aria-hidden="true" tabindex="-1"></a>  <span class="at">w1=</span> <span class="fl">0.33</span>, <span class="at">w2=</span><span class="fl">1.09</span>,</span>
<span id="cb7-12"><a href="#cb7-12" aria-hidden="true" tabindex="-1"></a>  <span class="at">plow.ast=</span>phi1, <span class="at">pupp.ast=</span>phi2, <span class="at">qlow.ast=</span>delta1<span class="sc">/</span><span class="dv">2</span>, <span class="at">qupp.ast=</span>delta,</span>
<span id="cb7-13"><a href="#cb7-13" aria-hidden="true" tabindex="-1"></a>  <span class="at">psi00=</span><span class="dv">40</span>, <span class="at">psi11=</span><span class="dv">60</span>,</span>
<span id="cb7-14"><a href="#cb7-14" aria-hidden="true" tabindex="-1"></a>  <span class="at">n.sim=</span><span class="dv">1000</span>, <span class="at">seed.sim=</span><span class="dv">100</span>)</span></code></pre></div>
<p>Some of the key arguments are detailed in Tables <a href="#tab:T1">1</a>, <a href="#tab:T2">2</a>, <a href="#tab:T3">3</a>, and <a href="#tab:T4">4</a>, in the Appendix. It should be noted that the TITE-BOIN-ET design has a
suspension rule which holds off the decision on dose allocation (i.e.,
patient enrollment to the next cohort) until adequate information is
collected, where the dose allocation is allowed only if more than 50% of
patients have finished the assessment at the current dose level.</p>
<p>We considered a scenario of the true toxicity and efficacy probabilities
as given in Figure 1(a):</p>
<div class="sourceCode" id="cb8"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb8-1"><a href="#cb8-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> toxprob <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="fl">0.05</span>,<span class="fl">0.15</span>,<span class="fl">0.25</span>,<span class="fl">0.35</span>,<span class="fl">0.45</span>,<span class="fl">0.55</span>)</span>
<span id="cb8-2"><a href="#cb8-2" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> effprob <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="fl">0.05</span>,<span class="fl">0.30</span>,<span class="fl">0.55</span>,<span class="fl">0.57</span>,<span class="fl">0.59</span>,<span class="fl">0.61</span>)</span></code></pre></div>
<p>and used (i) the observed efficacy probability for the efficacy
probability estimation and (ii) the highest estimated efficacy
probability as the measure to select the OBD:</p>
<div class="sourceCode" id="cb9"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb9-1"><a href="#cb9-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> estpt.method <span class="ot">&lt;-</span> <span class="st">&quot;obs.prob&quot;</span></span>
<span id="cb9-2"><a href="#cb9-2" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> obd.method   <span class="ot">&lt;-</span> <span class="st">&quot;max.effprob&quot;</span></span></code></pre></div>
<p>Then, the <code>tite.boinet()</code> is implemented with the previously specified
arguments:</p>
<div class="sourceCode" id="cb10"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb10-1"><a href="#cb10-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> <span class="fu">tite.boinet</span>(</span>
<span id="cb10-2"><a href="#cb10-2" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">n.dose=</span>n.dose, <span class="at">start.dose=</span>start.dose,</span>
<span id="cb10-3"><a href="#cb10-3" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">size.cohort=</span>size.cohort, <span class="at">n.cohort=</span>n.cohort,</span>
<span id="cb10-4"><a href="#cb10-4" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">toxprob=</span>toxprob, <span class="at">effprob=</span>effprob,</span>
<span id="cb10-5"><a href="#cb10-5" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">phi=</span>phi, <span class="at">delta=</span>delta,</span>
<span id="cb10-6"><a href="#cb10-6" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">tau.T=</span>tau.T, <span class="at">tau.E=</span>tau.E, <span class="at">accrual=</span>accrual,</span>
<span id="cb10-7"><a href="#cb10-7" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">estpt.method=</span>estpt.method, <span class="at">obd.method=</span>obd.method)</span></code></pre></div>
<p>and returns the following output:</p>
<div class="sourceCode" id="cb11"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb11-1"><a href="#cb11-1" aria-hidden="true" tabindex="-1"></a>Simulation results<span class="sc">:</span></span>
<span id="cb11-2"><a href="#cb11-2" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb11-3"><a href="#cb11-3" aria-hidden="true" tabindex="-1"></a>                 Dose1  Dose2  Dose3  Dose4  Dose5  Dose6</span>
<span id="cb11-4"><a href="#cb11-4" aria-hidden="true" tabindex="-1"></a>Toxicity prob.    <span class="fl">0.05</span>   <span class="fl">0.15</span>   <span class="fl">0.25</span>   <span class="fl">0.35</span>   <span class="fl">0.45</span>   <span class="fl">0.55</span></span>
<span id="cb11-5"><a href="#cb11-5" aria-hidden="true" tabindex="-1"></a>Efficacy prob.    <span class="fl">0.05</span>   <span class="fl">0.30</span>   <span class="fl">0.55</span>   <span class="fl">0.57</span>   <span class="fl">0.59</span>   <span class="fl">0.61</span></span>
<span id="cb11-6"><a href="#cb11-6" aria-hidden="true" tabindex="-1"></a>No. Pts treated   <span class="fl">3.60</span>   <span class="fl">6.40</span>  <span class="fl">14.60</span>   <span class="fl">7.40</span>   <span class="fl">3.00</span>   <span class="fl">0.90</span></span>
<span id="cb11-7"><a href="#cb11-7" aria-hidden="true" tabindex="-1"></a>Select %          <span class="fl">1.80</span>  <span class="fl">12.90</span>  <span class="fl">55.10</span>  <span class="fl">22.50</span>   <span class="fl">6.20</span>   <span class="fl">1.00</span></span>
<span id="cb11-8"><a href="#cb11-8" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb11-9"><a href="#cb11-9" aria-hidden="true" tabindex="-1"></a>No OBD %                 <span class="fl">0.5</span></span>
<span id="cb11-10"><a href="#cb11-10" aria-hidden="true" tabindex="-1"></a>Trial <span class="fu">duration</span> (days)  <span class="fl">476.5</span></span>
<span id="cb11-11"><a href="#cb11-11" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb11-12"><a href="#cb11-12" aria-hidden="true" tabindex="-1"></a>Trial design settings<span class="sc">:</span></span>
<span id="cb11-13"><a href="#cb11-13" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb11-14"><a href="#cb11-14" aria-hidden="true" tabindex="-1"></a>Target toxicity prob.    <span class="fl">0.330</span></span>
<span id="cb11-15"><a href="#cb11-15" aria-hidden="true" tabindex="-1"></a>Target efficacy prob.    <span class="fl">0.600</span></span>
<span id="cb11-16"><a href="#cb11-16" aria-hidden="true" tabindex="-1"></a>Lower toxicity boundary  <span class="fl">0.153</span></span>
<span id="cb11-17"><a href="#cb11-17" aria-hidden="true" tabindex="-1"></a>Upper toxicity boundary  <span class="fl">0.390</span></span>
<span id="cb11-18"><a href="#cb11-18" aria-hidden="true" tabindex="-1"></a>Lower efficacy boundary  <span class="fl">0.480</span></span>
<span id="cb11-19"><a href="#cb11-19" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb11-20"><a href="#cb11-20" aria-hidden="true" tabindex="-1"></a>Tox. assessment <span class="fu">window</span> (days)  <span class="dv">30</span></span>
<span id="cb11-21"><a href="#cb11-21" aria-hidden="true" tabindex="-1"></a>Eff. assessment <span class="fu">window</span> (days)  <span class="dv">45</span></span>
<span id="cb11-22"><a href="#cb11-22" aria-hidden="true" tabindex="-1"></a>Accrual <span class="fu">rate</span> (days)            <span class="dv">10</span></span>
<span id="cb11-23"><a href="#cb11-23" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb11-24"><a href="#cb11-24" aria-hidden="true" tabindex="-1"></a>Efficacy prob. estimation<span class="sc">:</span> obs.prob</span>
<span id="cb11-25"><a href="#cb11-25" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb11-26"><a href="#cb11-26" aria-hidden="true" tabindex="-1"></a>OBD selection<span class="sc">:</span> max.effprob</span></code></pre></div>
<p>The average number of patients treated at Dose 3 was 14.60, and Dose 3
was selected as an OBD in 55.10% of the simulated trials, on average.
The OBD was not selected in 0.5% of the simulated trials, on average.
The trial duration was an average of 476.5 days.</p>
<h4 class="unnumbered" data-number="4.3" id="gboin-et-1">gBOIN-ET</h4>
<p>The <code>gboinet()</code> function supports the conduct of simulation studies for
the gBOIN-ET design and returns a list of the summary results. The usage
of the <code>gboinet()</code> function is as follows:</p>
<div class="sourceCode" id="cb12"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb12-1"><a href="#cb12-1" aria-hidden="true" tabindex="-1"></a><span class="fu">gboinet</span>(</span>
<span id="cb12-2"><a href="#cb12-2" aria-hidden="true" tabindex="-1"></a>  n.dose, start.dose, size.cohort, n.cohort,</span>
<span id="cb12-3"><a href="#cb12-3" aria-hidden="true" tabindex="-1"></a>  toxprob, effprob, sev.weight, res.weight,</span>
<span id="cb12-4"><a href="#cb12-4" aria-hidden="true" tabindex="-1"></a>  phi, <span class="at">phi1=</span>phi<span class="sc">*</span><span class="fl">0.1</span>, <span class="at">phi2=</span>phi<span class="sc">*</span><span class="fl">1.4</span>, delta, <span class="at">delta1=</span>delta<span class="sc">*</span><span class="fl">0.6</span>,</span>
<span id="cb12-5"><a href="#cb12-5" aria-hidden="true" tabindex="-1"></a>  <span class="at">alpha.T1=</span><span class="fl">0.5</span>, <span class="at">alpha.E1=</span><span class="fl">0.5</span>, tau.T, tau.E,</span>
<span id="cb12-6"><a href="#cb12-6" aria-hidden="true" tabindex="-1"></a>  <span class="at">te.corr=</span><span class="fl">0.2</span>, <span class="at">gen.event.time=</span><span class="st">&quot;weibull&quot;</span>,</span>
<span id="cb12-7"><a href="#cb12-7" aria-hidden="true" tabindex="-1"></a>  accrual, <span class="at">gen.enroll.time=</span><span class="st">&quot;uniform&quot;</span>,</span>
<span id="cb12-8"><a href="#cb12-8" aria-hidden="true" tabindex="-1"></a>  <span class="at">stopping.npts=</span>size.cohort<span class="sc">*</span>n.cohort,</span>
<span id="cb12-9"><a href="#cb12-9" aria-hidden="true" tabindex="-1"></a>  <span class="at">stopping.prob.T=</span><span class="fl">0.95</span>, <span class="at">stopping.prob.E=</span><span class="fl">0.99</span>,</span>
<span id="cb12-10"><a href="#cb12-10" aria-hidden="true" tabindex="-1"></a>  <span class="at">estpt.method=</span><span class="st">&quot;obs.prob&quot;</span>, <span class="at">obd.method=</span><span class="st">&quot;max.effprob&quot;</span>,</span>
<span id="cb12-11"><a href="#cb12-11" aria-hidden="true" tabindex="-1"></a>  <span class="at">w1=</span><span class="fl">0.33</span>, <span class="at">w2=</span><span class="fl">1.09</span>,</span>
<span id="cb12-12"><a href="#cb12-12" aria-hidden="true" tabindex="-1"></a>  <span class="at">plow.ast=</span>phi1, <span class="at">pupp.ast=</span>phi2, <span class="at">qlow.ast=</span>delta1<span class="sc">/</span><span class="dv">2</span>, <span class="at">qupp.ast=</span>delta,</span>
<span id="cb12-13"><a href="#cb12-13" aria-hidden="true" tabindex="-1"></a>  <span class="at">psi00=</span><span class="dv">40</span>, <span class="at">psi11=</span><span class="dv">60</span>,</span>
<span id="cb12-14"><a href="#cb12-14" aria-hidden="true" tabindex="-1"></a>  <span class="at">n.sim=</span><span class="dv">1000</span>, <span class="at">seed.sim=</span><span class="dv">100</span>)</span></code></pre></div>
<p>Some of the key arguments are detailed in Tables <a href="#tab:T1">1</a>, <a href="#tab:T2">2</a>, <a href="#tab:T3">3</a>, and <a href="#tab:T4">4</a>, in the Appendix. Here, <code>toxprob</code> and <code>effprob</code> are matrices of true
quasi-Bernoulli toxicity and efficacy probabilities with a row length
equal to the number of outcome categories and a column length equal to
the number of dose levels investigated. <code>sev.weight</code> and <code>res.weight</code>
are weights assigned to toxicity and efficacy outcome categories
respectively. For example, considering the ETS and EES, we can use
<code>sev.weight=c(0.00,0.50,1.00,1.50)</code> for grade 0/1, 2, 3, and 4 toxicity
and <code>res.weight=c(0.00,0.25,1.00,3.00)</code> for PD, SD, PR, and CR efficacy
response, respectively</p>
<p>We considered a scenario of the true quasi-Bernoulli toxicity and
efficacy probabilities as given in Figure 1(b):</p>
<div class="sourceCode" id="cb13"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb13-1"><a href="#cb13-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> toxprob <span class="ot">&lt;-</span> <span class="fu">rbind</span>(<span class="fu">c</span>(<span class="fl">0.82</span>,<span class="fl">0.65</span>,<span class="fl">0.41</span>,<span class="fl">0.42</span>,<span class="fl">0.34</span>,<span class="fl">0.26</span>),</span>
<span id="cb13-2"><a href="#cb13-2" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>                  <span class="fu">c</span>(<span class="fl">0.10</span>,<span class="fl">0.20</span>,<span class="fl">0.34</span>,<span class="fl">0.28</span>,<span class="fl">0.31</span>,<span class="fl">0.34</span>),</span>
<span id="cb13-3"><a href="#cb13-3" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>                  <span class="fu">c</span>(<span class="fl">0.05</span>,<span class="fl">0.10</span>,<span class="fl">0.15</span>,<span class="fl">0.18</span>,<span class="fl">0.21</span>,<span class="fl">0.24</span>),</span>
<span id="cb13-4"><a href="#cb13-4" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>                  <span class="fu">c</span>(<span class="fl">0.03</span>,<span class="fl">0.05</span>,<span class="fl">0.10</span>,<span class="fl">0.12</span>,<span class="fl">0.14</span>,<span class="fl">0.16</span>))</span>
<span id="cb13-5"><a href="#cb13-5" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span></span>
<span id="cb13-6"><a href="#cb13-6" aria-hidden="true" tabindex="-1"></a><span class="er">&gt;</span> effprob <span class="ot">&lt;-</span> <span class="fu">rbind</span>(<span class="fu">c</span>(<span class="fl">0.30</span>,<span class="fl">0.20</span>,<span class="fl">0.05</span>,<span class="fl">0.05</span>,<span class="fl">0.05</span>,<span class="fl">0.05</span>),</span>
<span id="cb13-7"><a href="#cb13-7" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>                  <span class="fu">c</span>(<span class="fl">0.35</span>,<span class="fl">0.30</span>,<span class="fl">0.25</span>,<span class="fl">0.20</span>,<span class="fl">0.15</span>,<span class="fl">0.10</span>),</span>
<span id="cb13-8"><a href="#cb13-8" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>                  <span class="fu">c</span>(<span class="fl">0.30</span>,<span class="fl">0.40</span>,<span class="fl">0.20</span>,<span class="fl">0.25</span>,<span class="fl">0.30</span>,<span class="fl">0.30</span>),</span>
<span id="cb13-9"><a href="#cb13-9" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>                  <span class="fu">c</span>(<span class="fl">0.05</span>,<span class="fl">0.10</span>,<span class="fl">0.50</span>,<span class="fl">0.50</span>,<span class="fl">0.50</span>,<span class="fl">0.55</span>))</span></code></pre></div>
<p>The weights assigned to toxicity and efficacy outcome categories were
given by:</p>
<div class="sourceCode" id="cb14"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb14-1"><a href="#cb14-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> sev.weight <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="fl">0.00</span>,<span class="fl">0.50</span>,<span class="fl">1.00</span>,<span class="fl">1.50</span>)</span>
<span id="cb14-2"><a href="#cb14-2" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> res.weight <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="fl">0.00</span>,<span class="fl">0.25</span>,<span class="fl">1.00</span>,<span class="fl">3.00</span>)</span></code></pre></div>
<p>and we used (i) the observed efficacy probability for the efficacy
probability estimation and (ii) the highest estimated efficacy
probability as the measure to select the OBD:</p>
<div class="sourceCode" id="cb15"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb15-1"><a href="#cb15-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> estpt.method <span class="ot">&lt;-</span> <span class="st">&quot;obs.prob&quot;</span></span>
<span id="cb15-2"><a href="#cb15-2" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> obd.method   <span class="ot">&lt;-</span> <span class="st">&quot;max.effprob&quot;</span></span></code></pre></div>
<p>Then, the <code>gboinet()</code> is implemented with the previously specified
arguments:</p>
<div class="sourceCode" id="cb16"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb16-1"><a href="#cb16-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> <span class="fu">gboinet</span>(</span>
<span id="cb16-2"><a href="#cb16-2" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">n.dose=</span>n.dose, <span class="at">start.dose=</span>start.dose,</span>
<span id="cb16-3"><a href="#cb16-3" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">size.cohort=</span>size.cohort, <span class="at">n.cohort=</span>n.cohort,</span>
<span id="cb16-4"><a href="#cb16-4" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">toxprob=</span>toxprob, <span class="at">effprob=</span>effprob,</span>
<span id="cb16-5"><a href="#cb16-5" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">sev.weight=</span>sev.weight, <span class="at">res.weight=</span>res.weight,</span>
<span id="cb16-6"><a href="#cb16-6" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">phi=</span>phi, <span class="at">delta=</span>delta,</span>
<span id="cb16-7"><a href="#cb16-7" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">tau.T=</span>tau.T, <span class="at">tau.E=</span>tau.E, <span class="at">accrual=</span>accrual,</span>
<span id="cb16-8"><a href="#cb16-8" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">estpt.method=</span>estpt.method, <span class="at">obd.method=</span>obd.method)</span></code></pre></div>
<p>and returns the following output:</p>
<div class="sourceCode" id="cb17"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb17-1"><a href="#cb17-1" aria-hidden="true" tabindex="-1"></a>Simulation results<span class="sc">:</span></span>
<span id="cb17-2"><a href="#cb17-2" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-3"><a href="#cb17-3" aria-hidden="true" tabindex="-1"></a>                 Dose1  Dose2  Dose3  Dose4  Dose5  Dose6</span>
<span id="cb17-4"><a href="#cb17-4" aria-hidden="true" tabindex="-1"></a>Tox.cat1          <span class="fl">0.82</span>   <span class="fl">0.65</span>   <span class="fl">0.41</span>   <span class="fl">0.42</span>   <span class="fl">0.34</span>   <span class="fl">0.26</span></span>
<span id="cb17-5"><a href="#cb17-5" aria-hidden="true" tabindex="-1"></a>Tox.cat2          <span class="fl">0.10</span>   <span class="fl">0.20</span>   <span class="fl">0.34</span>   <span class="fl">0.28</span>   <span class="fl">0.31</span>   <span class="fl">0.34</span></span>
<span id="cb17-6"><a href="#cb17-6" aria-hidden="true" tabindex="-1"></a>Tox.cat3          <span class="fl">0.05</span>   <span class="fl">0.10</span>   <span class="fl">0.15</span>   <span class="fl">0.18</span>   <span class="fl">0.21</span>   <span class="fl">0.24</span></span>
<span id="cb17-7"><a href="#cb17-7" aria-hidden="true" tabindex="-1"></a>Tox.cat4          <span class="fl">0.03</span>   <span class="fl">0.05</span>   <span class="fl">0.10</span>   <span class="fl">0.12</span>   <span class="fl">0.14</span>   <span class="fl">0.16</span></span>
<span id="cb17-8"><a href="#cb17-8" aria-hidden="true" tabindex="-1"></a>nETS              <span class="fl">0.10</span>   <span class="fl">0.18</span>   <span class="fl">0.31</span>   <span class="fl">0.33</span>   <span class="fl">0.38</span>   <span class="fl">0.43</span></span>
<span id="cb17-9"><a href="#cb17-9" aria-hidden="true" tabindex="-1"></a>Eff.cat1          <span class="fl">0.30</span>   <span class="fl">0.20</span>   <span class="fl">0.05</span>   <span class="fl">0.05</span>   <span class="fl">0.05</span>   <span class="fl">0.05</span></span>
<span id="cb17-10"><a href="#cb17-10" aria-hidden="true" tabindex="-1"></a>Eff.cat2          <span class="fl">0.35</span>   <span class="fl">0.30</span>   <span class="fl">0.25</span>   <span class="fl">0.20</span>   <span class="fl">0.15</span>   <span class="fl">0.10</span></span>
<span id="cb17-11"><a href="#cb17-11" aria-hidden="true" tabindex="-1"></a>Eff.cat3          <span class="fl">0.30</span>   <span class="fl">0.40</span>   <span class="fl">0.20</span>   <span class="fl">0.25</span>   <span class="fl">0.30</span>   <span class="fl">0.30</span></span>
<span id="cb17-12"><a href="#cb17-12" aria-hidden="true" tabindex="-1"></a>Eff.cat4          <span class="fl">0.05</span>   <span class="fl">0.10</span>   <span class="fl">0.50</span>   <span class="fl">0.50</span>   <span class="fl">0.50</span>   <span class="fl">0.55</span></span>
<span id="cb17-13"><a href="#cb17-13" aria-hidden="true" tabindex="-1"></a>nEES              <span class="fl">0.18</span>   <span class="fl">0.26</span>   <span class="fl">0.59</span>   <span class="fl">0.60</span>   <span class="fl">0.61</span>   <span class="fl">0.66</span></span>
<span id="cb17-14"><a href="#cb17-14" aria-hidden="true" tabindex="-1"></a>No. Pts treated   <span class="fl">3.80</span>   <span class="fl">7.20</span>  <span class="fl">17.60</span>   <span class="fl">5.40</span>   <span class="fl">1.70</span>   <span class="fl">0.30</span></span>
<span id="cb17-15"><a href="#cb17-15" aria-hidden="true" tabindex="-1"></a>Select %          <span class="fl">2.90</span>   <span class="fl">8.20</span>  <span class="fl">63.10</span>  <span class="fl">19.50</span>   <span class="fl">5.50</span>   <span class="fl">0.70</span></span>
<span id="cb17-16"><a href="#cb17-16" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-17"><a href="#cb17-17" aria-hidden="true" tabindex="-1"></a>No OBD %                 <span class="fl">0.1</span></span>
<span id="cb17-18"><a href="#cb17-18" aria-hidden="true" tabindex="-1"></a>Trial <span class="fu">duration</span> (days)  <span class="fl">780.1</span></span>
<span id="cb17-19"><a href="#cb17-19" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-20"><a href="#cb17-20" aria-hidden="true" tabindex="-1"></a>Trial design settings<span class="sc">:</span></span>
<span id="cb17-21"><a href="#cb17-21" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-22"><a href="#cb17-22" aria-hidden="true" tabindex="-1"></a>Target toxicity prob.    <span class="fl">0.330</span></span>
<span id="cb17-23"><a href="#cb17-23" aria-hidden="true" tabindex="-1"></a>Target efficacy prob.    <span class="fl">0.600</span></span>
<span id="cb17-24"><a href="#cb17-24" aria-hidden="true" tabindex="-1"></a>Lower toxicity boundary  <span class="fl">0.153</span></span>
<span id="cb17-25"><a href="#cb17-25" aria-hidden="true" tabindex="-1"></a>Upper toxicity boundary  <span class="fl">0.390</span></span>
<span id="cb17-26"><a href="#cb17-26" aria-hidden="true" tabindex="-1"></a>Lower efficacy boundary  <span class="fl">0.480</span></span>
<span id="cb17-27"><a href="#cb17-27" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-28"><a href="#cb17-28" aria-hidden="true" tabindex="-1"></a>Tox. assessment <span class="fu">window</span> (days)  <span class="dv">30</span></span>
<span id="cb17-29"><a href="#cb17-29" aria-hidden="true" tabindex="-1"></a>Eff. assessment <span class="fu">window</span> (days)  <span class="dv">45</span></span>
<span id="cb17-30"><a href="#cb17-30" aria-hidden="true" tabindex="-1"></a>Accrual <span class="fu">rate</span> (days)            <span class="dv">10</span></span>
<span id="cb17-31"><a href="#cb17-31" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-32"><a href="#cb17-32" aria-hidden="true" tabindex="-1"></a>Efficacy prob. estimation<span class="sc">:</span> obs.prob</span>
<span id="cb17-33"><a href="#cb17-33" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb17-34"><a href="#cb17-34" aria-hidden="true" tabindex="-1"></a>OBD selection<span class="sc">:</span> max.effprob</span></code></pre></div>
<p>The average number of patients treated at Dose 3 was 17.60, and Dose 3
was selected as an OBD in 63.10% of the simulated trials, on average.
The OBD was not selected in 0.1% of the simulated trials, on average.
The trial duration was an average of 780.1 days.</p>
<h4 class="unnumbered" data-number="4.4" id="tite-gboin-et-1">TITE-gBOIN-ET</h4>
<p>The <code>tite.gboinet()</code> function supports the conduct of simulation studies
for the gBOIN-ET design and returns a list of the summary results. The
usage of the <code>tite.gboinet()</code> function is as follows:</p>
<div class="sourceCode" id="cb18"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb18-1"><a href="#cb18-1" aria-hidden="true" tabindex="-1"></a><span class="fu">tite.gboinet</span>(</span>
<span id="cb18-2"><a href="#cb18-2" aria-hidden="true" tabindex="-1"></a>  n.dose, start.dose, size.cohort, n.cohort,</span>
<span id="cb18-3"><a href="#cb18-3" aria-hidden="true" tabindex="-1"></a>  toxprob, effprob, sev.weight, res.weight,</span>
<span id="cb18-4"><a href="#cb18-4" aria-hidden="true" tabindex="-1"></a>  phi, <span class="at">phi1=</span>phi<span class="sc">*</span><span class="fl">0.1</span>, <span class="at">phi2=</span>phi<span class="sc">*</span><span class="fl">1.4</span>, delta, <span class="at">delta1=</span>delta<span class="sc">*</span><span class="fl">0.6</span>,</span>
<span id="cb18-5"><a href="#cb18-5" aria-hidden="true" tabindex="-1"></a>  <span class="at">alpha.T1=</span><span class="fl">0.5</span>, <span class="at">alpha.E1=</span><span class="fl">0.5</span>, tau.T, tau.E,</span>
<span id="cb18-6"><a href="#cb18-6" aria-hidden="true" tabindex="-1"></a>  <span class="at">te.corr=</span><span class="fl">0.2</span>, <span class="at">gen.event.time=</span><span class="st">&quot;weibull&quot;</span>,</span>
<span id="cb18-7"><a href="#cb18-7" aria-hidden="true" tabindex="-1"></a>  accrual, <span class="at">gen.enroll.time=</span><span class="st">&quot;uniform&quot;</span>,</span>
<span id="cb18-8"><a href="#cb18-8" aria-hidden="true" tabindex="-1"></a>  <span class="at">stopping.npts=</span>size.cohort<span class="sc">*</span>n.cohort,</span>
<span id="cb18-9"><a href="#cb18-9" aria-hidden="true" tabindex="-1"></a>  <span class="at">stopping.prob.T=</span><span class="fl">0.95</span>, <span class="at">stopping.prob.E=</span><span class="fl">0.99</span>,</span>
<span id="cb18-10"><a href="#cb18-10" aria-hidden="true" tabindex="-1"></a>  <span class="at">estpt.method=</span><span class="st">&quot;obs.prob&quot;</span>, <span class="at">obd.method=</span><span class="st">&quot;max.effprob&quot;</span>,</span>
<span id="cb18-11"><a href="#cb18-11" aria-hidden="true" tabindex="-1"></a>  <span class="at">w1=</span><span class="fl">0.33</span>, <span class="at">w2=</span><span class="fl">1.09</span>,</span>
<span id="cb18-12"><a href="#cb18-12" aria-hidden="true" tabindex="-1"></a>  <span class="at">plow.ast=</span>phi1, <span class="at">pupp.ast=</span>phi2, <span class="at">qlow.ast=</span>delta1<span class="sc">/</span><span class="dv">2</span>, <span class="at">qupp.ast=</span>delta,</span>
<span id="cb18-13"><a href="#cb18-13" aria-hidden="true" tabindex="-1"></a>  <span class="at">psi00=</span><span class="dv">40</span>, <span class="at">psi11=</span><span class="dv">60</span>,</span>
<span id="cb18-14"><a href="#cb18-14" aria-hidden="true" tabindex="-1"></a>  <span class="at">n.sim=</span><span class="dv">1000</span>, <span class="at">seed.sim=</span><span class="dv">100</span>)</span></code></pre></div>
<p>Some of the key arguments are detailed in Tables <a href="#tab:T1">1</a>, <a href="#tab:T2">2</a>, <a href="#tab:T3">3</a>, and <a href="#tab:T4">4</a>, in the Appendix. It should be noted that the TITE-gBOIN-ET design has a
suspension rule which holds off the decision on dose allocation (i.e.,
patient enrollment to the next cohort) until adequate information is
collected, where the dose allocation is allowed only if more than 50% of
patients have finished the assessment at the current dose level.</p>
<p>We considered a scenario of the true quasi-Bernoulli toxicity and
efficacy probabilities as given in Figure 1(b):</p>
<div class="sourceCode" id="cb19"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb19-1"><a href="#cb19-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> toxprob <span class="ot">&lt;-</span> <span class="fu">rbind</span>(<span class="fu">c</span>(<span class="fl">0.82</span>,<span class="fl">0.65</span>,<span class="fl">0.41</span>,<span class="fl">0.42</span>,<span class="fl">0.34</span>,<span class="fl">0.26</span>),</span>
<span id="cb19-2"><a href="#cb19-2" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>                  <span class="fu">c</span>(<span class="fl">0.10</span>,<span class="fl">0.20</span>,<span class="fl">0.34</span>,<span class="fl">0.28</span>,<span class="fl">0.31</span>,<span class="fl">0.34</span>),</span>
<span id="cb19-3"><a href="#cb19-3" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>                  <span class="fu">c</span>(<span class="fl">0.05</span>,<span class="fl">0.10</span>,<span class="fl">0.15</span>,<span class="fl">0.18</span>,<span class="fl">0.21</span>,<span class="fl">0.24</span>),</span>
<span id="cb19-4"><a href="#cb19-4" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>                  <span class="fu">c</span>(<span class="fl">0.03</span>,<span class="fl">0.05</span>,<span class="fl">0.10</span>,<span class="fl">0.12</span>,<span class="fl">0.14</span>,<span class="fl">0.16</span>))</span>
<span id="cb19-5"><a href="#cb19-5" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span></span>
<span id="cb19-6"><a href="#cb19-6" aria-hidden="true" tabindex="-1"></a><span class="er">&gt;</span> effprob <span class="ot">&lt;-</span> <span class="fu">rbind</span>(<span class="fu">c</span>(<span class="fl">0.30</span>,<span class="fl">0.20</span>,<span class="fl">0.05</span>,<span class="fl">0.05</span>,<span class="fl">0.05</span>,<span class="fl">0.05</span>),</span>
<span id="cb19-7"><a href="#cb19-7" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>                  <span class="fu">c</span>(<span class="fl">0.35</span>,<span class="fl">0.30</span>,<span class="fl">0.25</span>,<span class="fl">0.20</span>,<span class="fl">0.15</span>,<span class="fl">0.10</span>),</span>
<span id="cb19-8"><a href="#cb19-8" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>                  <span class="fu">c</span>(<span class="fl">0.30</span>,<span class="fl">0.40</span>,<span class="fl">0.20</span>,<span class="fl">0.25</span>,<span class="fl">0.30</span>,<span class="fl">0.30</span>),</span>
<span id="cb19-9"><a href="#cb19-9" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>                  <span class="fu">c</span>(<span class="fl">0.05</span>,<span class="fl">0.10</span>,<span class="fl">0.50</span>,<span class="fl">0.50</span>,<span class="fl">0.50</span>,<span class="fl">0.55</span>))</span></code></pre></div>
<p>The weights assigned to toxicity and efficacy outcome categories were
given by:</p>
<div class="sourceCode" id="cb20"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb20-1"><a href="#cb20-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> sev.weight <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="fl">0.00</span>,<span class="fl">0.50</span>,<span class="fl">1.00</span>,<span class="fl">1.50</span>)</span>
<span id="cb20-2"><a href="#cb20-2" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> res.weight <span class="ot">&lt;-</span> <span class="fu">c</span>(<span class="fl">0.00</span>,<span class="fl">0.25</span>,<span class="fl">1.00</span>,<span class="fl">3.00</span>)</span></code></pre></div>
<p>and we used (i) the observed efficacy probability for the efficacy
probability estimation and (ii) the highest estimated efficacy
probability as the measure to select the OBD:</p>
<div class="sourceCode" id="cb21"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb21-1"><a href="#cb21-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> estpt.method <span class="ot">&lt;-</span> <span class="st">&quot;obs.prob&quot;</span></span>
<span id="cb21-2"><a href="#cb21-2" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> obd.method   <span class="ot">&lt;-</span> <span class="st">&quot;max.effprob&quot;</span></span></code></pre></div>
<p>Then, the <code>tite.gboinet()</code> is implemented with the previously specified
arguments:</p>
<div class="sourceCode" id="cb22"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb22-1"><a href="#cb22-1" aria-hidden="true" tabindex="-1"></a><span class="sc">&gt;</span> <span class="fu">tite.gboinet</span>(</span>
<span id="cb22-2"><a href="#cb22-2" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">n.dose=</span>n.dose, <span class="at">start.dose=</span>start.dose,</span>
<span id="cb22-3"><a href="#cb22-3" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">size.cohort=</span>size.cohort, <span class="at">n.cohort=</span>n.cohort,</span>
<span id="cb22-4"><a href="#cb22-4" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">toxprob=</span>toxprob, <span class="at">effprob=</span>effprob,</span>
<span id="cb22-5"><a href="#cb22-5" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">sev.weight=</span>sev.weight, <span class="at">res.weight=</span>res.weight,</span>
<span id="cb22-6"><a href="#cb22-6" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">phi=</span>phi, <span class="at">delta=</span>delta,</span>
<span id="cb22-7"><a href="#cb22-7" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">tau.T=</span>tau.T, <span class="at">tau.E=</span>tau.E, <span class="at">accrual=</span>accrual,</span>
<span id="cb22-8"><a href="#cb22-8" aria-hidden="true" tabindex="-1"></a><span class="sc">+</span>   <span class="at">estpt.method=</span>estpt.method, <span class="at">obd.method=</span>obd.method)</span></code></pre></div>
<p>and returns the following output:</p>
<div class="sourceCode" id="cb23"><pre class="sourceCode r"><code class="sourceCode r"><span id="cb23-1"><a href="#cb23-1" aria-hidden="true" tabindex="-1"></a>Simulation results<span class="sc">:</span></span>
<span id="cb23-2"><a href="#cb23-2" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb23-3"><a href="#cb23-3" aria-hidden="true" tabindex="-1"></a>                 Dose1  Dose2  Dose3  Dose4  Dose5  Dose6</span>
<span id="cb23-4"><a href="#cb23-4" aria-hidden="true" tabindex="-1"></a>Tox.cat1          <span class="fl">0.82</span>   <span class="fl">0.65</span>   <span class="fl">0.41</span>   <span class="fl">0.42</span>   <span class="fl">0.34</span>   <span class="fl">0.26</span></span>
<span id="cb23-5"><a href="#cb23-5" aria-hidden="true" tabindex="-1"></a>Tox.cat2          <span class="fl">0.10</span>   <span class="fl">0.20</span>   <span class="fl">0.34</span>   <span class="fl">0.28</span>   <span class="fl">0.31</span>   <span class="fl">0.34</span></span>
<span id="cb23-6"><a href="#cb23-6" aria-hidden="true" tabindex="-1"></a>Tox.cat3          <span class="fl">0.05</span>   <span class="fl">0.10</span>   <span class="fl">0.15</span>   <span class="fl">0.18</span>   <span class="fl">0.21</span>   <span class="fl">0.24</span></span>
<span id="cb23-7"><a href="#cb23-7" aria-hidden="true" tabindex="-1"></a>Tox.cat4          <span class="fl">0.03</span>   <span class="fl">0.05</span>   <span class="fl">0.10</span>   <span class="fl">0.12</span>   <span class="fl">0.14</span>   <span class="fl">0.16</span></span>
<span id="cb23-8"><a href="#cb23-8" aria-hidden="true" tabindex="-1"></a>nETS              <span class="fl">0.10</span>   <span class="fl">0.18</span>   <span class="fl">0.31</span>   <span class="fl">0.33</span>   <span class="fl">0.38</span>   <span class="fl">0.43</span></span>
<span id="cb23-9"><a href="#cb23-9" aria-hidden="true" tabindex="-1"></a>Eff.cat1          <span class="fl">0.30</span>   <span class="fl">0.20</span>   <span class="fl">0.05</span>   <span class="fl">0.05</span>   <span class="fl">0.05</span>   <span class="fl">0.05</span></span>
<span id="cb23-10"><a href="#cb23-10" aria-hidden="true" tabindex="-1"></a>Eff.cat2          <span class="fl">0.35</span>   <span class="fl">0.30</span>   <span class="fl">0.25</span>   <span class="fl">0.20</span>   <span class="fl">0.15</span>   <span class="fl">0.10</span></span>
<span id="cb23-11"><a href="#cb23-11" aria-hidden="true" tabindex="-1"></a>Eff.cat3          <span class="fl">0.30</span>   <span class="fl">0.40</span>   <span class="fl">0.20</span>   <span class="fl">0.25</span>   <span class="fl">0.30</span>   <span class="fl">0.30</span></span>
<span id="cb23-12"><a href="#cb23-12" aria-hidden="true" tabindex="-1"></a>Eff.cat4          <span class="fl">0.05</span>   <span class="fl">0.10</span>   <span class="fl">0.50</span>   <span class="fl">0.50</span>   <span class="fl">0.50</span>   <span class="fl">0.55</span></span>
<span id="cb23-13"><a href="#cb23-13" aria-hidden="true" tabindex="-1"></a>nEES              <span class="fl">0.18</span>   <span class="fl">0.26</span>   <span class="fl">0.59</span>   <span class="fl">0.60</span>   <span class="fl">0.61</span>   <span class="fl">0.66</span></span>
<span id="cb23-14"><a href="#cb23-14" aria-hidden="true" tabindex="-1"></a>No. Pts treated   <span class="fl">3.90</span>   <span class="fl">7.20</span>  <span class="fl">15.70</span>   <span class="fl">6.20</span>   <span class="fl">2.40</span>   <span class="fl">0.60</span></span>
<span id="cb23-15"><a href="#cb23-15" aria-hidden="true" tabindex="-1"></a>Select %          <span class="fl">3.00</span>   <span class="fl">8.10</span>  <span class="fl">61.00</span>  <span class="fl">20.70</span>   <span class="fl">5.90</span>   <span class="fl">1.20</span></span>
<span id="cb23-16"><a href="#cb23-16" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb23-17"><a href="#cb23-17" aria-hidden="true" tabindex="-1"></a>No OBD %                 <span class="fl">0.1</span></span>
<span id="cb23-18"><a href="#cb23-18" aria-hidden="true" tabindex="-1"></a>Trial <span class="fu">duration</span> (days)  <span class="fl">441.0</span></span>
<span id="cb23-19"><a href="#cb23-19" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb23-20"><a href="#cb23-20" aria-hidden="true" tabindex="-1"></a>Trial design settings<span class="sc">:</span></span>
<span id="cb23-21"><a href="#cb23-21" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb23-22"><a href="#cb23-22" aria-hidden="true" tabindex="-1"></a>Target toxicity prob.    <span class="fl">0.330</span></span>
<span id="cb23-23"><a href="#cb23-23" aria-hidden="true" tabindex="-1"></a>Target efficacy prob.    <span class="fl">0.600</span></span>
<span id="cb23-24"><a href="#cb23-24" aria-hidden="true" tabindex="-1"></a>Lower toxicity boundary  <span class="fl">0.153</span></span>
<span id="cb23-25"><a href="#cb23-25" aria-hidden="true" tabindex="-1"></a>Upper toxicity boundary  <span class="fl">0.390</span></span>
<span id="cb23-26"><a href="#cb23-26" aria-hidden="true" tabindex="-1"></a>Lower efficacy boundary  <span class="fl">0.480</span></span>
<span id="cb23-27"><a href="#cb23-27" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb23-28"><a href="#cb23-28" aria-hidden="true" tabindex="-1"></a>Tox. assessment <span class="fu">window</span> (days)  <span class="dv">30</span></span>
<span id="cb23-29"><a href="#cb23-29" aria-hidden="true" tabindex="-1"></a>Eff. assessment <span class="fu">window</span> (days)  <span class="dv">45</span></span>
<span id="cb23-30"><a href="#cb23-30" aria-hidden="true" tabindex="-1"></a>Accrual <span class="fu">rate</span> (days)            <span class="dv">10</span></span>
<span id="cb23-31"><a href="#cb23-31" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb23-32"><a href="#cb23-32" aria-hidden="true" tabindex="-1"></a>Efficacy prob. estimation<span class="sc">:</span> obs.prob</span>
<span id="cb23-33"><a href="#cb23-33" aria-hidden="true" tabindex="-1"></a></span>
<span id="cb23-34"><a href="#cb23-34" aria-hidden="true" tabindex="-1"></a>OBD selection<span class="sc">:</span> max.effprob</span></code></pre></div>
<p>The average number of patients treated at Dose 3 was 15.70, and Dose 3
was selected as an OBD in 61.00% of the simulated trials, on average.
The OBD was not selected in 0.1% of the simulated trials, on average.
The trial duration was an average of 441.0 days.</p>
<h3 data-number="5" id="summary"><span class="header-section-number">5</span> Summary</h3>
<p>The concept of OBD is now widely accepted as an alternative to MTD in
oncology dose-finding trials, and the BOIN-ET design family is simple
and flexible enough to establish the OBD while accounting for toxicity
and efficacy in the framework of dose-finding. The
<a href="https://CRAN.R-project.org/package=boinet"><strong>boinet</strong></a> package has been
developed to support the conduct of simulation studies to assess
operating characteristics of BOIN-ET, TITE-BOIN-ET, gBOIN-ET, and
TITE-gBOIN-ET designs. Users can choose design parameters in flexible
and straightforward ways depending on their own application, and several
options regarding methods to estimate the efficacy probability and
measures to select the OBD are applicable. The package would assist
practitioners in efficiently assessing the design features of their
studies.</p>
<h3 class="unnumbered" id="appendix-key-arguments-used-in-boinet-tite.boinet-gboinet-and-tite.gboinet-function">Appendix: Key arguments used in <code>boinet()</code>, <code>tite.boinet()</code>, <code>gboinet()</code>, and <code>tite.gboinet()</code> function</h3>
<div id="tab:T1">
<table style="width:99%;">
<caption><span id="tab:T1">Table 1: </span> Arguments regarding target (quasi-Bernoulli) toxicity
and efficacy probability.</caption>
<colgroup>
<col style="width: 5%" />
<col style="width: 93%" />
</colgroup>
<thead>
<tr class="header">
<th style="text-align: left;">Argument</th>
<th style="text-align: left;">Description</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: left;"><code>phi</code></td>
<td style="text-align: left;">Numeric value between 0 and 1 specifying the target (quasi-Bernoulli) toxicity probability. Represents the maximum acceptable toxicity rate. Default is 0.3 (30%).</td>
</tr>
<tr class="even">
<td style="text-align: left;"><code>phi1</code></td>
<td style="text-align: left;">Numeric value specifying the highest (quasi-Bernoulli) toxicity probability that is deemed sub-therapeutic such that dose-escalation should be pursued. Default is phi*0.1.</td>
</tr>
<tr class="odd">
<td style="text-align: left;"><code>phi2</code></td>
<td style="text-align: left;">Numeric value specifying the lowest (quasi-Bernoulli) toxicity probability that is deemed overly toxic such that dose de-escalation is needed. Default is phi*1.4.</td>
</tr>
<tr class="even">
<td style="text-align: left;"><code>delta</code></td>
<td style="text-align: left;">Numeric value between 0 and 1 specifying the target (quasi-Bernoulli) efficacy probability. Represents the desired minimum efficacy rate. Default is 0.6 (60%).</td>
</tr>
<tr class="odd">
<td style="text-align: left;"><code>delta1</code></td>
<td style="text-align: left;">Numeric value specifying the minimum probability deemed efficacious such that the dose levels with efficacy &lt; delta1 are considered sub-therapeutic. Default is delta*0.6.</td>
</tr>
</tbody>
</table>
</div>
<div id="tab:T2">
<table style="width:100%;">
<caption><span id="tab:T2">Table 2: </span> Arguments regarding data generation.</caption>
<colgroup>
<col style="width: 4%" />
<col style="width: 94%" />
</colgroup>
<thead>
<tr class="header">
<th style="text-align: left;">Argument</th>
<th style="text-align: left;">Description</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: left;"><code>alpha.T1</code></td>
<td style="text-align: left;">Numeric value specifying the probability that a (quasi-Bernoulli) toxicity outcome occurs in the late half of the toxicity assessment window. Used for event time generation. Default is 0.5.</td>
</tr>
<tr class="even">
<td style="text-align: left;"><code>alpha.E1</code></td>
<td style="text-align: left;">Numeric value specifying the probability that a (quasi-Bernoulli) efficacy outcome occurs in the late half of the efficacy assessment window. Used for event time generation. Default is 0.5.</td>
</tr>
<tr class="odd">
<td style="text-align: left;"><code>te.corr</code></td>
<td style="text-align: left;">Numeric value between -1 and 1 specifying the correlation between toxicity and efficacy, specified as Gaussian copula parameter. Default is 0.2 (weak positive correlation).</td>
</tr>
<tr class="even">
<td style="text-align: left;"><code>gen.event.time</code></td>
<td style="text-align: left;">Character string specifying the distribution for generating event times. Options are "weibull" (default) or "uniform". A bivariate Gaussian copula model is used to jointly generate the time to first toxicity and efficacy outcome, where the marginal distributions are set to Weibull distribution when <code>gen.event.time="weibull"</code>, and uniform distribution when <code>gen.event.time="uniform"</code>.</td>
</tr>
<tr class="odd">
<td style="text-align: left;"><code>gen.enroll.time</code></td>
<td style="text-align: left;">Character string specifying the distribution for enrollment times. Options are "uniform" (default) or "exponential". Uniform distribution is used when <code>gen.enroll.time="uniform"</code>, and exponential distribution is used when <code>gen.enroll.time="exponential"</code>.</td>
</tr>
</tbody>
</table>
</div>
<div id="tab:T3">
<table style="width:99%;">
<caption><span id="tab:T3">Table 3: </span> Arguments regarding early study termination criteria.</caption>
<colgroup>
<col style="width: 7%" />
<col style="width: 91%" />
</colgroup>
<thead>
<tr class="header">
<th style="text-align: left;">Argument</th>
<th style="text-align: left;">Description</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: left;"><code>stopping.npts</code></td>
<td style="text-align: left;">Integer specifying the maximum number of patients per dose for early study termination. If the number of patients at the current dose reaches this criterion, the study stops the enrollment and is terminated. Default is size.cohort*n.cohort.</td>
</tr>
<tr class="even">
<td style="text-align: left;"><code>stopping.prob.T</code></td>
<td style="text-align: left;">Numeric value between 0 and 1 specifying the early study termination threshold for toxicity. If P(toxicity &gt; phi) &gt; stopping.prob.T, the dose levels are eliminated from the investigation. Default is 0.95.</td>
</tr>
<tr class="odd">
<td style="text-align: left;"><code>stopping.prob.E</code></td>
<td style="text-align: left;">Numeric value between 0 and 1 specifying the early study termination threshold for efficacy. If P(efficacy &lt; delta1) &gt; stopping.prob.E, the dose levels are eliminated from the investigation. Default is 0.99.</td>
</tr>
</tbody>
</table>
</div>
<div id="tab:T4">
<table style="width:99%;">
<caption><span id="tab:T4">Table 4: </span> Arguments regarding optimal biological dose (OBD)
selection.</caption>
<colgroup>
<col style="width: 5%" />
<col style="width: 93%" />
</colgroup>
<thead>
<tr class="header">
<th style="text-align: left;">Argument</th>
<th style="text-align: left;">Description</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td style="text-align: left;"><code>estpt.method</code></td>
<td style="text-align: left;">Character string specifying the method for estimating efficacy probabilities. Options: "obs.prob" (observed efficacy probabilities/rates), "fp.logistic" (fractional polynomial), or "multi.iso" (model averaging of multiple unimodal isotonic regression). Default is "obs.prob".</td>
</tr>
<tr class="even">
<td style="text-align: left;"><code>obd.method</code></td>
<td style="text-align: left;">Character string specifying the method for OBD selection. Options: "utility.weighted", "utility.truncated.linear", "utility.scoring", or "max.effprob" (default).</td>
</tr>
<tr class="odd">
<td style="text-align: left;"><code>w1</code></td>
<td style="text-align: left;">Numeric value specifying the weight for toxicity-efficacy trade-off in "utility.weighted" method. Default is 0.33.</td>
</tr>
<tr class="even">
<td style="text-align: left;"><code>w2</code></td>
<td style="text-align: left;">Numeric value specifying the penalty weight for toxic doses in "utility.weighted" method. Default is 1.09.</td>
</tr>
<tr class="odd">
<td style="text-align: left;"><code>plow.ast</code></td>
<td style="text-align: left;">Numeric value specifying the lower toxicity threshold for "utility.truncated.linear" method. Default is phi1.</td>
</tr>
<tr class="even">
<td style="text-align: left;"><code>pupp.ast</code></td>
<td style="text-align: left;">Numeric value specifying the upper toxicity threshold for "utility.truncated.linear" method. Default is phi2.</td>
</tr>
<tr class="odd">
<td style="text-align: left;"><code>qlow.ast</code></td>
<td style="text-align: left;">Numeric value specifying the lower efficacy threshold for "utility.truncated.linear" method. Default is delta1/2.</td>
</tr>
<tr class="even">
<td style="text-align: left;"><code>qupp.ast</code></td>
<td style="text-align: left;">Numeric value specifying the upper efficacy threshold for "utility.truncated.linear" method. Default is delta.</td>
</tr>
<tr class="odd">
<td style="text-align: left;"><code>psi00</code></td>
<td style="text-align: left;">Numeric value specifying the utility score for (toxicity=no, efficacy=no) in "utility.scoring" method. Default is 40.</td>
</tr>
<tr class="even">
<td style="text-align: left;"><code>psi11</code></td>
<td style="text-align: left;">Numeric value specifying the utility score for (toxicity=yes, efficacy=yes) in "utility.scoring" method. Default is 60.</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="sourceCode" id="cb24"><pre class="sourceCode r distill-force-highlighting-css"><code class="sourceCode r"></code></pre></div>
<h3 class="appendix" data-number="6" id="cran-packages-used"><span class="header-section-number">6</span> CRAN packages used</h3>
<p><a href="https://cran.r-project.org/package=boinet">boinet</a>, <a href="https://cran.r-project.org/package=Keyboard">Keyboard</a>, <a href="https://cran.r-project.org/package=escalation">escalation</a></p>
<h3 class="appendix" data-number="7" id="cran-task-views-implied-by-cited-packages"><span class="header-section-number">7</span> CRAN Task Views implied by cited packages</h3>
<p><a href="https://cran.r-project.org/view=ClinicalTrials">ClinicalTrials</a></p>
<h3 class="appendix" data-number="8" id="note"><span class="header-section-number">8</span> Note</h3>
<p>This article is converted from a Legacy LaTeX article using the
<a href="https://cran.r-project.org/package=texor">texor</a> package.
The pdf version is the official version. To report a problem with the html,
refer to CONTRIBUTE on the R Journal homepage.</p>
<div id="refs" class="references csl-bib-body hanging-indent" data-entry-spacing="0" role="list">
<div id="ref-ades:2024" class="csl-entry" role="listitem">
L. Ades, T. Cluzeau, T. Comont, L. Aguinaga, A. Stamatoullas, M. Meunier, E. Gyan, A. Garnier, M. D’Aveni, S. Thepot, et al. Combining <span>ESA</span> and <span>Luspatercept</span> in non-<span>RS</span> <span>MDS</span> patients having failed <span>ESA</span> - results of the phase 1-2 part a of the <span>GFM</span> combola study. <em>blood</em>, 144: 351–352, 2024. URL <a href="https://doi.org/10.1182/blood-2024-204791">https://doi.org/10.1182/blood-2024-204791</a>.
</div>
<div id="ref-barlow:1972" class="csl-entry" role="listitem">
R. E. Barlow, D. J. Bartholomew, J. M. Bremner and H. D. Brunk. <em>Statistical inference under order restrictions: The theory and application of isotonic regression.</em> London: Wiley, 1972.
</div>
<div id="ref-bril:1984" class="csl-entry" role="listitem">
G. Bril, R. Dykstra, C. Pillers and T. Robertson. Isotonic regression in two independent variables. <em>Journal of the Royal Statistical Society: Series C (Applied Statistics)</em>, 33(3): 352–357, 1984. URL <a href="https://doi.org/10.2307/2347723">https://doi.org/10.2307/2347723</a>.
</div>
<div id="ref-kristian:2024" class="csl-entry" role="listitem">
K. Brock, D. Slade and M. Sweeting. <em>Escalation: A modular approach to dose-finding clinical trials.</em> 2024. URL <a href="https://CRAN.R-project.org/package=escalation">https://CRAN.R-project.org/package=escalation</a>. <span>R</span> package version 0.1.10.
</div>
<div id="ref-calabrese:2001" class="csl-entry" role="listitem">
E. J. Calabrese and L. A. Baldwin. U-shaped dose-responses in biology, toxicology, and public health. <em>Annual Review of Public Health</em>, 22: 15–33, 2001. URL <a href="https://doi.org/10.1146/annurev.publhealth.22.1.15">https://doi.org/10.1146/annurev.publhealth.22.1.15</a>.
</div>
<div id="ref-corbaux:2019" class="csl-entry" role="listitem">
P. Corbaux, M. El-Madani, M. Tod, J. Peron, D. Maillet, J. Lopez, G. Freyer and B. You. Clinical efficacy of the optimal biological dose in earlyphase trials of anti-cancer targeted therapies. <em>European Journal of Cancer</em>, 120: 40–46, 2019. URL <a href="https://doi.org/10.1016/j.ejca.2019.08.002">https://doi.org/10.1016/j.ejca.2019.08.002</a>.
</div>
<div id="ref-fraisse:2021" class="csl-entry" role="listitem">
J. Fraisse, D. Dinart, D. Tosi, C. Bellera and C. Mollevi. Optimal biological dose: A systematic review in cancer phase i clinical trials. <em>BMC Cancer</em>, 21(60): 2021. URL <a href="https://doi.org/10.1186/s12885-021-07782-z">https://doi.org/10.1186/s12885-021-07782-z</a>.
</div>
<div id="ref-li:2020" class="csl-entry" role="listitem">
P. Li, R. Liu, J. Lin and Y. Ji. <span>TEPI</span>-2 and <span>UBI</span>: Designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy. <em>Journal of Biopharmaceutical Statistics</em>, 30(6): 979–992, 2020. URL <a href="https://doi.org/10.1080/10543406.2020.1814802">https://doi.org/10.1080/10543406.2020.1814802</a>.
</div>
<div id="ref-lin:2017" class="csl-entry" role="listitem">
R. Lin and G. Yin. <span>STEIN</span>: A simple toxicity and efficacy interval design for seamless phase i/II clinical trials. <em>Statistics in Medicine</em>, 36(26): 4106–4120, 2017. URL <a href="https://doi.org/10.1002/sim.7428">https://doi.org/10.1002/sim.7428</a>.
</div>
<div id="ref-lin:2020c" class="csl-entry" role="listitem">
R. Lin and Y. Yuan. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. <em>Biostatistics</em>, 21(4): 807–824, 2020. URL <a href="https://doi.org/10.1093/biostatistics/kxz007">https://doi.org/10.1093/biostatistics/kxz007</a>.
</div>
<div id="ref-lin:2020b" class="csl-entry" role="listitem">
R. Lin, Y. Zhou, F. Yan, D. Li and Y. Yuan. <span>BOIN</span>12: <span>Bayesian</span> optimal interval phase i/II trial design for utility-based dose finding in immunotherapy and targeted therapies. <em>JCO Precision Oncology</em>, 4: PO.20.00257, 2020. URL <a href="https://doi.org/10.1200/PO.20.00257">https://doi.org/10.1200/PO.20.00257</a>.
</div>
<div id="ref-lin:2021" class="csl-entry" role="listitem">
X. Lin and Y. Ji. Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology. <em>Statistical Methods in Medical</em>, 30(3): 843–856, 2021. URL <a href="https://doi.org/10.1177/0962280220977009">https://doi.org/10.1177/0962280220977009</a>.
</div>
<div id="ref-lin:2020a" class="csl-entry" role="listitem">
X. Lin and Y. Ji. The joint i3+3 (Ji3+3) design for phase i/II adoptive cell therapy clinical trials. <em>Journal of Biopharmaceutical Statistics</em>, 30(6): 993–1005, 2020. URL <a href="https://doi.org/10.1080/10543406.2020.1818250">https://doi.org/10.1080/10543406.2020.1818250</a>.
</div>
<div id="ref-lorusso:2010" class="csl-entry" role="listitem">
P. M. LoRusso, S. A. Boerner and L. Seymour. An overview of the optimal planning, design, and conduct of phase i studies of new therapeutics. <em>Clinical Cancer Research</em>, 16(6): 1710–1718, 2010. URL <a href="https://doi.org/10.1158/1078-0432.CCR-09-1993">https://doi.org/10.1158/1078-0432.CCR-09-1993</a>.
</div>
<div id="ref-penel:2011" class="csl-entry" role="listitem">
N. Penel, A. Adenis, S. Clisant and J. Bonneterre. Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: Comparison of cytotoxic versus non-cytotoxic drugs. <em>Investigational New Drugs</em>, 29(6): 1414–1419, 2011. URL <a href="https://doi.org/10.1007/s10637-010-9490-7">https://doi.org/10.1007/s10637-010-9490-7</a>.
</div>
<div id="ref-postel:2009" class="csl-entry" role="listitem">
S. Postel-Vinay, H.-T. Arkenau, D. Olmos, J. E. Ang, J. Barriuso, S. Ashley, U. Banerji, J. De-Bono, I. Judson and S. Kaye. Clinical benefit in phase-i trials of novel molecularly targeted agents: Does dose matter? <em>British Journal of Cancer</em>, 100(9): 1373–1378, 2009. URL <a href="https://doi.org/10.1038/sj.bjc.6605030">https://doi.org/10.1038/sj.bjc.6605030</a>.
</div>
<div id="ref-reynolds:2010" class="csl-entry" role="listitem">
A. R. Reynolds. Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. <em>Dose Response</em>, 8(3): 253–284, 2010. URL <a href="https://doi.org/10.2203/dose-response.09-049.Reynolds">https://doi.org/10.2203/dose-response.09-049.Reynolds</a>.
</div>
<div id="ref-riviere:2018" class="csl-entry" role="listitem">
M.-K. Riviere, Y. Yuan, J.-H. Jourdan, F. Dubois and S. Zohar. Phase i/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. <em>Statistical Methods in Medical Research</em>, 27(2): 466–479, 2018. URL <a href="https://doi.org/10.1177/0962280216631763">https://doi.org/10.1177/0962280216631763</a>.
</div>
<div id="ref-takeda:2022b" class="csl-entry" role="listitem">
K. Takeda, S. Morita and M. Taguri. G<span>BOIN-ET</span>: The generalized <span>Bayesian</span> optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials. <em>Biometrical Journal</em>, 64(7): 1178–1191, 2022a. URL <a href="https://doi.org/10.1002/bimj.202100263">https://doi.org/10.1002/bimj.202100263</a>.
</div>
<div id="ref-takeda:2020" class="csl-entry" role="listitem">
K. Takeda, S. Morita and M. Taguri. <span>TITE-BOIN-ET</span>: Time-to-event <span>Bayesian</span> optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes. <em>Pharmaceutical Statistics</em>, 19(3): 335–349, 2020. URL <a href="https://doi.org/10.1002/pst.1995">https://doi.org/10.1002/pst.1995</a>.
</div>
<div id="ref-takeda:2018" class="csl-entry" role="listitem">
K. Takeda, M. Taguri and S. Morita. <span>BOIN-ET</span>: <span>Bayesian</span> optimal interval design for dose finding based on both efficacy and toxicity outcomes. <em>Pharmaceutical Statistics</em>, 17(4): 383–395, 2018. URL <a href="https://doi.org/10.1002/pst.1864">https://doi.org/10.1002/pst.1864</a>.
</div>
<div id="ref-takeda:2022a" class="csl-entry" role="listitem">
K. Takeda, Q. Xia, S. Liu and A. Rong. <span>TITE-</span>g<span>BOIN</span>: Time-to-event <span>Bayesian</span> optimal interval design to accelerate dose-finding accounting for toxicity grades. <em>Pharmaceutical Statistics</em>, 21(2): 496–506, 2022b. URL <a href="https://doi.org/10.1002/pst.2182">https://doi.org/10.1002/pst.2182</a>.
</div>
<div id="ref-takeda:2023" class="csl-entry" role="listitem">
K. Takeda, Y. Yamaguchi, M. Taguri and S. Morita. <span>TITE-</span>g<span>BOIN-ET</span>: Time-to-event generalized <span>Bayesian</span> optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes. <em>Biometrical Journal</em>, 64(7): e2200265, 2023. URL <a href="https://doi.org/10.1002/bimj.202200265">https://doi.org/10.1002/bimj.202200265</a>.
</div>
<div id="ref-thall:2004" class="csl-entry" role="listitem">
P. F. Thall and J. D. Cook. Dose-finding based on efficacy-toxicity trade-offs. <em>Biometrics</em>, 60(3): 684–693, 2004. URL <a href="https://doi.org/10.1111/j.0006-341X.2004.00218.x">https://doi.org/10.1111/j.0006-341X.2004.00218.x</a>.
</div>
<div id="ref-weber:2015" class="csl-entry" role="listitem">
J. S. Weber, J. C. Yang, M. B. Atkins and M. L. Disis. Toxicities of immunotherapy for the practitioner. <em>Journal of Clinical Oncology</em>, 33(18): 2092–2099, 2015. URL <a href="https://doi.org/10.1200/JCO.2014.60.0379">https://doi.org/10.1200/JCO.2014.60.0379</a>.
</div>
<div id="ref-yamaguchi:2025" class="csl-entry" role="listitem">
Y. Yamaguchi and K. Takeda. <em>Boinet: Conduct simulation study of <span>Bayesian</span> optimal interval design with <span>BOIN-ET</span> family.</em> 2025. URL <a href="https://CRAN.R-project.org/package=boinet">https://CRAN.R-project.org/package=boinet</a>. <span>R</span> package version 1.3.0.
</div>
<div id="ref-yamaguchi:2024" class="csl-entry" role="listitem">
Y. Yamaguchi, K. Takeda, S. Yoshida and K. Maruo. Optimal biological dose selection in dose-finding trials with model-assisted designs based on efficacy and toxicity: A simulation study. <em>Journal of Biopharmaceutical Statistics</em>, 34(3): 379–393, 2024. URL <a href="https://doi.org/10.1080/10543406.2023.2202259">https://doi.org/10.1080/10543406.2023.2202259</a>.
</div>
<div id="ref-yin:2020" class="csl-entry" role="listitem">
J. Yin and Y. Yuan. Checkerboard: A <span>Bayesian</span> efficacy and toxicity interval design for phase i/II dose-finding trials. <em>Journal of Biopharmaceutical Statistics</em>, 30(6): 1006–1025, 2020. URL <a href="https://doi.org/10.1080/10543406.2020.1815033">https://doi.org/10.1080/10543406.2020.1815033</a>.
</div>
<div id="ref-xiaomeng:2025" class="csl-entry" role="listitem">
X. Yuan, C. Li, H. Sun, L. Tang and H. Pan. <em>Keyboard: <span>Bayesian</span> designs for early phase clinical trials.</em> 2025. URL <a href="https://CRAN.R-project.org/package=Keyboard">https://CRAN.R-project.org/package=Keyboard</a>. <span>R</span> package version 0.1.3.
</div>
<div id="ref-yuan:2007" class="csl-entry" role="listitem">
Y. Yuan, R. Chappell and H. Bailey. The continual reassessment method for multiple toxicity grades: A <span>Bayesian</span> quasi-likelihood approach. <em>Biometrics</em>, 63(1): 173–179, 2007. URL <a href="https://doi.org/10.1111/j.1541-0420.2006.00666.x">https://doi.org/10.1111/j.1541-0420.2006.00666.x</a>.
</div>
<div id="ref-yuan:2019" class="csl-entry" role="listitem">
Y. Yuan, J. J. Lee and S. G. Hilsenbeck. Model-assisted designs for early-phase clinical trials: Simplicity meets superiority. <em>JCO Precision Oncology</em>, 3: PO.19.00032, 2019. URL <a href="https://ascopubs.org/doi/10.1200/PO.19.00032">https://ascopubs.org/doi/10.1200/PO.19.00032</a>.
</div>
<div id="ref-yuan:2016" class="csl-entry" role="listitem">
Y. Yuan, H. Q. Nguyen and P. F. Thall. <em><span>Bayesian</span> designs for phase i-II clinical trials.</em> New York: Chapman; Hall/CRC, 2016.
</div>
<div id="ref-zhou:2019" class="csl-entry" role="listitem">
Y. Zhou, J. J. Lee and Y. Yuan. A utility-based <span>Bayesian</span> optimal interval (<span>U-BOIN</span>) phase i/II design to identify the optimal biological dose for targeted and immune therapies. <em>Statistics in Medicine</em>, 38(28): 5299–5316, 2019. URL <a href="https://doi.org/10.1002/sim.8361">https://doi.org/10.1002/sim.8361</a>.
</div>
</div>
<!--radix_placeholder_article_footer-->
<!--/radix_placeholder_article_footer-->
</div>

<div class="d-appendix">
</div>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

<!--radix_placeholder_site_after_body-->
<!--/radix_placeholder_site_after_body-->
<!--radix_placeholder_appendices-->
<div class="appendix-bottom">
  <h3 id="references">References</h3>
  <div id="references-listing"></div>
  <h3 id="reuse">Reuse</h3>
  <p>Text and figures are licensed under Creative Commons Attribution <a rel="license" href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a>. The figures that have been reused from other sources don't fall under this license and can be recognized by a note in their caption: "Figure from ...".</p>
  <h3 id="citation">Citation</h3>
  <p>For attribution, please cite this work as</p>
  <pre class="citation-appendix short">Yamaguchi, et al., "boinet: An R Package for Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes", The R Journal, 2025</pre>
  <p>BibTeX citation</p>
  <pre class="citation-appendix long">@article{RJ-2025-012,
  author = {Yamaguchi, Yusuke and Takeda, Kentaro and Maruo, Kazushi},
  title = {boinet: An R Package for Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes},
  journal = {The R Journal},
  year = {2025},
  note = {https://doi.org/10.32614/RJ-2025-012},
  doi = {10.32614/RJ-2025-012},
  volume = {17},
  issue = {2},
  issn = {2073-4859},
  pages = {15-34}
}</pre>
</div>
<!--/radix_placeholder_appendices-->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">
<!--radix_placeholder_navigation_after_body--><html><body>
<div class="distill-site-nav distill-site-footer">
<p>© The R Foundation, <a href="mailto:r-journal@r-project.org">web page
contact</a>.</p>
</div>
<!--/radix_placeholder_navigation_after_body-->
</body></html>


</body>

</html>
